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1.1 Introduction to influenza viruses 
1.1.1 Influenza virus classification 
Influenza viruses are the cause of highly contagious acute respiratory disease, 
known as influenza or “flu”, which has afflicted humans and animals since ancient 
times. Influenza viruses belong to the Orthomyxoviridae family. This family is divided 
into types A, B, C and D, based on the genetic and antigenic differences between 
their nucleoprotein (NP) and matrix (M) proteins. Influenza D viruses were first 
identified in 2011, and so far have only been isolated from pigs and cattle (Collin et 
al., 2015; Ducatez et al., 2015; Hause et al., 2014; Hause et al., 2013). It is generally 
assumed that humans are the exclusive natural host for influenza B and C viruses, 
but both viruses also sporadically infect pigs and some other mammals (Hause et al., 
2013; Leyva-Grado et al., 2012; Manuguerra & Hannoun, 1992; Yuanji & 
Desselberger, 1984). Influenza A viruses infect a wide range of avian and 
mammalian species, and humans, pigs and horses are the main mammalian hosts 
(Fouchier et al., 2003; Harder & Vahlenkamp, 2010; Webster et al., 1992). The 
influenza A viruses are further divided into subtypes, based on the antigenic nature of 
their surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). So far, 18 
different HAs (numbered as H1 to 18) and 11 NAs (N1 to 11) have been identified. All 
known subtypes of influenza A viruses have been found among birds, except 
subtypes H17N10 and H18N11 that have only been found in bats. Humans and pigs, 
in contrast, are susceptible to a limited number of subtypes (Table 1). Influenza B, C 
and D viruses will not be discussed further in this thesis. 
Though influenza virus is an important human pathogen, it was first isolated from 
poultry. A disease causing extremely high mortality in domestic fowl was first 
described in 1878 and became known as “fowl plague”. As early as 1901 the 
causative agent was shown to be an ultra-filterable agent, although it was not until 
1955 that the close relationship between this agent and mammalian influenza virus 
was demonstrated. Isolation of influenza virus from pigs also preceded that from 
humans. The virus was the causative agent of a “novel” disease of pigs, termed 
“swine influenza (SI)”, with clinical signs similar to those observed in humans. The 
illness in swine was first described during the 1918 human pandemic. In 1930, Shope 
demonstrated that swine influenza virus (SIV) could be transmitted between pigs 
using ultrafiltered material (Shope, 1931), and three years later a similar virus was 
eventually isolated from a human patient. The virus was propagated by inoculating a 
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filtrate of the patient’s throat washings into the noses of ferrets, which are highly 
susceptible to influenza virus (Smith et al., 1995). The isolate was later classified as 
influenza virus and this was followed in 1940 and 1947 by the isolation and 
classification of influenza B and C viruses, respectively. 
The current system of nomenclature of influenza viruses designates the type, host, 
place, strain number (if any), year of isolation and antigenic subtype of a virus. For 
example, a swine H3N2 virus isolated in Flanders in 1998 was designated 
A/Swine/Flanders/1/1998 (H3N2). 
 
1.1.2  Structure of influenza A virus 
Influenza A virus has a spherical or filamentous morphology and is medium sized, 
with a diameter of 80 to 120 nm. The virus is enveloped, and the lipid membrane of 
the virion is derived from the host cell in which the virus has replicated. The influenza 
virus genome consists of eight unique segments of negative, single-stranded RNA. 
Each RNA segment encodes only one protein, except for segment 7 and 8, which 
encode two. From the surface of the envelope extend the two transmembrane 
glycoproteins HA and NA (Figure 1). A third transmembrane protein, matrix protein 
M2, works as ion channel and plays an important role in uncoating of the virus in the 
cellular endosome. The matrix protein M1 forms a layer beneath the envelope and 
thus gives structure to the virus and encapsidates the ribonucleoprotein (RNP) 
complexes. RNP complexes consist of ribonucleic acid (RNA) associated with NP as 
well as the polymerases PA, PB1 and PB2 that are responsible for RNA replication 
and transcription. The proteins NS1 and NS2 are also associated with the virus and 
are no longer considered to be non-structural proteins: NS2 is found in the virion and 
mediates the export of RNPs from the nucleus to the cytoplasm (O'Neill et al., 1998), 
while NS1 is found mainly in infected cells but also at low levels within the influenza 
virion. It was shown to repress innate antiviral mechanisms in infected host cells 
(Hutchinson et al., 2014). In some strains, the RNA segment 2 encodes not only the 
PB1 protein, but also a second protein, called PB1-F2. 
 
1.1.3 Emergence of novel influenza viruses and virus evolution 
Due to the lack of proofreading of RNA polymerase, mutations in the influenza virus 
genome occur frequently, resulting in an error rate of around 1×10-5 substitutions per 
nucleotide per replication cycle (Parvin et al., 1986; Sanjuan et al., 2010). The 
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surface glycoproteins, HA and NA, are the most important antigens for inducing 
protective immunity in the host. Due to an accumulation of mutations in the HA and 
NA genes, the proteins will undergo minor structural changes over time, which are 
known as “antigenic drift”. Antigenic drift allows influenza viruses to escape from 
pre-existing immunity, and it is the reason why the virus strains in the human 
influenza vaccines are updated every few years.  
Due to the segmented genome, influenza viruses can “mix and match” gene 
segments upon simultaneous infection of the same host cell with two or more 
different viruses. This is designated “genetic reassortment”. In some cases, a new 
reassortant virus occurs with a different combination of HA and/or NA genes from the 
virus that was previously dominant in the population. This is known as “antigenic 
shift”. While antigenic drift is the cause of the regular recurrence of influenza 
epidemics, antigenic shift may cause an influenza pandemic, which refers to an 
epidemic that spreads on a worldwide scale and infects a large proportion of the 
human population. The pandemic occurs when a virus meets two requirements: 1) a 
large proportion of the population lacks immunity against the virus, and 2) the virus 
has the ability to spread efficiently from person to person. Three different 
mechanisms may lead to the emerge of a pandemic influenza virus (Figure 2): 1) 
Direct transfer of whole virus from another species. This is probably what occurred in 
1918 when the H1N1 “Spanish flu” virus entered the human population from the 
avian reservoir. It resulted in the most devastating pandemic in known history and 
was responsible for an estimated 20 to 40 million deaths (Patterson & Pyle, 1991). 2) 
Genetic reassortment between animal and human influenza viruses,  
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Table 1. Influenza A viruses HA and NA subtypes that have become established in birds, 
humans, pigs and other animals (adapted from the US CDC website 
http://www.cdc.gov/flu/about/viruses/transmission.htm#subtypes) 
HA  NA 
Subtype Birds Human Pigs Bats / Other  Subtype Birds Human Pigs Bats / Other 
H1 
  
  
 N1 
   
 
H2 
  
 
 
 N2 
   
Dog 
H3 
  
 
Dog, horse  N3 
 
  Seal 
H4 
 
 
 
 
 N4 
 
   
H5 
 
 
 
 
 N5 
 
   
H6 
 
 
 
 
 N6 
 
   
H7 
 
 
 Horse  N7 
 
  Horse 
H8 
 
 
 
 
 N8 
 
  Dog, horse 
H9 
 
 
 
 
 N9 
 
   
H10 
 
 
 
 
 N10    
 
H11 
 
   
 N11    
 
H12 
 
   
      
H13 
 
   
      
H14 
 
   
      
H15 
 
   
      
H16 
 
   
      
H17 
   
 
      
H18 
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Figure 1. The structure of influenza A virus (adapted from Nelson and Holmes 2007). 
 
producing a virus with a new HA subtype. As a result of reassortment, the H2N2 
“Asian flu” virus, responsible for the pandemic of 1957, acquired the HA, NA and PB1 
gene segments from an avian virus and kept the other five segments from the human 
H1N1 strain already in circulation. The H3N2 “Hong Kong flu” virus of 1968 acquired 
HA and PB1 segments of avian origin and the remaining six segments from the 
H2N2 virus. 3) Recycling of an HA that has disappeared from the human population 
long ago. The 1918 H1N1 pandemic influenza virus is the common ancestor of 
human seasonal and “classical” swine H1N1 influenza viruses, and has undergone 
significant antigenic drift in humans, but nearly remained in antigenic stasis in swine 
(Kash et al., 2010; Skountzou et al., 2010). The virus that caused the 2009 H1N1 
pandemic is a reassortant virus that contains the NA and M genes from the European 
H1avN1 SIV lineage, and the remaining genes from the North American triple-
reassortant H1N2 SIV lineage, which bears the “classical” swine H1 (Garten et al., 
2009; Smith et al., 2009). Consequently, only people born before 1940-50 had been 
previously exposed to human seasonal H1N1 viruses with an H1 related to that of 
2009 pandemic H1N1 virus (pH1N1), and a pandemic was possible because younger 
people lacked cross-reactive anti-H1 antibodies (CDC, 2009; Hancock et al., 2009; 
Ikonen et al., 2010; Skowronski et al., 2011).  
Chapter 1 
18 
Fi
gu
re
 2
. G
en
et
ic
 re
la
tio
ns
hi
ps
 a
m
on
g 
in
flu
en
za
 A
 v
iru
se
s 
of
 h
um
an
, E
ur
op
ea
n 
sw
in
e,
 a
nd
 (s
el
ec
te
d)
 N
or
th
 A
m
er
ic
an
 s
w
in
e 
lin
ea
ge
s,
 
19
18
-2
00
9.
 
General introduction 
19 
1.2  Influenza A viruses in pigs and in humans 
1.2.1 Epidemiology of swine influenza viruses worldwide 
Three influenza virus subtypes – H1N1, H3N2 and H1N2 – are currently circulating in 
swine worldwide, but the origins and the antigenic and genetic characteristics of 
these SIV subtypes differ in different continents or regions of the world. In Europe, 
the predominant H1N1 SIVs are entirely of avian origin. They were introduced from 
waterfowl to pigs in 1979 and are referred to as the avian-like H1N1 (H1avN1) SIV 
(Pensaert et al., 1981). Shortly after the human Hong Kong influenza pandemic in 
1968, H3N2 influenza viruses were isolated in European pigs (Ottis et al., 1982; 
Tumova et al., 1980), but they only became widespread after reassortment with the 
H1avN1 SIV in the early 1980s . Those reassortant H3N2 SIVs inherited the 6 
internal genes from the latter lineage, and retained the human-like HA and HA genes 
(Campitelli et al., 1997; Castrucci et al., 1993). Another reassortant virus of H1N2 
subtype was first reported in 1994 in the United Kingdom and then throughout 
Europe (Brown et al., 1995; Brown et al., 1998; Van Reeth et al., 2000). This human-
like H1N2 (H1huN2) virus contains an HA of a human seasonal H1N1 virus from the 
1980s, a NA of swine H3N2 virus origin and internal genes of swine H1avN1 virus 
origin (Brown et al., 1998). Thus, the three major virus lineages share common 
internal genes, but they have genetically and antigenically distinguishable HAs and/or 
NAs. 
These three major SIV lineages have been co-circulating for many years in the 
European swine population, but the prevalence and incidence of individual subtypes 
varied from one country to another (Kyriakis et al., 2011; Kyriakis et al., 2013; Van 
Reeth et al., 2008). Since 2000, new reassortant viruses between these three SIV 
lineages or between SIVs and human seasonal influenza viruses have been detected 
occasionally (Kyriakis et al., 2011), but the situation was rather stable in European 
pig herds until the emergence of the swine-origin pH1N1 virus in 2009 (Simon et al., 
2014b). Approximately one month after the isolation of the pH1N1 virus in humans, 
the virus was transmitted back to swine, with the first pH1N1 virus being isolated 
from a pig herd in Alberta, Canada, in May 2009 (Howden et al., 2009). Since then, 
pH1N1 viruses were associated with outbreaks in swine in Europe (Howard et al., 
2011), Asia (Vijaykrishna et al., 2010), Africa (Njabo et al., 2012), Australia (Holyoake 
et al., 2011), and South America (Pereda et al., 2010). Pigs were shown to be highly 
susceptible to this pH1N1 virus (Brookes et al., 2010; Lange et al., 2009), and the 
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establishment of pH1N1 in pigs has complicated the SI epidemiology in many 
countries because the virus has reassorted with pre-existing H1N1, H1N2 and H3N2 
SIVs. In Europe, a growing number of reassortants between the four SIV lineages 
has been reported in recent years (Harder et al., 2013; Moreno et al., 2013; Rose et 
al., 2013; Trebbien et al., 2013), and viruses containing 1 to 7 genes of the pH1N1 
virus with the HA and/or NA of previously established SIVs are now common in 
several European countries (Chiapponi et al., 2014; Lange et al., 2013; Simon et al., 
2014a). 
In North America, SI was first recognized in pigs in the Midwestern United States (US) 
in 1918 as a respiratory disease that coincided with the human Spanish flu pandemic. 
Since then, this classical swine lineage H1N1 virus derived from the 1918 pandemic 
virus established itself in US swine and has remained relatively stable at the genetic 
and antigenic levels for nearly 80 years. The epidemiology of SIVs in the US 
dramatically changed after 1998 when triple-reassortant H3N2 viruses containing 
gene segments from the classical swine virus (NP, M, NS), H3N2 human seasonal 
virus (PB1, HA, NA) and avian influenza virus (AIV) (PB2, PA) (Zhou et al., 1999) 
became successfully established in the pig population (Webby et al., 2000). This 
genome composition of SIV is referred to as the triple-reassortant internal gene 
(TRIG) cassette (Vincent et al., 2008b). These triple-reassortant H3N2 viruses 
cocirculated with classical H1N1 viruses in swine and exchanged genome segments 
via reassortment, generating reassortant H1N1 or H1N2 viruses (Karasin et al., 2002; 
Webby et al., 2004). The triple-reassortant H3N2 SIVs were classified as H3 clusters 
I to III, a result of three separate human seasonal H3 gene introductions in 1995 (H3-
I), 1997 (H3-II), and 1996 (H3-III), respectively (Richt et al., 2003). Swine H3-IV 
evolved from cluster III and was first reported in 2005, but remained relatively stable 
until 2010 (Olsen et al., 2006). From 1998 to 2009, the majority, if not all H1 and H3 
viruses isolated from swine contain the TRIG constellation (Evseenko et al., 2011; 
Lorusso et al., 2011; Nfon et al., 2011a; Nfon et al., 2011b).  
Currently, viruses of six distinct antigenic HA types are cocirculating in swine in the 
US and Canada: H1α, H1β, H1δ, H1γ, pandemic H1, and H3 (cluster IV) (reviewed in 
(Lorusso et al., 2012)). The introduction of the pH1N1 virus and reassortment with 
triple-reassortant H3N2 SIVs has altered both the genotype and phenotype of the 
previously stable swine H3-IV viruses. At least 10 H3N2 genotype patterns emerged 
in the US (Kitikoon et al., 2013). The H3N2 genotype that inherited only the M gene 
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from the pH1N1 virus in particular has raised public health concerns in recent years. 
This virus, called “H3N2pM” when isolated from pigs, and called “H3N2 variant” or 
“H3N2v” when isolated from humans, was detected more frequently than any other 
genotype (~36 % of H3N2-TRIG/pH1N1 reassortant viruses) (Kitikoon et al., 2013).  
In Asia, the epidemiology of SIVs is far more complicated than that in Europe or 
North America. The first wholly human-like H3N2 were first isolated from pigs in 
Taiwan soon after the Hong Kong pandemic (Kundin, 1970). In the next years, 
almost all of the major human H3N2 variants could be introduced into the pig 
population, but most were prevalent at a low level within a small geographic location, 
and failed to become established in pigs except for the A/Port Chalmers/1/73, 
A/Victoria/3/75 and A/Sydney/05/97 variants (Shortridge et al., 1979; Shortridge & 
Webster, 1979; Shortridge et al., 1977; Yu et al., 2008a). Besides those entire 
human-like viruses, various H3N2 reassortant viruses have been reported throughout 
Asia, and some resemble European double reassortant or North American triple 
reassortant virus lineage (Pan et al., 2009; Takemae et al., 2008; Vijaykrishna et al., 
2011; Yu et al., 2008a), whereas other SIVs have emerged locally and are clearly 
unique for Asia (Nerome et al., 1995; Ngo et al., 2012; Shu et al., 1994; Sun et al., 
2009). The cocirculating of so many genetically diverse SIVs has further resulted in 
multiple and complex reassortant viruses (Bi et al., 2010; Chen et al., 2014; Yu et al., 
2008a).  
In South America, limited serological surveys in Venezuela, Colombia and Brazil 
have revealed that H3N2 subtypes are prevailing in swine (Perfumo, 2010). However, 
neither virus isolation nor sequencing analysis had been reported before 2008. In late 
2008, a wholly human H3N2 was isolated from pigs, which shares of 96-98% 
nucleotide identities with human seasonal H3N2 viruses from 2000-03 (Cappuccio et 
al., 2011). This represents an independent human-to-swine transmission event that is 
distinguishable from those in Europe and North America. 
 
1.2.2 Antigenic evolution of H3N2 viruses in humans and in pigs 
Most, if not all H3N2 SIVs contain human-origin HA and NA genes, but the antigenic 
evolution of H3N2 viruses is usually slower in pigs than in humans (Van Reeth et al., 
2012). Because of the short average life span of pigs, SIVs evolution may be 
determined to only a limited extent by herd immune pressure, which is the driving 
force of antigenic drift of influenza viruses in humans. Whereas the human H3N2 
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virus requires frequent antigenic changes of HA to ensure that a sufficiently large 
pool of immunologically susceptible hosts is available, the vast majority of pigs are 
killed at the age of 6 months, and the susceptible pig population is continuously 
renewed, thus limiting immune pressure. Only adult sows used for breeding live long 
enough to experience more than one influenza season, and therefore may create 
some degree of immune pressure, leading to the (slow) antigenic drift of SIVs (de 
Jong et al., 2007). 
It has been shown that European swine and human seasonal H3N2 viruses have a 
similar rate of genetic evolution in their HA1 region during 1982-2002 (~5 × 10-3 and 
~6 × 10-3 substitutions per nucleotide per year, respectively), but swine viruses 
apparently mutate in regions that are less important for the antigenic properties (de 
Jong et al., 2007; Nerome et al., 1995). Moreover, antigenic drift in the HA1 is ~6 
times slower in European H3N2 SIVs than in their human counterparts (de Jong et al., 
2007). As for human seasonal H3N2 viruses, 13 different antigenic clusters have 
been identified between 1975 and 2011 (Smith et al., 2004; Westgeest et al., 2014) 
and the human H3N2 vaccine component has been updated 21 times during this 
period. European H3N2 SIVs have been grouped into two antigenic clusters (de Jong 
et al., 2007). Compared to cluster 1 viruses (1984-1993), the later cluster 2 viruses 
(1993-2001) showed reduced cross-reactivity with A/Port Chalmers/1/73, which is 
assumed to be the ancestor human virus for European H3N2 SIVs, in 
hemagglutination-inhibition (HI) assays with post-infection ferret sera (de Jong et al., 
2007; de Jong et al., 1999). Yet sera from pigs vaccinated with a commercial A/Port 
Chalmers/1/73 vaccine discriminated less well between both antigenic clusters than 
the ferret sera, and the A/Port Chalmers/1/73-based vaccine significantly reduced 
lung virus titers against challenge with the cluster 2 viruses sw/Flanders/1/98, 
sw/Oedenrode/7C/96 and sw/Gent/172/08 (De Vleeschauwer et al., 2015; Heinen et 
al., 2001b; Van Reeth et al., 2001).  
The North American H3N2 SIVs have shown more antigenic diversity than their 
European counterparts. Antigenic diversity has been demonstrated between the four 
clusters of H3N2 SIVs (Gramer et al., 2007; Richt et al., 2003). The newly emerged 
genotypes within cluster IV viruses since 2011 show an increasing antigenic diversity. 
Antisera produced against contemporary swine H3 isolates had low cross-HI 
reactivity to cluster I virus, older cluster IV isolates and inconsistent cross-reactivity 
among the new subclusters (Kitikoon et al., 2013). Based on the cross-HI assays 
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with post-vaccination swine sera, cluster IV viruses circulating between 2006 and 
2013 have been differentiated into two major antigenic groups, with some isolates 
from 2010-2013 located as outliers in the antigenic map (Lewis et al., 2014). Genetic 
analysis has identified 6 amino acid positions (145, 155, 156, 158, 159, and 189) in 
HA1 that are critical for the antigenic phenotype of those H3N2 SIVs, and changes in 
only one or two of these amino acids are thought to be sufficient for antigenic 
switches. The key amino acid positions are strikingly similar to the 7 amino acids that 
have been shown to drive human antigenic switches from 1968 to 2003 (Koel et al., 
2013). 
As most studies focus on the antigenic drifts of the HA, knowledge on the antigenic 
evolution of the NA is relatively limited. For humans seasonal H3N2 viruses during 
1968-2009, the overall rates of evolutionary change were lower for NA than for HA1 
at the nucleotide level (Westgeest et al., 2012). Neuraminidase-inhibition assays with 
ferret post-infection sera has demonstrated the NA drifted antigenically in a 
noncontinuous pattern, which did not correspond closely with HA drift (Sandbulte et 
al., 2011). So far, knowledge about the genetic and antigenic drift of NAs in H3N2 
SIVs remains quite limited. 
 
1.2.3  Transmission of H3N2 influenza viruses from swine to humans  
Some influenza viruses may remain in evolutionary stasis in pigs for decades after 
the disappearance of their ancestor from the human population. Those SIVs may 
jump back into humans when the human population immunity has waned to 
sufficiently low levels, and the pH1N1 is the most notable example. For H3N2 SIVs, 
only sporadic and dead-end human infections have been reported occasionally since 
the 1990s (Figure 3). Due to weak or non-existent surveillance systems in large parts 
of the world, estimates of the prevalence of these zoonotic infections should be made 
with caution. 
In 1993, the European H3N2 SIV was isolated from a one-year-old girl and a two-
year-old boy in the Netherlands (Claas et al., 1994). The children, who were living in 
geographically distinct regions, developed mild respiratory symptoms. Neither child 
had been in close contact with pigs, but the father of the boy had regular contact with 
pigs through his occupation. A similar H3N2 SIV was isolated from a 10-month-old 
girl in Hong Kong in 1999 (Gregory et al., 2001). In 2014, a H3N2 SIV infection was 
isolated from a 67-year-old immunocompromised man, and the local pig farm that he 
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visited before the sickness was identified as the source of infection  (Piralla et al., 
2015).  
The first reported North American triple-reassortant H3N2 SIV zoonotic infection case 
occurred in Ontario, Canada, in 2005. The virus was isolated from an adult swine 
farmer (Olsen et al., 2006). In 2006, another case of H3N2 SIV infection was 
identified in a Canadian 7-month-old boy. The infant lived on a farm with pigs and 
other animals but he had no direct contact with those animals (Robinson et al., 2007). 
Between 2009 and 2010, triple-reassortant H3N2 SIVs were detected in 7 people in 
the US ranging from 9-month-old to 45-year-old (Shu et al., 2012). From July 2011 to 
October 2014, a total of 343 cases of infection with a novel swine-origin H3N2v virus 
were reported in 13 states in the US, with 18 people being hospitalized and 1 death 
(http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm). Of the eight gene segments 
of H3N2v, all but the M gene were similar to those of triple-reassortant H3N2 SIV 
currently circulating in North America, and to those of H3N2 SIVs isolated from 
humans during 2009-10. However, the M gene of H3N2v virus is inherited from the 
pH1N1 virus. The patients have a median age of 7 years old, and the majority 
reported agricultural fair attendance (93%) and/or contact with swine (95%) prior to 
illness. Limited person-to-person H3N2v virus transmission was reported, but there 
was no evidence of sustained person-to-person transmission (Jhung et al., 2013).  
 
1.3 Pathogenesis and immune responses to influenza A virus in the pig 
1.3.1 Clinical features and pathogenesis of influenza viruses in the pig 
Swine influenza is an acute febrile, respiratory disease characterized by fever 
(usually in the range 40.5-41.7 ºC), apathy, anorexia, coughing. The disease may 
progress to open-mouthed breathing and dyspnea, especially when animals are 
forced to move. Generally, recovery is rapid, usually 5-7 days after the onset of 
clinical signs. Uncomplicated SIV infections cause low mortality (usually less than 
1%), but morbidity can reach 100% (Van Reeth et al., 2012). Secondary bacterial 
infections can increase the severity of illness. The gross lesions found in 
uncomplicated SI are mainly those of a viral pneumonia and are most often limited to 
the apical and cardiac lobes of the lungs, although in severe cases more than half of 
the lung may be affected. The altered lung areas are consolidated and dark red or 
purple-red in color, contrasting sharply with normal tissue. 
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Infection with SIV is generally limited to the epithelial cells of nasal mucosa, tonsils, 
trachea, bronchi, bronchioles and alveoli (Brown et al., 1993; De Vleeschauwer et al., 
2009a; Heinen et al., 2000; Lanza et al., 1992). Besides those tissues, SIVs can also 
be isolated from ethmoid, tracheobronchial lymph nodes (TBLN) and bronchoalveolar 
lavage fluid (BALF). Virus shedding and transmission occur almost exclusively via 
the respiratory route, and the brain stem is the single extra-respiratory tissue where 
low titers of virus were occasionally detected by both polymerase chain reaction 
(PCR) assay and virus isolation, but no specific infected cells were detected by 
immunofluorescence (IF) assay (De Vleeschauwer et al., 2009a). Only one study 
reported viremia of low titer and short duration (Brown et al., 1993). 
Infection and replication of influenza viruses in host cells progresses very rapidly, 
while virus clearance is also extremely rapid. In most experimental studies, nasal 
virus shedding starts at 1 day post-inoculation (dpi) for 5-6 days, occasionally 7 days. 
SIVs have a preference for the lower versus upper respiratory tract. Virus titers in the 
lungs may reach up to 108 egg infectious doses 50 (EID50) per gram of tissue 
(Haesebrouck & Pensaert, 1986; Van Reeth et al., 1998), and IF and 
immunohistochemical (IHC) studies demonstrate massive numbers of viral antigen-
positive cells in the bronchial, bronchiolar, and alveolar epithelia, compared to fewer 
positive cells in the nasal mucosa (Brown et al., 1993; De Vleeschauwer et al., 2009a; 
Haesebrouck & Pensaert, 1986; Van Reeth et al., 1998).  
Infection with SIV can be easily reproduced by experimental inoculation of influenza 
naïve pigs using aerosol, intranasal (IN), or intratracheal (IT) inoculation routes. 
However, the kinetics of virus replication in the respiratory tract, clinical 
manifestations and the severity of lung inflammation vary remarkably depending on 
the inoculation route and dose. Typical SI clinical signs, that is, high fever (≥40.5 °C), 
lethargy, anorexia, pronounced tachypnea and expiratory dyspnea, and lung 
inflammation is most reproducibly accomplished by IT inoculation of high doses of 
virus (≥107.0 EID50) (De Vleeschauwer et al., 2009a; Van Reeth et al., 1998; Van 
Reeth et al., 2002). Less invasive methods, such as IN inoculation or IT inoculation 
with a low dose, result in mild or entirely subclinical infections (Landolt et al., 2003; 
Larsen et al., 2000).  
Proinflammatory cytokines produced by the host during the very acute stage of an 
infection probably play a critical role in SI disease development. Titers of interferon-α 
and -γ (IFN-α and -γ), tumor necrosis factor-α (TNF-α), interleukin-1, -6 and -12 in 
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BALF are extremely high after high-dose IT inoculation, and they coincide with the 
peak of disease (Van Reeth et al., 1998; Van Reeth et al., 2002). Experimental 
studies support the concept that a high amount of virus that reaches the deeper 
airways and the resulting production of infectious virus likely determine the extent of 
cytokine production in the lungs, which in turn determines the severity of illness. 
However, many cytokines also have antiviral and immunostimulating effects, and 
thus may contribute to the clearance of influenza viruses. Little differences have been 
found in the pathogenesis or virulence between SIV lineages or strains (Van Reeth et 
al., 2012). The pH1N1 virus has shown a similar pathogenetic course in pigs as the 
SIVs that are endemic in swine populations (Brookes et al., 2010; Lange et al., 2009). 
Inoculation of pigs with AIV or some human influenza virus strains may result in a 
mild to subclinical infection, consistent with low-to-moderate virus titers in the 
respiratory tissues (De Vleeschauwer et al., 2009b; Landolt et al., 2003; Van Reeth 
et al., 1998).  
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1.3.2 Immune responses to influenza viruses in the pig 
Much of our knowledge about immune mechanisms operating against influenza virus 
has been gained from studies in humans and rodents, there are only a limited 
number of specific studies in swine. In general, after exposure to an influenza virus, 
the first line of host defense is formed by the innate immune system, which is quick 
but lacks specificity and memory. It consists of physical barriers (i.e., mucus and 
collectins) and innate cellular immune responses. Innate immune cells like 
macrophages, dendritic cells (DC) rapidly exit the respiratory tract, and travel via 
afferent lymph to regional lymph nodes or via the blood to the spleen, to deliver 
antigen to naïve and memory T and B cells. Alveolar macrophages and natural killer 
(NK) cells also have a direct role in limiting virus replication and dissemination. 
Interferons (IFN) are produced early in infection and may reduce viral spread by 
inducing an antiviral state in host cells and by activation of cytotoxic T cells (CTLs) 
and NK cells, thereby contributing to recovery from infection (van de Sandt et al., 
2012).  
In addition to the non-specific immune mechanisms, adaptive immune responses are 
needed for the ultimate elimination of the virus. The latter is highly specific but is 
relatively slow upon first encounter with a pathogen. However, as a result of 
immunological memory, the adaptive response reacts faster and stronger after a 
second encounter with the same or a closely related pathogen. The adaptive immune 
response consists of cellular (virus-specific CD4+ and CD8+ T cells) and humoral 
(virus-specific antibodies) immunity. 
The cell-mediated immunity (CMI), mediated by virus-specific CD4+ T cells and CD8+ 
T cells, is directed against conserved regions in all internal and surface proteins of 
the virus. To be recognized by T cells, viral antigens must be degraded into small 
immunogenic peptides in antigen-presenting cells and presented on the surface of 
these cells in association with molecules of the major histocompatibility complex 
(MHC). CD4+ T cells are activated by peptides derived from exogenous, 
phagocytosed antigens, which are displayed by MHC class II molecules. In contrast, 
CD8+ T cells are activated by peptides that are generally derived from de novo, 
intracellular synthesis of viral protein and these are presented in association with 
MHC class I molecules. Activated CD4+ T cells can be differentiated into CD4+ T 
helper 1 (Th1) or Th2 cells (Zhu & Paul, 2010). Th2 cells stimulate B cells to 
proliferate and differentiate into antibody producing plasma cells (Okoye & Wilson, 
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2011). Th1 cells are mainly involved in helping CD8+ T cells to proliferate and 
differentiate to CTLs (Mosmann et al., 1986), and are essential for the induction of 
memory CD8+ T cells (Deliyannis et al., 2002). The CTLs are considered to be the 
key players of the CMI response. After activation, they migrate to the site of infection 
where they recognize and kill influenza virus-infected cells and the viruses 
reproducing within them (Nakanishi et al., 2009). CTLs are mainly directed against 
epitopes on the NP, which is highly conserved among influenza A viruses.  
Neutralizing antibodies are the most important line of defense against influenza 
infection, and they are mainly directed against the viral HA protein. By binding to the 
HA receptor binding site in the globular head, neutralizing antibodies can block viral 
entry by either preventing the attachment of the virus to sialic acid receptors on host 
cells or by interfering with HA-mediated viral fusion (Brandenburg et al., 2013). The 
NA protein is also a target of neutralizing antibodies. By inhibiting the enzymatic 
activity of NA, NA antibodies can prevent influenza viruses from penetrating host 
mucus layer that is rich in heavily sialylated glycoproteins, and therefore prevent 
influenza viruses from entering respiratory epithelia (Cohen et al., 2013), and limit the 
fusion of the influenza virus into host cells (Su et al., 2009). Those antibodies also 
interfere with the last phase of the viral replication cycle by limiting newly formed 
viruses releasing from host cells. Antibodies to the more conserved NP and M 
proteins are also produced during influenza virus infection (Potter & Oxford, 1979). 
Though they cannot prevent an infection, they contribute to the protection by killing 
infected cells through antibody-dependent mechanisms.  
Experimental pig infection studies with SIV have shown that antibodies can be 
detected in serum by HI and virus-neutralization (VN) assays at 7-10 days post-
infection and peak by 2-3 weeks (Larsen et al., 2000; Van Reeth et al., 2006). 
Antibodies to the NA and NP are detected in post-infection swine sera (Heinen et al., 
2001a; Heinen et al., 2000; Van Reeth et al., 2003), as well as moderate antibody 
levels to M1, and low and variable antibody levels to the external part of M2 (Kitikoon 
et al., 2008). Antibodies to NP have also been detected in nasal secretions and BALF 
(Heinen et al., 2001a; Heinen et al., 2000; Kitikoon et al., 2006; Kitikoon et al., 2009; 
Larsen et al., 2001; Larsen et al., 2000). The HA-specific IgA and IgG responses 
have been detected in respiratory secretions and BALF, as well as in serum, where 
IgM is the first immunoglobulin produced (Lee et al., 1995). Both IgA and IgG 
antibodies can be locally produced in the respiratory tract, and the SIV-specific 
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antibody-secreting cell responses peaked at 2-3 weeks post-infection (Larsen et al., 
2000). IgG antibodies can also transudate from serum into alveolar epithelium and 
contribute to the protection in the lung. Data on CMI in the pig are even more limited, 
and studies have mainly measured Th cell activity in the circulation, because it is 
technically difficult to quantify CTLs in pigs or to demonstrate T cells in the airways. 
Proliferating lymphocytes in BALF and blood increased from 7 dpi onwards, and 
these cells have shown inter-subtypic cross-reaction upon in vitro re-stimulation 
(Heinen et al., 2001a). Pigs infected with the pH1N1 showed activated CD4+ and 
CD8+ T cells in the peripheral blood on 6 dpi (Lange et al., 2009). Moderate numbers 
of cells producing IFN-γ have been demonstrated in the porcine nasal mucosa after 
infection with SIV. Yet, cell numbers were much higher in TBLN and spleen, and they 
peaked 3 weeks post-infection.  
 
1.3.3 Homologous, heterovariant and heterosubtypic immunity 
After primary infection with influenza virus, virus-specific IgA and IgG antibody 
secreting cells (ASCs) as well as Th and CTLs will be present in the tissues lining the 
respiratory tract and in the local lymph nodes. The immune system has built up a 
memory that will lead to a faster, stronger, more localized and more accurate 
secondary response, upon a second infection with the same or a closely related virus 
strain. This immunity is called homologous immunity. It is primarily mediated by 
memory B cells and the VN antibodies they produce and can be life-long (reviewed in 
(Subbarao et al., 2006)). As an example, in 1977, the H1N1 virus first reappeared in 
the human population since 1957, the people who had been infected 20 years 
previously with similar H1N1 viruses were still resistant to infection or disease (Fox et 
al., 1982).  
While immunity protects against re-infection with the same or a similar virus, it is less 
protective or absent when a more distant virus is encountered. This immunity is 
defined as heterovariant immunity when the protection is conferred by previous 
exposure to a virus of the same HA and NA subtype (i.e. between two H3N2 
variants), or heterosubtypic immunity when conferred by previously exposure to a 
virus of another HA and/or NA subtype (i.e. between H3N2 and H1N1/H1N2). Those 
“broader” protections can occur in the absence of detectable HI antibodies in serum, 
and antibodies against more conserved viral proteins, especially mucosal antibodies, 
as well as CMI are likely to contribute to the protection. 
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Cross-protection between different influenza viruses in rodents, ferrets, and humans 
Heterovariant immunity has been demonstrated in mice and ferrets under 
experimental conditions. Prior infection with a seasonal H1N1 virus from the 1930s-
40s protected mice against a lethal challenge with mouse-adapted pH1N1 virus 
(Skountzou et al., 2010). Likewise, prior infection of ferrets with a seasonal H1N1 
virus from the 1930s-40s resulted in a significant reduction in virus titers in nasal 
turbinates and lungs after challenge with the pH1N1 (O'Donnell et al., 2012). In 
contrast, prior infection or vaccination with a more recent seasonal H1N1 strain from 
the 1990s-2000s, which is far less related to pH1N1, provided minimal protection 
against pH1N1 challenge in mice and ferrets (Laurie et al., 2010; Manicassamy et al., 
2010; O'Donnell et al., 2012). 
It is believed that partial, but limited cross-protective heterovariant immunity may 
exist in humans between variants within the same HA and NA subtype, and the 
extent of cross-protection depends on the antigenic relatedness between viral HA 
and NA genes. As an illustration, elderly people who have been exposed to historic 
human seasonal H1N1 viruses prior to 1950s had pre-existing antibodies against the 
pH1N1 virus and were relatively spared from contracting infections and developing 
disease in the 2009 H1N1 pandemic (Hancock et al., 2009; Ikonen et al., 2010; Reed 
& Katz, 2010; Yu et al., 2008). In contrast, the pH1N1 attack rates were highest in 
young adults and children, even though they had substantial pre-existing antibodies 
and CMI to seasonal H1N1 viruses from the 2000s (Skowronski et al., 2011). Human 
seasonal H1N1 and H3N2 viruses continuously undergo antigenic drift, and immunity 
to previous strains may not be able to provide sufficient protection to the new 
emerged variant strains. For example, an A/Fujian/411/2002-like virus caused an 
unusually severe 2003–2004 flu season in humans. Only two amino acid 
substitutions in HA (H155T, Q156H) were sufficient for this A/Fujian/411/2002-like 
virus to become antigenically distinct from the precursor A/Panama/2007/1999-like 
virus (Jin et al., 2005). As a result of the rapid antigenic drift of seasonal strains, the 
seed strains in influenza vaccines are updated every 2-3 years to ensure their 
protective efficiency in humans (Hay et al., 2001; Russell et al., 2008).  
Heterosubtypic immunity has also been repeatedly reported in laboratory animals. 
While such immunity usually does not provide sterilizing immunity (i.e. prevent 
infection), it may clearly reduce virus replication and mortality. Schulman and 
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Kilbourne showed that prior infection with an H1N1 strain protected mice from 
subsequent challenge with an otherwise lethal dose of H2N2 virus (Schulman & 
Kilbourne, 1965). Many subsequent studies have confirmed and extended those 
observations. For example, prior infection of mice or cotton rats with H1N1 or pH1N1 
did not prevent the subsequent H3N2 challenge infection, but virus clearance was 
accelerated in the nose and lung (Hillaire et al., 2011; Kreijtz et al., 2007; Straight et 
al., 2006). Reductions in both shedding and transmission of pH1N1 have been 
demonstrated in guinea pigs previously exposed to seasonal H3N2 viruses (Steel et 
al., 2010). In ferrets, prior infection with pH1N1 or a seasonal H1N1 virus resulted in 
a 1-2 days shorter duration of nasal excretion after challenge with a seasonal H3N2 
virus (Laurie et al., 2010; Yetter et al., 1980).  
Heterosubtypic immunity is much debated in humans. A report on cross-subtype 
protection in humans during either concurrent or successive H3N2 and H1N1 
epidemics in Japanese high schools revealed that a significantly smaller proportion of 
students were infected with H1N1 following an H3N2 epidemic compared to students 
without previous exposure to the H3N2 virus (Sonoguchi et al., 1985). However, 
previous infection of children <3 years old with H1N1 or H3N2 influenza provides little 
protection against experimental challenge with attenuated heterosubtypic strains 
(Steinhoff et al., 1993). Similarly, at the start of the 1957 pandemic, when H2N2 
viruses spread through a population in which H1N1 influenza was endemic, there 
was no evidence of cross-protection of children, although there was evidence of 
partial heterosubtypic protection of adults with extensive past influenza exposure 
(Epstein, 2006). 
Compared to the long-lasting homologous immunity, heterosubtypic immunity is 
usually short-lived. Liang et al used the mouse model to demonstrate that 
heterosubtypic immunity in the nose began to disappear at about 4-5 months post-
infection, but it remained in the lung for over 7 months (Liang et al., 1994). In humans, 
memory T cells to influenza, particularly CD8+ CTL activities, also wane over time, 
with a half-life of 2-3 years (McMichael et al., 1983). This may explain the generally 
weaker heterosubtypic immunity observed in humans than in laboratory animals, as 
experimental studies are performed with several weeks between infections, while 
most human influenza infections have an interval of several years. Because memory 
B- and T- cells decline over time, experimental studies tend to overestimate the 
extent of cross-protection between viruses in the field. 
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Cross-protection between different influenza viruses in pigs 
In pigs, infection with SIV of one subtype may confer at least partial heterovariant 
protection from subsequent infections (reviewed in (Van Reeth & Ma, 2013)). For 
example, a nearly complete protection has been observed between North American 
α- and γ-cluster H1 SIVs (Vincent et al., 2008a), and between a European H1avN1 
SIV and a North American triple-reassortant H1N1 SIV (De Vleeschauwer et al., 
2011) as well as the pH1N1 virus (Busquets et al., 2010), despite up to 20-30% 
amino acid sequence differences in the HA1 of the priming and challenge viruses. In 
these studies, the challenge virus was either undetectable in nasal swabs or lung 
tissues of these previously infection-immune pigs, or virus isolation rates and viral 
titers were significantly reduced compared to those in challenge controls. Cross-
protection between SIVs of different subtypes (heterosubtypic protection) was much 
weaker. Prior infection with European H1avN1 could not prevent the subsequent 
infection of a European H1huN2 (Van Reeth et al., 2003), or a European H3N2 SIV 
(Heinen et al., 2001a), but nasal shedding was on average 1-2 days shorter than in 
challenge control pigs. In all of the above studies, cross-protection occurred in the 
absence of cross-reactive HI antibodies in the serum, but there are some indications 
for the protective role of cross-reactive serum VN and/or NI antibodies. Antibodies in 
nasal washes and BALF, and CMI responses may also contribute to the broad 
protection, but their relative contributions as well as the target viral proteins remain to 
be identified. 
 
1.4 The pig as a model for influenza compared to mice and ferrets 
Influenza in pigs has gained significant interest since the 2009 swine-origin H1N1 
pandemic, as well as the use of pigs as a model for human influenza. Pigs are 
physiologically, anatomically, and immunologically similar to humans (Lefevre et al., 
2012). In contrast to the mouse lung, the porcine lung has marked similarities to its 
human counterpart in terms of the structure of the tracheobronchial tree, lung 
physiology, airway morphology, abundance of airway submucosal glands, and 
patterns of glycoprotein synthesis (Goco et al., 1963; Ibrahim et al., 2006). Pigs can 
be naturally infected by a wide range of both avian and human viruses, and the 
clinical manifestations and pathogenesis after infection with swine-adapted influenza 
viruses closely resemble those of human influenza (Van Reeth et al., 2012). This 
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close similarity has recently also been confirmed for pH1N1 virus (Brookes et al., 
2010; Lange et al., 2009). In humans and swine, virus replication occurs mainly 
locally in the upper and lower respiratory tract, and the cell receptor distributions with 
respect to α2,6-and α2,3-linked galactose are strikingly similar in them (van Riel et al., 
2007). In both species, α2,6-linkages predominate in the upper respiratory tract, 
whereas α2,3-linked galactose is restricted to the epithelium of the lower respiratory 
tract. This results in efficient replication of viruses with human-like but not avian-like 
receptor specificity in the epithelial cells of the upper respiratory tract (Van Poucke et 
al., 2010). This may at least partially explain the relatively high resistance of both 
pigs and humans to infection with AIVs such as the H5N1 subtype (Lipatov et al., 
2008). Ferrets, in contrast, are highly susceptible to H5N1 infections (Zitzow et al., 
2002). In ferrets, seasonal viruses predominantly replicate in the upper respiratory 
tract, and alveolar infection and pneumonitis are less pronounced (Maher & 
DeStefano, 2004; Smith & Sweet, 1988). Mice, on the other hand, are not natural 
hosts for influenza viruses and infection typically leads to lethal pulmonary infection 
(Bouvier & Lowen, 2010). Also, many clinical signs of influenza virus infection in 
humans are not present in mice (Bouvier & Lowen, 2010; Thangavel & Bouvier, 
2014). Furthermore, viruses generally require prior adaptation in order to achieve 
productive infection and clinically apparent signs of disease. The adapted virus may 
eventually become antigenically and/or phenotypically very different from the initial 
strain (Margine & Krammer, 2014). 
Although mice and ferrets have been most frequently used to study protective 
immunity against influenza, especially for human influenza vaccine evaluation, the 
limitations of those models are obvious (Table 2). The immune responses vary in 
different mouse strains (Srivastava et al., 2009), and protecting mice against 
influenza virus is much easier than natural influenza virus hosts like pigs (Dormitzer 
et al., 2011). The course of influenza virus infection and pathogenesis in ferrets 
closely resembles that in humans (Belser et al., 2011; Thangavel & Bouvier, 2014; 
van der Laan et al., 2008), but influenza seronegative ferrets are extremely difficult to 
obtain. Another limitation of the ferret model is the lack of specific reagents for 
studying the ferret immune system. The immune responses in pigs are remarkably 
similar to those in humans, and the cytokine profiles in BALF of SIV-infected pigs are 
also identical to those observed in nasal lavage fluids of experimentally infected 
humans (Hayden et al., 1998; Van Reeth et al., 1998). The advantage of pigs over 
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the ferret model is the availability of more immunological reagents and methods 
(Summerfield, 2009), including extensive information on swine leukocyte antigens. 
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1. Most, if not all swine influenza viruses (SIVs) of H3N2 subtype have derived their 
hemagglutinin (HA) and neuraminidase (NA) proteins from H3N2 viruses that 
once circulated in the human population. But after their transmission to and 
adaptation to swine, these viruses have followed distinct evolutionary pathways 
than their human precursors. The evolution of European H3N2 SIVs from 1984 to 
2002 has been described by de Jong et al (de Jong et al., 1999; de Jong et al., 
2007), but there is no information about the more recent viruses. We therefore 
aimed to characterize the genetic and antigenic evolution of European H3N2 SIVs 
isolated between 1998 and 2012, and to compare it with that of North American 
swine and human H3N2 viruses in the same time period.  
 
2. The genetic and antigenic properties of SIVs are distinct in different continents, 
and the introduction of a novel “exotic” SIV may pose a threat to swine 
populations. The H3N2 variant or H3N2v is a North American swine-origin virus, 
in which all but the M gene segments differ from those of European H3N2 SIVs. 
The virus is also of public health concern, because it has caused 343 zoonotic 
infections between 2011 and 2014. We have examined the extent of cross-
protection against this virus in pigs previously infected with the European H3N2 
SIV and the associated immune mechanisms.  
 
3. The 2009 pandemic H1N1 virus (pH1N1) has become established in swine shortly 
after the start of the 2009 pandemic and it is co-circulating with previously 
established SIVs in swine populations worldwide. We aimed to study the extent of 
cross-protection between different European SIV lineages, more specifically 1) 
between pH1N1 and three different European H1 SIV lineages, and 2) between 
these H1 viruses and a European H3N2 SIV. Because the pH1N1 is a shared 
virus between humans and swine, and pigs are a valuable animal model for 
human influenza, this study may give indications as to whether the high 
population immunity to pH1N1 in humans may offer some protection against 
infections with previously established SIVs. 
 
4. The pH1N1 virus contains the HA from the historical 1918 pandemic H1N1 virus, 
which has disappeared from the human population for decades. This virus has 
been maintained in the swine reservoir and it has ultimately reassorted with other 
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SIVs to give rise to the pH1N1 virus. H3N2 SIVs also contain historical human-like 
HAs and NAs, so that similar events could occur with these viruses in the future. 
Therefore, H3N2 viruses of swine have recently been added to the WHO 
pandemic preparedness list. The pandemic risk of H3N2 SIVs is determined in 
part by the extent to which pre-existing immunity to human seasonal H3N2 
viruses can cross-protect against H3N2 viruses of swine. We first used pigs as a 
model for humans to assess whether immunity resulting from infection with an old 
(1975) or a more recent (2005) human seasonal H3N2 virus protects against a 
European H3N2 SIV after experimental challenge. Subsequently, we have 
examined sera from people of various age categories for the prevalence of 
antibodies against European and North American swine-origin H3N2 viruses, as 
well as human seasonal H3N2 viruses of various decades. 
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3.1 Abstract 
Swine influenza viruses (SIVs) of H3N2 subtype have become established in 
European pigs since 1984, and they are double reassortants derived from human 
seasonal H3N2 viruses and European H1N1 SIVs. Analyses of European H3N2 SIVs 
during 1998-2012 revealed that their hemagglutinin (HA) and neuraminidase (NA) 
nucleotide sequences changed over time, but the amino acid sequences in antigenic 
regions remained largely conserved, especially the immunodominant sites. 
Consistent with the genetic evolution, antigenic analyzes using the hemagglutination-
inhibition (HI) assay and neuraminidase-inhibition (NI) assay show European H3N2 
SIVs have remained in antigenic stasis since 1998. We compared our data with the 
genetic and antigenic evolution of H3N2 viruses in North American swine and 
humans. 
 
3.2 Introduction 
Since the Hong Kong pandemic in 1968, the H3N2 pandemic virus and its 
descendants have not only been circulating in humans, but they were also isolated 
from pigs (Shortridge et al., 1979; Shortridge et al., 1977). In Europe, H3N2 viruses 
were occasionally isolated in pigs in 1970s (Tumova et al., 1980), but they have only 
become established in the mid 1980s after reassorting with endemic H1N1 swine 
influenza viruses (SIVs). Those established H3N2 SIVs contain human-like 
hemagglutinin (HA) and neuraminidase (NA) genes, whereas all internal genes are of 
avian-like H1N1 SIV origin (Campitelli et al., 1997; Castrucci et al., 1993). Genetic 
analysis of the HA1 segments reveals that those H3N2 SIVs are most related to 
human seasonal H3N2 viruses in 1973-75 (de Jong et al., 2007; Qiu et al., 2015; Qiu 
et al., 2013). Previous studies by de Jong et al report the occurrence of considerable 
antigenic drift in H3N2 SIVs (de Jong et al., 2007; de Jong et al., 1999). The authors 
also classified European H3N2 SIVs into cluster 1 viruses (1984-1993) and cluster 2 
viruses (1993-2002), with the latter showing reduced cross-reactivity with A/Port 
Chalmers/1/73 in the hemagglutination-inhibition (HI) assay. Based on these, the 
authors recommended a replacement of the A/Port Chalmers/1/73 strain in the SIV 
vaccine. Our previous study has shown a A/Port Chalmers/1/73-based commercial 
vaccine induced similar high HI antibody titers against European H3N2 SIVs from 
1998-2012 in pigs, which were 2- or 4- fold lower than the homologous A/Port 
Chalmers/1/73 titer (De Vleeschauwer et al., 2015). Those vaccinated pigs showed 
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significantly reduced lung virus titers after experimental challenge with a European 
H3N2 SIV sw/Gent/172/08. A similar strong protection induced by A/Port 
Chalmers/1/73-based commercial vaccine has also been observed after challenge of 
pigs with the earlier European H3N2 SIV strain sw/Fanders/1/98 or 
sw/Oedenrode/7C/96 (Heinen et al., 2001; Van Reeth et al., 2001). 
In North America, pigs were free of H3N2 viruses until 1998, when triple-reassortant 
H3N2 viruses containing gene segments from the classical swine virus (NP, M, NS), 
H3N2 human seasonal influenza virus (PB1, HA, NA) and avian influenza virus (PB2, 
PA) became successfully established in the pig population (Webby et al., 2000; Zhou 
et al., 1999). This genome composition of SIV is referred to as the triple-reassortant 
internal gene (TRIG) cassette (Vincent et al., 2008). Those TRIG H3N2 SIVs have 
been grouped into I-III clusters, as a result of three separate human seasonal H3 
gene introductions in 1995 (H3-I), 1997 (H3-II), and 1996 (H3-III), respectively 
(Webby et al., 2000). Low cross-reactivity was reported among clusters (Leuwerke et 
al., 2008; Richt et al., 2003). Swine H3 cluster IV evolved from cluster III and was first 
reported in 2005 (Olsen et al., 2006), but remained relatively stable until 2010 
(Kitikoon et al., 2013a). The introduction of the 2009 pandemic H1N1 virus (pH1N1) 
and reassortment with previously established SIVs including H3N2 altered both the 
genotype and phenotype of H3-IV viruses. At least 10 H3N2 genotype patterns have 
been identified in the United State (US) since August 2011 (Kitikoon et al., 2013b).  
In spite of H3N2 SIVs circulating in both Europe and North America have their HA 
derived from human seasonal H3N2 viruses, the HAs seem to drift more slowly in 
pigs than in humans. In North America, TRIG H3N2 SIVs have shown antigenic drift 
in HA during 1998-2013, albeit less intensive compared to their human counterparts 
(Lewis et al., 2014). The HA antigenic evolution of European H3N2 SIVs during 
1982-2002 occurred at a rate approximately six times slower than the rate in human 
viruses (de Jong et al., 2007). But knowledge about the more recent virus isolates 
after 2002 remains limited until the present study. Also, NA is another important 
antigenic determinant of influenza viruses besides HA, but antigenic characterization 
of NA is limited, especially in SIV research. In the present study, we aimed to 
investigate the genetic and antigenic evolution of both HA and NA from European 
H3N2 SIVs, and mainly focus on isolates in 1998-2012. We also aimed to compare 
such evolution with those of human seasonal and North American swine H3N2 
viruses, where possible. 
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3.3 Materials and methods 
Sequences of HA1 and NA genes of sw/Gent/1/84, and all available sequences in 
Genbank from European H3N2 SIVs during 1998-2012 were used for studying 
genetic evolution. To calculate the average rate of nucleotide substitutions in HA1 or 
NA, we measured the genetic distance in the Maximum-likelihood (ML) phylogenetic 
tree from sw/Gent/1/84 to each isolate. The sw/Gent/1/84 virus is one of the first 
human-like reassortant H3N2 SIVs isolated in Europe, and is assumed to be the 
ancestor virus for European H3N2 SIVs. In addition, we compared the HA1 and NA 
amino acid sequences of sw/Gent/1/84, commercial vaccine seed strains A/Port 
Chalmers/73, sw/Belgium/220/92, and sw/Bakum/1769/03,  and a selection of H3N2 
SIVs circulating from 1998 to 2012. Residue differences at putative antigenic sites of 
the HA1 and NA, as defined by others (Colman et al., 1983; Underwood, 1982; Wiley 
et al., 1981), were identified by alignment using MEGA 5.05 software 
(http://www.megasoftware.net/). 
To study the antigenic evolution of H3N2 SIVs, HI and neuraminidase-inhibition (NI) 
assays using hyperimmune or post-vaccination swine sera were performed as 
previously described (Sandbulte et al., 2009; Van Reeth et al., 2003). Hyperimmune 
swine sera were raised against each of 8 representative European H3N2 SIV isolates 
from different years. The pigs were inoculated intranasally with live influenza viruses, 
three weeks later they were injected intramuscularly (2 ml) and intradermally (1 ml) 
with the same virus in combination with complete Freund's adjuvant. Hyperimmune 
sera were collected when the homologous HI titer was ≥320. Post-vaccination sera 
were prepared in previous studies with commercial inactivated whole virus vaccines 
(De Vleeschauwer et al., 2015; Kyriakis et al., 2010). Sera were collected at two 
weeks after the booster vaccination. Antibody titers were expressed as the reciprocal 
of the highest serum dilution that showed complete inhibition of HA of 4 
hemagglutinating units of virus (HI assay), or 50% reduction of NA activity (NI assay). 
Starting dilutions were 1:10 in both assays.  
 
3.4 Results and discussions 
3.4.1 Genetic evolution 
The genetic evolution in terms of nucleotide substitutions of H3N2 SIVs seemed to 
have occurred at similar rates in HA1 and NA (Figure 1). At the nucleotide level, 
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H3N2 SIVs have evolved on average at a rate of change in ML distance of 0.0035 
and 0.0023 per year (~3.5 and 3.4 nucleotide substitutions per year) in HA1 and NA, 
respectively, from 1998 to 2012. Similar substitution rates of HA1 were observed in 
human and European swine H3N2 viruses during 1982-2002 (de Jong et al., 2007), 
as well as in human and North American swine H3N2 viruses during 1998-2012 
(Lewis et al., 2014).  
 
 
Figure 1. Rates of genetic evolution of hemagglutinin (A) and neuraminidase (B) of European 
H3N2 swine influenza viruses during 1998-2012. The genetic distance to the ancestor virus 
sw/Gent/1/84 was calculated from the maximum-likelihood phylogenetic tree, plotted as a function of 
time. The slope gives the rate of evolution of nucleotide substitutions per year. The regression lines for 
panels A and B had slopes of 0.0035 and 0.0023, respectively. 
 
Amino acid differences at presumed antigenic sites of the HA are shown in Figure 2. 
SIVs during 1998-2012 evolved to differ from the ancestral virus sw/Gent/1/84 by six 
amino acids in all five antigenic sites: 53, 137, 145, 217, 220 and 278. The 
sequences in immunodominant antigenic site A and B were almost identical in those 
SIVs. In contrast, during the same time period North American swine and human 
H3N2 viruses have obtained as many as 7 and 8 residue substitutions in sites A and 
B, respectively (Lewis et al., 2014). Those viruses also had close relatedness in the 
antigenic sites of the NA (data now shown). 
 
3.4.2 Antigenic evolution 
The antigenic evolution of H3N2 SIVs during 1998-2012 was characterized by cross-
HI and cross-NI assays (Table 1 and 2). Those viruses have shown similar strong 
cross-reactions to hyperimmune swine sera against sw/Gent/1/84 as well as to all 
three post-vaccination swine sera. This indicates little antigenic drift occurred in HA 
(A) HA (B) NA 
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or NA during virus evolution, and is in good agreement with the observed few 
changes in antigenic sites and with previous challenge studies (De Vleeschauwer et 
al., 2015; Heinen et al., 2001; Van Reeth et al., 2001), but it disagrees with the 
previous conclusion that H3N2 SIVs have experienced significant antigenic drift 
during 1982-2002 (de Jong et al., 2007; de Jong et al., 1999). However, their 
conclusion was challenged by the fact that in the same study, ferret anti-sera against 
A/Victoria/3/75, sw/Brisbane/1/84 or sw/Ommel/97 discriminated the two clusters less 
well as compared to anti-A/Port Chalmers/1/73 sera.  
During 1998-2012, North American H3N2 SIVs seemed to have experienced more 
antigenic drift in the HA1 than their European counterparts. As an illustration, 
Kitikoon et al have shown that hyperimmune swine sera against contemporary swine 
H3 isolates after 2010 had low cross-reactivity to the old cluster I virus 
(sw/Texas/4199-2/1998), older cluster IV isolates (sw/Minnesota/01146/2006) and 
inconsistent cross-reactivity among the recent isolates (Kitikoon et al., 2013b; Lewis 
et al., 2014). A similar comparison for the NA was not possible because the NA 
antigenic evolution of North American H3N2 SIVs has not been studied yet. Human 
seasonal  
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H3N2 viruses seemed to have the most prominent antigenic drift in HA1 compared to 
their European and North American swine counterparts, as human seasonal strains 
tend to have a significantly reduced or undetectable HI titer to a strain isolated 3-5 
years apart (Hay et al., 2001; Russell et al., 2008). A significant antigenic drift has 
also been observed in NAs of human seasonal H3N2 viruses. For example, 
Sandbulte et al used ferret post-infection antisera to study the NA antigenic evolution 
of human seasonal H3N2 viruses during 1968-2007 (Sandbulte et al., 2011). In that 
study, cross-NI reactions within human seasonal H3N2 viruses were asymmetrical: 
some antisera against old strains have lost cross-reactivity with more recent strains, 
whereas sera against more recent viruses often retained variable cross-reactivity with 
the old strains. 
The differences in the antigenic drift rates in the three H3N2 virus lineages may be 
due to a different host immune pressure. Seasonal influenza occurs globally with an 
annual attack rate estimated at 5%-10% in adults and 20%-30% in children 
(WHO). Human H3N2 viruses require frequent antigenic changes in the HA to ensure 
that a sufficiently large pool of immunologically susceptible hosts is available. In pigs, 
because of the short average life span (~ 6 months) and the continuous renewal of 
the pig population, influenza virus evolution may experience less immune pressure in 
pigs than in humans. But the vaccination coverage differences in European and 
North American population may have an impact on the different viral drift rates. It is 
reported in the US, 70% of large producers vaccinated breeding females and 
approximately 20% vaccinated weaned pigs in 2006 (Vincent et al., 2008). In 
Belgium, however, SIV vaccines are used in <20% of breeding females and rarely 
used for weaned pigs. Moreover, in contrast to Europe, live transport of millions of 
pigs is very common in swine farming in the US, which may promote the 
dissemination and evolution of SIVs (Nelson et al., 2015). Furthermore, the several 
separate introductions of the human-like H3 HAs into North American swine, and the 
frequent reassortment events between H3N2 SIVs and other influenza viruses may 
contribute to the more antigenic diversity of H3N2 SIVs in North America compared 
to that in Europe. 
 
3.4.3 Conclusions 
Taken together, we found that European H3N2 SIVs from 1998-2012 remained in an 
antigenic stasis and retained high relatedness to the prototype virus sw/Gent/1/84. 
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More significant antigenic drift has been observed in North American swine and 
human H3N2 viruses, even though the nucleotide substitution rates were similar in all 
three lineages. Based on our observation, we assume that there is not an urgent 
need for updating the H3N2 component in European swine influenza vaccine. 
However, like in the US, the epidemiology of European SIVs has become more 
complex after the establishment of pH1N1 in pigs, and reassortants between those 
two lineages have been isolated and some are now common in certain regions 
(Chiapponi et al., 2014; Simon et al., 2014). Genetic and antigenic characterization of 
those newly emerged reassortant H3N2 SIVs and surveillance should be continued 
to warrant a broad knowledge of H3N2 SIVs in Europe. 
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4.1.1 Abstract 
The swine-origin H3N2 variant (H3N2v) influenza viruses, which have infected 343 
humans in the United States (US) since August 2011, are genetically and 
antigenically distinct from the H3N2 swine influenza viruses (SIVs) circulating in 
Europe. Although the H3N2v virus has so far never been isolated in Europe, it may 
be introduced by export of pigs from the US to other continents. This study was 
designed to examine to what extent pigs previously infection with a European H3N2 
SIVs would be protected against a H3N2v challenge infection. Influenza naïve pigs 
were first inoculated intranasally with a European H3N2 SIV and 8 weeks later 
followed with a H3N2v virus. Infection with the European H3N2 SIV induced minimal 
H3N2v virus-neutralization (VN) antibodies, and no hemagglutination-inhibition (HI) 
and neuraminidase-inhibition (NI) antibodies in serum. Cross-reactive IgA and IgG 
antibody secreting cells (ASCs) and IFN-γ secreting cells (SCs) specific to H3N2v 
were demonstrated, especially in nasal mucosa. Upon H3N2v challenge, the 
magnitude and duration of virus excretion and virus titers in respiratory tissues at 
day 3 post-challenge were significantly reduced in European H3N2 SIV-inoculated 
pigs compared to previously uninoculated challenge control pigs. This protection was 
associated with vigorous IgG and IgA ASC boost responses to H3N2v, which were 
by far most pronounced in the nasal mucosa. Our data show partial protection 
between H3N2 viruses of two distinct lineages, and support the notion that the pig is 
a valuable model to study mucosal immune responses and to improve our 
understanding of broad-spectrum immunity to influenza. 
 
4.1.2 Introduction 
Both European and North American swine influenza viruses (SIVs) have their 
hemagglutin (HA) and neuraminidase (NA) derived from historical human seasonal 
H3N2 viruses, but their origin and genetic constellations are different. In Europe, 
H3N2 SIVs are derived from descendants of the A/Hong Kong/1/68 pandemic H3N2 
virus which crossed the species barrier to pigs in the 1970s, but they have evolved 
further through genetic reassortment with the endemic avian-like H1N1 SIV. This has 
resulted in H3N2 SIVs with human-like HA and NA genes and avian-like internal 
genes (Campitelli et al., 1997; Castrucci et al., 1993). In North America, H3N2 
viruses only appeared in swine since 1998. They are known as triple-reassortant 
viruses because their HA, NA and polymerase B1 genes are derived from human 
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seasonal H3N2 viruses from the 1990s, and the remaining internal genes are of 
avian influenza virus and classical H1N1 SIV origin (Webby et al., 2000). Since 2009, 
novel reassortant H3N2 viruses with variable numbers of internal genes derived from 
the 2009 pandemic H1N1 (pH1N1) virus have been reported frequently and this has 
further complicated the epidemiology of swine influenza in the US (Kitikoon et al., 
2013). In 2009-2012, these novel pH1N1 reassortants accounted for 54% of H3N2 
SIVs isolated (Kitikoon et al., 2013). Reassortant viruses with seven genes from the 
“triple-reassortant” H3N2 SIVs and only the matrix (M) gene from the pH1N1 virus 
have become one of the dominant genotypes (Kitikoon et al., 2013). These viruses, 
called “H3N2 variant” or “H3N2v” when isolated from humans, have caused 343 
human infections in the US from July 2011 through October 2014 
(http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm). This H3N2v virus and 
related North American H3N2 SIVs have not yet been isolated from Europe. This 
raises the question as to whether pigs immune to European H3N2 SIVs would be 
protected against infection with the antigenically and genetically distinct H3N2v if the 
latter virus was introduced in Europe.  
Infection with a live H1N1 or H3N2 influenza virus in pigs may provide potent and 
broad cross-protective immunity against another strain of the same HA and NA 
subtype (heterovariant protection), despite of the absence of cross-reactive 
hemagglutination-inhibition (HI) antibodies in serum. For example, pigs that had been 
previously infected with a historical human seasonal H3N2 virus in 1975 were 
completely protected against challenge infection with a European H3N2 SIV (Qiu et 
al., 2013). In similar experiments, a prior infection of European H1N1 SIV protected 
pigs against challenge with the pH1N1 (Busquets et al., 2010) or with a North 
American H1N1 SIV (De Vleeschauwer et al., 2011). Knowledge about what 
constitutes protective immunity in pigs is sparse, although there is some indication 
that the nasal wash IgA antibodies target to the challenge virus are more related to 
broaden immunity than serum IgG antibodies (Loving et al., 2013). In mice and 
humans, where immune mechanisms are much more extensively studied, IgA and 
IgG antibodies in the respiratory tract and interferon-γ (IFN-γ) responses contribute to 
the heterovariant protection against influenza (Clements et al., 1986; He et al., 2015; 
Liew et al., 1984; Renegar et al., 2004; Tamura et al., 2005; Wagner et al., 1987). 
Interestingly, the relative importance of each immune component in this process is 
controversial, and they seem to be partially redundant, since high degrees of 
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protection were also observed in B cell or IFN-γ deficient mice (Bot et al., 1998; 
Mozdzanowska et al., 2000). 
In pigs, HA-specific antibody responses in respiratory secretions, bronchoalveolar 
lavage fluid (BALF), and sera have been detected post SIV infection (Lee et al., 
1995). Larsen et al have used enzyme-linked immunosorbent spot (ELISpot) assays 
to demonstrate infection with SIV could induce virus-specific IgA and IgG antibody 
secreting cells (ASCs) in nasal mucosa that peaked on day 21 post inoculation with a 
North American H1N1 SIV (Larsen et al., 2000). In the same study, virus-specific 
IFN-γ secreting cells (ISCs) have been detected in spleen, tracheobronchial lymph 
nodes (TBLNs) and nasal mucosa by the ELISpot assay, which reached a peak on 
day 21 post-inoculation. However, how those antibodies, ASCs and ISCs are 
associated with cross-protection remains undefined. In this study, we aimed to 
investigate to what extent prior infection with a European H3N2 SIV confers 
protection against H3N2v challenge infection in pigs, as well as the nature of 
protective immunity. Cellular and humoral immune responses were examined 
systemically and at respiratory tract mucosal surfaces: antibody titers were measured 
in serum, nasal secretions and BALF by virus-neutralization (VN), or together with HI 
and neuraminidase-inhibition (NI) assays, and virus-specific IgG and IgA ASC as well 
as ISC responses in airway and peripheral blood were determined by ELISpot 
assays.  
 
4.1.3 Materials and methods 
4.1.3.1 Viruses 
Viruses used for pig inoculation were sw/Gent/172/08 (sw/Gent/08) and 
A/Indiana/08/11 (A/IN/11), which represent European H3N2 SIVs and North 
American H3N2v viruses, respectively. Those two viruses and 
sw/Wisconsin/H04YS2/04 (sw/WI/04) were included in in vitro immunological assays. 
The latter virus is a North American triple-reassortant H1N1 SIV, which has all the 
internal genes except M very similar to those of A/IN/11, and it was therefore used to 
estimate immune responses against the internal proteins of the H3N2v. Viruses used 
for pig inoculation were propagated in the allantoic cavity of 10-day-old embryonated 
chicken eggs (sw/Gent/08) or in  Madin-Darby canine kidney (MDCK) cells (A/IN/11) 
for ≤3 passages. Virus stocks used in immunological assays underwent one 
additional passage in eggs or MDCK cells.  
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4.1.3.2 Inoculation and challenge of pigs 
Thirty-five 5-week-old pigs were obtained from a conventional farm and were 
randomly assigned to three groups. All those pigs were confirmed to be seronegative 
to all endemic European SIVs by HI and VN assays prior to the experiment. Each 
group was housed in a separate biosafety level-2 HEPA-filtered isolation unit. After 
acclimation for 1 week, two groups were inoculated with sw/Gent/08 (n=12) or 
A/IN/11 (n=11), respectively. One group was left uninoculated and served as the 
challenge control group (n=12). Eight weeks later, all groups were challenged with 
A/IN/11. All inoculations were performed intranasally with 7.0 log10 50% tissue culture 
infectious doses (TCID50) influenza virus in 3 ml (1.5 ml per nostril) as described 
elsewhere. In each group, pigs were euthanized before the inoculation (n=4), and at 
3 and 7 dpc (n=3 or 4). 
 
4.1.3.3 Collection of samples 
To determine virus excretion, nasal swabs were collected daily from all pigs from 0-7 
days post-primary inoculation (dpi) and from 0-7 days post-challenge (dpc), or until 
euthanasia. Blood samples for serological examinations were collected from all pigs 
prior to the first inoculation and challenge. To determine virus replication in the 
respiratory tract, five samples (nasal mucosa olfactory part, tonsil, and trachea, the 
apical, cardiac, and diaphragmatic lobes of the left and right lung, and accessory lung) 
were collected separately for virus titration at necropsy. Gross lung lesions were 
scored by visual inspection. At necropsy, additional nasal swabs and BALF were 
collected to determine mucosal antibody titers to influenza viruses. BALF was 
obtained by lavaging the right lung with 200 ml of phosphate-buffered saline (PBS). 
Also, nasal mucosa respiratory part, TBLNs, and blood were collected for isolation of 
mononuclear cells (MNCs). 
 
4.1.3.4 Virus titration 
Cotton swabs were weighed before and after collection to determine virus titers per 
100 mg nasal secretions. Swabs from both nostrils were suspended in 1 ml sterile 
PBS supplemented with antibiotics. Tissues were weighed and homogenized in 
sterile PBS with antibiotics to obtain 20% (w/v) homogenates. Nasal swab specimens 
and tissue homogenates were titrated in MDCK cells as described elsewhere (Van 
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Reeth et al., 2003). Virus titers were expressed as log10 50% tissue culture infectious 
doses (TCID50) per 100 milligram (nasal swabs) or per gram (tissues).  
 
4.1.3.5 Serological assays 
Serum antibody responses were examined in HI, VN and NI assays, as described 
elsewhere (Leuwerke et al., 2008; Sandbulte et al., 2009; Van Reeth et al., 2003). All 
sera were examined against sw/Gent/08, A/IN/11, and sw/WI/04 in all three assays. 
Antibody titers were expressed as the reciprocal of the highest serum dilution that 
showed complete inhibition of HA of 4 hemagglutinating units (HAU) of virus (HI 
assay), 50% neutralization of 100 TCID50 of virus in MDCK cells (VN assay), or 
50% reduction of NA activity (NI assay). Nasal swabs and BALF collected at 
euthanasia were tested in VN assays against the challenge virus A/IN/11 only. 
Starting dilutions were 1:2 in the VN assay, and 1:10 in the HI and NI assays.  
 
4.1.3.6 Isolation of MNCs 
To obtain MNCs for analysis from the nasal mucosa, mucosal tissues were carefully 
peeled from the medial side of the ventral turbinates and from the nasal septum as 
described elsewhere (Larsen et al., 2000). Tissues were physically disrupted and 
digested with 1 mg/ml collagenase IV (Invitrogen) and 0.01 mg/ml DNase I (Roche) 
in RPMI-1640 (Gibco) supplemented with 5% fetal calf serum, 100 mg/ml of 
gentamicin, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 °C for 3-4 h. The 
supernatant of this digestion was filtered through a series of cell strainers at 70- and 
40-µm and washed twice with Dulbecco's Phosphate-Buffered Saline (Solarbio). The 
cell suspension was centrifuged over a discontinuous Percoll (GE Healthcare) 
density gradient (1.080 g/ml and 1.055 g/ml). TBLNs were mechanically disrupted 
through a 60-mesh tissue smashing screen (Sigma). The cell suspensions and 
peripheral blood were centrifuged over Ficoll-Paque Plus gradient (GE Healthcare, 
1.078 g/ml). Following Percoll or Ficoll-Paque Plus purification, cells at the interface 
were collected and washed twice in DPBS. Those purified MNCs were suspended in 
complete RPMI (RPMI 1640 enriched with 10% fetal bovine serum, 2 mM L-
glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 mg/ml of 
gentamicin, 100 U/ml penicillin and 100 mg/ml streptomycin). The viability of each 
MNC preparation was assessed by trypan blue staining and >95% of the cells were 
confirmed to be viable.  
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4.1.3.7 ELISpot assays for antibody secreting cells (ASCs) 
An ELISpot assay for IgG and IgA ASCs was performed as previously described 
(Kitikoon et al., 2014) with slight modifications. Briefly, 96-well membrane plates 
(MAIPS4510, Millipore) were prewetted with 70% ethanol, washed, and coated 
overnight at 4°C with 200 HAU of live purified influenza virus. Wells coated with 
purified sham MDCK medium served as negative controls. The next day, the plate 
was washed and blocked with complete RPMI for 2 h at 37°C. The blocking medium 
was removed, wells were incubated at 37°C and 5% CO2 for 18 h with 5 × 105, 5 × 
104, and 5 × 103 MNCs (each dilution in duplicate). After incubation, plates were 
washed and incubated with anti-porcine IgG or IgA monoclonal antibody for 2 h at 
37°C. Then, plates were washed and incubated with 0.5 µg/ml horseradish 
peroxidase-labeled (HRP) goat anti-mouse immunoglobulins (DAKO) for 1 h at 37°C. 
After washing, spots were developed using TMB Substrate System (Sigma). Plates 
were scanned and spots were enumerated using CTL-ImmunoSpot S5 UV analyzer 
and ImmunoSpot software.  
 
4.1.3.8 ELISpot assays for ISC 
An ELISpot assay for ISC was performed as previously described (Brockmeier et al., 
2012; Gorres et al., 2011) with slight modifications. Briefly, 96-well membrane plates 
(MAIPS4510, Millipore) were prewetted with 70% ethanol, washed, and coated 
overnight at 4°C with 6 µg/ml anti-porcine IFN-γ (P2G10; BD Biosciences). The next 
day, the plate was washed and blocked with complete RPMI for 2 h at 37°C. The 
blocking medium was removed, and 5 × 105 MNCs were seeded per well. Treatment 
preparations were added to appropriate wells (each treatment was carried out in 
duplicate), and the plates were incubated for 18 h at 37°C and 5% CO2. Treatments 
included live purified influenza virus at a multiplicity of infection (MOI) of 1, purified 
sham MDCK medium, or concanavalin A added at 5 µg/ml. After 18 h, plates were 
washed and incubated with 0.5 µg/ml anti-porcine IFN-γ detection antibody (P2C11; 
BD Biosciences) for 2 h at 37°C. Then, plates were washed and incubated with 0.5 
µg/ml streptavidin-HRP conjugate for 1 h at 37°C (Invitrogen). After washing, spots 
were developed using TMB Substrate System (Sigma). Plates were scanned and 
spots were enumerated using CTL-ImmunoSpot S5 UV analyzer and ImmunoSpot 
software.  
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4.1.3.9 Statistics 
Samples that tested negative for virus were given a numeric value of 1.6 log10 TCID50 
per 100 milligram (nasal swabs) or per gram (tissues). Samples that tested negative 
in the serological assays were assigned a value corresponding to half of the 
minimum detectable titer. Viral shedding of each virus was quantified by calculation 
of the area under the curve (AUC), which is obtained by plotting viral titers versus 
each time point of sample collection. Mann-Whitney U tests were used to compare 
antibody titers, virus titers in respiratory tissues, and numbers of ASC or ISC. P<0.05 
was considered statistically significant. 
 
4.1.4 Results 
4.1.4.1 Genetic relationship between viruses 
Percentages of amino acid identity between the HA1, NA, M, and NP of A/IN/11, 
sw/Gent/08 and WI/04 are summarized in Table 1. The two H3N2 viruses had an 
amino acid identity of 79.6% in HA1 and 82.5% in NA, with 18 and 20 amino acid 
differences in the respective H3 and N2 antigenic sites. As expected, the M protein of 
A/IN/11 was most similar to that of sw/Gent/08 (97.0% homology), whereas the NP 
protein of A/IN/11 was most related to that of WI/04 (98.6% homology). 
 
Table 1. Comparisons of genes of the H3N2v virus A/IN/11 used for challenge and sw/Gent/08 
(H3N2) and sw/WI/04 (H1N1) viruses 
 % identity* to A/IN/11 genes 
 HA1 NA M NP 
sw/Gent/08 79.6 82.5 97.0 93.2 
sw/WI/04 40.1 42.0 92.9 98.6 
*: % identity at the amino acid level. 
 
4.1.4.2 Virus replication in nasal swabs and respiratory tissues 
After the primary inoculation with A/IN/11 or sw/Gent/08, all pigs had high virus titers 
(up to 6.7 TCID50/100 mg) in nasal swabs for 5-6 days. Mean virus titers in nasal 
swabs of each group are shown in Figure 1. The average AUC was 24.5 for A/IN/11, 
and 23.7 for sw/Gent/08. The challenge control pigs tested virus-negative at all time 
points (AUC=0). After challenge with A/IN/11, all challenge controls shed high titers 
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of virus (up to 7.2 TCID50/100 mg) for 5-6 days, with an AUC of 24.1. Virus excretion 
was undetectable in the A/IN/11-A/IN/11 group (AUC=0) and significantly reduced in 
the sw/Gent/08-A/IN/11 group in both magnitude and duration (AUC=8.2). 
 
 
Figure 1. Nasal virus excretion after primary inoculation with sw/Gent/08 or A/IN/11 and after 
challenge with A/IN/11. Nasal swabs were collected daily from all pigs from 0-7 days post-primary 
inoculation (dpi) and from 0-7 days post-challenge (dpc), or until euthanasia. Mean virus titers in nasal 
swabs of each group are given. The horizontal broken line represents the detection limit (1.7 log10 
TCID50/100 mg). 
 
Tissues of the respiratory tract were negative for the challenge virus in all 3 groups 
at 0 and 7 dpc. At 3 dpc, virus titers were high in all 4 challenge control pigs and 
undetectable in A/IN/11-A/IN/11 pigs (Figure 2). Virus isolation rates and virus titers 
in all examined tissues were significantly reduced in sw/Gent/08-A/IN/11 pigs 
(p<0.05).  
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Figure 2. Virus titers in the respiratory tract 3 days after challenge with A/IN/11 in challenge 
controls and pigs previously infected with A/IN/11 or sw/Gent/08 virus. Four pigs were analyzed 
in each group and bars represent mean virus titers with standard deviation (SD). Numbers above the 
bars represent the number of positive pigs in each group. The horizontal broken line represents the 
detection limit (1.7 log10 TCID50/g). 
 
4.1.4.3 Serological profile before and after the primary inoculation 
All pigs were seronegative to A/IN/11, sw/Gent/08 and sw/WI/04 in all assays prior to 
the primary inoculation. Eight weeks after the primary inoculation with A/IN/11 or 
sw/Gent/08 (at the time of challenge), pigs had the highest antibody titers (p<0.05) to 
the homologous virus in all assays, and geometric mean titers (GMTs) are shown in 
Table 2. Cross-reactivity between both H3N2 viruses was minimal in the VN assay, 
and absent in HI and NI assays. The challenge controls remained seronegative to all 
three influenza viruses. 
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Table 2. Geometric mean antibody titers at 8 weeks after primary inoculation in 
hemagglutination-inhibition (HI), virus-neutralization (VN), and neuraminidase-inhibition (NI) 
assays 
Groups 
No. of 
pigs 
Antibody titer against 
A/IN/11  sw/Gent/08  sw/WI/04 
HI VN NI  HI VN NI  HI VN NI 
A/IN/11-A/IN/11 11 75 466 75  <10 5 <10  <10 <2 <10 
sw/Gent/08-A/IN/11 12 <10 7 <10  30 204 202  <10 <2 <10 
A/IN/11 challenge control 12 <10 <2 <10  <10 <2 <10  <10 <2 <10 
Abbreviations: A/IN/11, A/Indiana/08/11 (H3N2 variant); sw/Gent/08: sw/Gent/172/08 (H3N2 SIV); sw/WI/04: sw/Wisconsin/2004 
(H1N1 SIV). 
 
4.1.4.4 VN antibodies to the challenge virus in serum, nasal swabs, and BALF 
before and after A/IN/11 challenge 
At the time of challenge, VN antibodies to the A/IN/11 challenge virus were detected 
in serum, nasal swabs, and BALF of A/IN/11-A/IN/11 pigs (Figure 3). Minimal 
antibody titers were found in sw/Gent/08-A/IN/11 pigs, in serum only. After challenge 
with A/IN/11, VN antibodies to the challenge virus were for the first time detected in 
challenge controls in serum, nasal swabs and BALF at 7 dpc, while such antibodies 
remained at pre-challenge level in A/IN/11-A/IN/11 pigs in all tissue samples (p>0.05). 
The sw/Gent/08-A/IN/11 pigs developed or had an increase in VN antibodies to 
A/IN/11, titers in serum and nasal swabs were higher than those in both other groups 
(p<0.05). 
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Figure 3. Virus-neutralizing (VN) antibody titers against the challenge virus A/IN/11 in serum, 
bronchoalveolar lavage fluid (BALF), and nasal swabs in pigs euthanized at 0, 3 and 7 days 
post challenge. Bars represent geometric mean VN antibody titers with standard deviation (4 pigs per 
group at each time point, except for the A/IN/11-A/IN/11 group at 7 dpc [n=3]); the horizontal broken 
line represents the detection limit (2); * p<0.05. 
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4.1.4.5 Influenza virus specific ASC responses 
At the time of challenge, all challenge control pigs had undetectable influenza virus-
specific IgA and IgG ASC in nasal mucosa, TBLN and blood (Figure 4, 5 and 6). In 
contrast, pigs inoculated with sw/Gent/08 or A/IN/11 showed IgA and IgG ASC 
responses against all three viruses, predominantly in nasal mucosa. Cross-reaction 
was stronger between the two H3N2 viruses than between H3N2 and H1N1 viruses. 
Responses to IN/11 in respect of IgG ASCs were significantly higher in the A/IN/11- 
than sw/Gent/08-inoculated group (40 and 4 ASCs per 106 MNCs, respectively; 
p<0.05) (Figure 4), whereas IN/11-specific IgA ASC responses were similar in both 
groups (81 and 23 ASCs per 106 MNCs, respectively; p>0.05).  
After challenge with A/IN/11, IgA and IgG ASC responses to the challenge virus were 
detected in challenge control pigs at 7 dpc, mainly in peripheral blood (11 IgA and 
115 IgG ASC per 106 MNCs) and only few in nasal mucosa. This was in contrast with 
the more substantial ASC responses in nasal mucosa in the other two groups. In 
nasal mucosa, IgA and IgG ASCs specific to IN/11 showed minimal increases in the 
A/IN/11-A/IN/11 pigs post-challenge. In contrast, the sw/Gent/08-A/IN/11 group 
exhibited a 20-fold increase in IgA and a 200-fold increase in IgG ASC responses to 
A/IN/11 at 7 dpc (476 IgA and 789 IgG ASC per 106 MNCs). Meanwhile, IgA and IgG 
ASC responses to sw/Gent/08 and sw/WI/04 increased to similar levels as those to 
A/IN/11 (p>0.05), which were significantly greater than those in both other groups 
(p<0.05). 
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Figure 4. Kinetics of IgA and IgG antibody and IFN-γ secreting cell responses specific to 
A/IN/11, sw/Gent/08 and sw/WI/04 before and after challenge with A/IN/11 in nasal mucosa (4 
pigs per group at each time point, except for the A/IN/11- A/IN/11 group at 7 dpc [n=3]). The dots 
and triangles represent individual pigs; the horizontal line represents the group geometric mean. ASCs: 
antibody secreting cells; SC: secreting cells. 
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Figure 5. Kinetics of IgA and IgG antibody and IFN-γ secreting cell responses specific to 
A/IN/11, sw/Gent/08 and sw/WI/04 before and after challenge with A/IN/11 in tracheobronchial 
lymph nodes (4 pigs per group at each time point, except for the A/IN/11- A/IN/11 group at 7 dpc 
[n=3]). The dots and triangles represent individual pigs; the horizontal line represents the group 
geometric mean. ASCs: antibody secreting cells; SC: secreting cells. 
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Figure 6. Kinetics of IgA and IgG antibody and IFN-γ secreting cell responses specific to 
A/IN/11, sw/Gent/08 and sw/WI/04 before and after challenge with A/IN/11 in peripheral blood (4 
pigs per group at each time point, except for the A/IN/11- A/IN/11 group at 7 dpc [n=3]). The dots 
and triangles represent individual pigs; the horizontal line represents the group geometric mean. ASCs: 
antibody secreting cells; SC: secreting cells. 
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4.1.4.6 Influenza virus specific IFN-γ responses 
At the time of challenge, challenge control pigs had few influenza virus-specific ISCs 
(≤2 per 106 MNCs) in nasal mucosa, TBLN and blood (Figure 4, 5 and 6). In contrast, 
sw/Gent/08- and A/IN/11-inoculated pigs had ISC responses to all three viruses, 
which were at similar levels (p>0.05) and predominantly in nasal mucosa. Numbers 
of A/IN/11-specific ISC in nasal mucosa were similar between A/IN/11- and 
sw/Gent/08-inoculated pigs (234 and 131 ISCs per 106 MNCs, respectively; p>0.05) 
(Figure 4).  
After challenge with A/IN/11, A/IN/11-specific ISC responses were induced in 
challenge control pigs in nasal mucosa, TBLN, and most in peripheral blood at 7 dpc 
(113, 47 and 328 ISCs per 106 MNCs, respectively). The A/IN/11-A/IN/11 pigs 
showed a mild increase in ISCs specific to A/IN/11 at 7 dpc, especially in the nasal 
mucosa and peripheral blood (799 and 154 ISCs per 106 MNCs, respectively). 
Meanwhile, ISCs to sw/Gent/08 and sw/WI/04 also increased to similar levels as 
those to A/IN/11 (p>0.05). ISC responses to all three viruses remained at pre-
challenge level in sw/Gent/08-A/IN/11 pigs (p>0.05).  
  
4.1.5 Discussion 
Pigs previously infected with a European H3N2 SIV were partially protected against a 
North American H3N2v, as shown by reduced virus titers in nasal swabs and 
respiratory tissues post-challenge. Both swine-origin H3N2 viruses have their HA and 
NA genes originate from historical human seasonal H3N2 viruses from different 
decades, and they are genetically and antigenically distinct from one another. There 
was approximately 80% amino acid identity between their HAs and NAs, no 
detectable cross-reactivity in HI and NI assays and minimal cross-reactivity in the VN 
assay. A similar significant reduction in the magnitude and duration of nasal virus 
shedding of A/IN/11 was observed in ferrets pre-infected with a recent human 
seasonal H3N2 virus A/Perth/16/2009 (Houser et al., 2013). The two viruses had 
86% amino acid identity in their HA1 segments, and cross-reactivity was 
undetectable in HI assays with ferret post-infection sera. Yet, a complete cross-
protection can occur between H3N2 viruses with greater genetic relatedness, as 
between sw/Gent/08 and a historical human seasonal H3N2 virus A/Victoria/3/75 that 
have their HAs and NAs of the same origin (Qiu et al., 2013). The rapid viral 
clearance in sw/Gent/08-inoculated pigs after A/IN/11 challenge correlated well with 
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the higher A/IN/11-specific VN antibody titers in serum and nasal swabs, and the 
higher A/IN/11-specific IgA and IgG ASC responses in nasal mucosa at 7 dpc than 
those in challenge controls. The ASC responses appear to target at least in part the 
viral internal proteins, as the response to H1N1 SIV showed a parallel albeit lower 
increase after challenge in sw/Gent/08-inoculated pigs. Our results are in agreement 
with a previous report in which infection with pH1N1 primed for memory B cell 
responses in human nasal-associated lymphoid tissues, which produce cross-
reactive antibodies to human seasonal H1N1 viruses as well as avian H5N1 viruses 
(Mahallawi et al., 2013). In the present study, ISC responses, which target the 
conserved epitopes in surface and internal proteins, showed a higher level of cross-
reactivity among all three viruses than ASC responses, since similar recall responses 
were obtained after the primary infection against all three viruses. However, virus-
specific ISC responses did not increase after the heterovariant virus challenge. This 
points towards a more significant role of antibody-mediated immunity and is in line 
with a study in the mouse model. In the latter study, seasonal H1N1 influenza virus 
infection induced cross-protective immunity to the pH1N1 virus through a CD8+ T 
cell-independent, B cell-dependent mechanism (Fang et al., 2012). On the other 
hand, protection against the homologous A/IN/11 virus in our study was associated 
with an anamnestic response of virus-specific ISC in the nasal mucosa 7 dpc, 
suggesting a T cell memory response, whereas an increase in IgA ASC in nasal 
mucosa 3 dpc suggested a memory response but this could not be confirmed 7 dpc. 
Nevertheless VN antibodies were present in these pigs at re-infection, so that 
immune complexes will have been formed. It is well-known that antigen complexed 
with IgG is much more efficient in inducing CD4+ T cell responses than soluble 
antigen (de Jong et al., 2006), whereas suppression of antibody responses has been 
described for particulate antigen, most likely by B cell epitope masking (Hjelm et al., 
2006). In a previous study re-infection of pigs with the same homologous SIV also 
resulted in increased virus-specific ISC responses in nasal mucosa, TBLN and 
spleen at 14 dpc, but minimal increases in virus-specific IgG and IgA ASC responses 
(Larsen et al., 2000).  
Our study is in agreement with the previous mentioned study that demonstrates the 
nasal mucosa is the predominant site of both IgG and IgA ASCs after SIV infection 
(Larsen et al., 2000). The locally produced antibodies may directly contribute to the 
protection in the upper respiratory tract. Indeed, the sw/Gent/08-A/IN/11 pigs had 
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highest A/IN/11-specific VN antibody titers in nasal swabs but similar titers in BALF 
compared to the other two groups at 7 dpc, suggesting A/IN/11-specific VN 
antibodies in nasal swabs were at least partially locally produced. The highest post-
challenge VN antibody titers against A/IN/11 were found in serum, which may be due 
to the fact that nasal swabs and BALF samples are much more diluted than serum 
samples during sample collection and processing. In spite of the local immunity in 
nasal mucosa, the challenge virus was found to replicate mainly in the upper 
respiratory tract of the sw/Gent/08-A/IN/11 pigs, while it was largely undetectable in 
the lungs. Although not examined in this study, studies in mice suggest the strong 
virological protection in the lungs may be associated with influenza virus-specific 
ASCs located in the lung parenchyma (Baumgarth & Kelso, 1996; Jones & Ada, 
1987). In addition, systemic IgG antibodies can much more easily transudate into 
alveolar epithelia than to the nasal mucosa (Renegar et al., 2004; Rudin et al., 1999), 
and they may reduce virus replication in the lung. Our study also shows nasal 
mucosa is the predominant site of ISCs, which does not agree with the previous 
report that shows ISC responses were detected predominantly in the TBLN and 
spleen after intranasal inoculation with a H1N1 SIV  (Larsen et al., 2000). We did not 
include spleen for ELISpot analysis, but we found the ISCs in nasal mucosa induced 
by infection with either sw/Gent/08 or A/IN/11 were almost 20-fold more than those in 
Larsen’s study at 42 dpi. 
Our study in pigs is in agreement with the observation in humans that pre-existing 
infection-immunity can offer significant protection against an antigenically distinct 
strain within the same subtype, though infection is not completely prevented. As an 
example, young adults and children with substantial antibody and CMI responses to 
contemporary seasonal H1N1 viruses in 2000s were still infected by the pH1N1 virus 
(Skowronski et al., 2011). In contrast, protecting mice against influenza virus is very 
easy (Dormitzer et al., 2011). Our study suggest pigs may serve as a valuable model 
to study protective immunity against influenza. Pigs are the natural hosts for 
influenza viruses and they are readily susceptible to a variety of human influenza A 
viruses without prior adaption. The pathogenesis of influenza is remarkably similar in 
pigs and in humans, and there are also striking similarities in their immune responses 
(Khatri et al., 2010; Van Reeth et al., 2012). Both IgG and IgA antibodies in nasal 
secretions have been correlated with protection against influenza in humans (Boyce 
et al., 1999; Clements et al., 1986; Clements et al., 1983). The nasal associated 
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lymphoid tissues are considered to be important induction sites for both mucosal and 
systemic immunity to influenza viruses in humans and pigs (Wiley et al., 2001; 
Zuercher et al., 2002), but it is usually very difficult to obtain those tissues from 
humans. Unlike ferrets and mice, the large size of respiratory tissues as well as the 
availability of various immunological reagents allows using pigs to study the mucosal 
and cellular immune responses against influenza. 
In summary, our study has shown prior infection with an H3N2 influenza virus failed 
to prevent the challenge infection of a genetically and antigenically distinct strain in 
pigs, but virus replication in both upper and lower respiratory tract was reduced. This 
heterovariant protection was associated with substantial IgA and IgG ASC boost 
responses in nasal mucosa. The pig can serve as a valuable model to study human 
mucosal immune responses and to improve our understanding of broad-spectrum 
immunity to influenza. 
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4.2.1 Abstract 
Pigs are natural hosts for the same influenza virus subtypes as humans and are a 
valuable model for cross-protection studies with influenza. In this study we have used 
the pig model to examine the extent of virological protection between a) the 2009 
pandemic H1N1 (pH1N1) virus and three different European H1 swine influenza virus 
(SIV) lineages, and b) these H1 viruses and a European H3N2 SIV. Pigs were 
inoculated intranasally with representative strains of each virus lineage with 6- and 
17-week intervals between H1 inoculations and between H1 and H3 inoculations, 
respectively. Virus titers in nasal swabs and/or tissues of the respiratory tract were 
determined after each inoculation. There was substantial though differing cross-
protection between pH1N1 and other H1 viruses, which was directly correlated with 
the relatedness in the viral hemagglutinin (HA) and neuraminidase (NA) proteins. 
Cross-protection against H3N2 was almost complete in pigs with immunity to H1N2, 
but was weak in H1N1/pH1N1-immune pigs. In conclusion, post-infection immunity 
may offer substantial cross-lineage protection against viruses of the same HA and/or 
NA subtype. True heterosubtypic protection, in contrast, appears to be minimal in 
natural influenza virus hosts. We discuss our findings in the light of the zoonotic and 
pandemic risks of SIVs. 
 
4.2.2 Introduction 
Swine influenza viruses (SIVs) are important for the swine industry and as zoonotic 
agents. Moreover, they can lead to the emergence of novel pandemic influenza 
viruses for humans. In Europe, four lineages of SIV are enzootic in swine populations. 
An H1N1 virus of wholly avian origin became established in European swine in 1979 
(Pensaert et al., 1981). In the mid 1980s, this H1N1 virus reassorted with 
descendants of the 1968 Hong Kong human pandemic H3N2 virus (Campitelli et al., 
1997; Castrucci et al., 1993). The resulting H3N2 SIV lineage has human-like 
hemagglutinin (HA) and neuraminidase (NA) genes and avian-like internal genes. 
The third lineage, H1N2, was first reported in 1994, and is a reassortant virus that 
retained most of the genotype of the H3N2 viruses, but has acquired an H1 gene 
from human seasonal viruses from the 1980s (Brown et al., 1998; Van Reeth et al., 
2000). The 2009 pandemic H1N1 (pH1N1) virus is a reassortant with the NA and 
matrix (M) genes derived from the European avian-like H1N1 SIV and the remaining 
genes from North American triple-reassortant H1 SIVs (Garten et al., 2009). The 
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pH1N1 virus was first detected in humans in April 2009 and only later in swine, but it 
has become widespread in swine worldwide due to large-scale reverse zoonotic 
transmissions (Nelson & Vincent, 2015). Thus, while all four SIV lineages have a 
distinct HA and/or NA, the pH1N1 also has a different set of internal genes compared 
to the three previously established SIVs. A growing number of reassortants between 
these four lineages has been reported in recent years, especially between pH1N1 
and previously established SIVs (Simon et al., 2014).  
The increasing number of H1 SIV lineages in Europe and other continents, and the 
geographic differences in the prevailing lineages have spurred interest in the extent 
of cross-protection between them. Prior infection with a European avian-like H1N1 
SIV largely protects against subsequent infection with the pH1N1 (Busquets et al., 
2010), or with a North American triple-reassortant H1N1 SIV (De Vleeschauwer et al., 
2011), despite the absence of cross-reactive serum hemagglutination-inhibition (HI) 
antibodies against the challenge virus. It remains unknown to what extent prior 
infection with pH1N1 offers protection against the previously established European 
H1 SIVs. This question is also of public health concern as the global spread of 
pH1N1 may generate cross-reactive immunity to some H1 SIVs in the human 
population, making them less likely candidates for future pandemics.  
Apart from cross-protection between variants of the same HA subtype, cross-
protection between viruses of different HA subtypes (heterosubtypic protection) has 
also been described. Heterosubtypic protection has been repeatedly shown in 
rodents and ferrets (Kreijtz et al., 2007; Laurie et al., 2010; Liang et al., 1994; 
Straight et al., 2006; Yetter et al., 1980), but only rarely in natural hosts of influenza. 
In an experimental pig infection study with European SIVs, only one out of five H1N1-
immune pigs tested positive for the H3N2 challenge virus in oropharyngeal swabs, 
for 1 day only. However, challenge control pigs in that study also had minimal virus 
titers in oropharyngeal swabs, and nasal swabs or tissues of the respiratory tract 
were not examined (Heinen et al., 2001). Epidemiological data support the existence 
of heterosubtypic immunity in humans that were exposed simultaneously or 
consecutively to epidemic human seasonal H1N1 and H3N2 viruses (Lavenu et al., 
2004; Sonoguchi et al., 1985). Also, the 1957 pandemic H2N2 virus appeared to 
have a lower disease incidence in adults previously infected with an H1N1 virus 
(Epstein, 2006). Yet, the significance and importance of heterosubtypic immunity in 
natural influenza virus hosts remain unclear. In this study, we sought to study cross-
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protection between a) pH1N1 and various H1 SIVs, and b) these distinct H1 SIVs 
and H3N2. We use the pig as a natural host for SIVs and a model for influenza in 
humans. 
 
4.2.3 Material and methods 
4.2.3.1 Viruses and their genetic and antigenic relationships 
Viruses for pig inoculation were propagated in embryonated chicken eggs and used 
at the third or fourth passage. Their genetic constellations are shown in Figure 1. 
A/California/04/09 is a representative pH1N1, while sw/Gent/28/10 (H1N1), 
sw/Gent/26/12 (H1N2) and sw/Gent/172/08 (H3N2) are representative for SIVs that 
are enzootic in Western Europe. Sw/Cotes d'Armor/0046/08 is an occasionally 
reported reassortant H1N1 (rH1N1) SIV with the H1 derived from the European 
H1N2 SIV lineage and the N1 from the European H1N1 lineage (Kyriakis et al., 2011).  
The sequences of the HA1 and NA segments of the 5 viruses were available in 
GenBank (accession numbers FN646093, FN646099, KC142127, KC142128 and 
KP406524-KP406529). The HA1 and NA segments were compared at the amino 
acid level using the MEGALIGN program (DNASTAR, Madison, WI, USA). Amino 
acid differences at putative antigenic sites of the H1 and N2 proteins, as defined 
previously (Brownlee & Fodor, 2001; Colman et al., 1983), were identified by 
alignment using MEGA5 software (Brownlee & Fodor, 2001; Colman et al., 1983). 
Antigenic characterization of the 5 viruses was performed by HI, virus-neutralization 
(VN) and neuraminidase-inhibition (NI) assays, using pig sera collected at 2 weeks 
after inoculation with each individual virus. 
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Figure 1. Genetic constellations of the 5 viruses used in this study. Abbreviations: PB2, 
polymerase basic 2; PB1, polymerase basic 1; PA, polymerase acidic; HA, hemagglutinin; NP, 
nucleoprotein; NA, neuraminidase; M, matrix; NS, nonstructural; TRIG, triple-reassortant internal 
genes, which derived from swine (M, NS and NP), human (PB1) and avian (PB2 and PA) influenza 
viruses forming a constellation of genes that is well conserved in North American swine influenza 
viruses. 
 
4.2.3.2 Experimental design 
Forty 6-week-old pigs from an influenza negative farm were randomly assigned to 8 
groups (n=5) as shown in Table 1. Each group was housed in a separate biosafety 
level-2 HEPA-filtered isolation unit. All experiments were authorized by the Ethical 
and Animal Welfare Committee of the Faculty of Veterinary Medicine, Ghent 
University. Virus inoculations of pigs were performed intranasally, using 7.0 log10 
50% egg infectious doses (EID50) of the respective viruses in 3 ml (1.5 ml per nostril). 
Pigs were unanesthetized and held in a vertical position with the neck stretched. The 
inoculum was instilled into the middle nasal cavity by insertion of a 15-mm plastic 
cannula attached to a 5-ml syringe. 
The first experiment was designed to examine whether infection-immunity to pH1N1 
offers protection against infection with European H1 SIVs (Table 1). Four groups of 
pigs (A, B, C and D) were inoculated with pH1N1 virus, and the remaining four 
groups (E, F, G and H) were mock-inoculated with phosphate-buffered saline (PBS). 
Six weeks later, the pH1N1-immune pigs were challenged with the same pH1N1 
virus (group A), or with one of three European H1 SIVs: H1N1 (group B), rH1N1 
(group C), or H1N2 (group D). Three groups of influenza naïve pigs served as H1N1 
Cross-protection between pH1N1 and SIVs 
101 
(group E), rH1N1 (group F), and H1N2 (group G) challenge control groups. Group H 
was inoculated again with PBS. To determine virus excretion, nasal swabs for virus 
titration were collected daily from all pigs from 0-8 days post-primary inoculation (dpi) 
and 0-7 days post-challenge (dpc). Blood samples for serology were collected at 0 
and 14 dpi, and at 0, 5, 7, 10 and 14 dpc. 
The second experiment aimed at studying the heterosubtypic protection between H1 
and H3 viruses (Table 1). Six groups from the first experiment (A, B, D, E, G and H) 
were challenged with H3N2, 17 weeks after the previous virus inoculation. Nasal 
swabs for virus titration were collected daily from all pigs from 0-7 dpc, or until 
euthanasia. Two pigs per group were euthanized at 4 dpc to examine virus titers of 
the entire respiratory tract: nasal mucosa respiratory and olfactory regions, tonsil, 
trachea, apical, cardiac, and diaphragmatic lobes of the left and right lungs, and the 
accessory lung lobe. Each tissue sample was collected and titrated separately. Blood 
samples for serology were collected at 0 and 14 dpc. 
 
Table 1. Experimental design 
 Viruses used for inoculation  
 Experiment 1  Experiment 2  
Group 7 weeksa  13 weeksa  30 weeksa  
A pH1N1  pH1N1  H3N2  
B pH1N1  H1N1  H3N2  
C pH1N1  rH1N1  -  
D pH1N1  H1N2  H3N2  
E PBS  H1N1  H3N2  
F PBS  rH1N1  -  
G PBS  H1N2  H3N2  
H PBS  PBS  H3N2  
a The age of pigs at the time of virus inoculation. 
 
4.2.3.3 Virus titration 
Sterile nasal swabs (Copan 160C, Copan Italia S.p.A.) were weighed before and 
after collection to determine virus titers per 100 mg nasal secretions. Swabs from 
both nostrils were suspended in 1 ml sterile PBS supplemented with antibiotics. 
Tissues were weighed and homogenized in sterile PBS with antibiotics to obtain 20% 
(w/v) homogenates. Nasal swab specimens and tissue homogenates were titrated in 
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Madin-Darby canine kidney (MDCK) cells by the 50% tissue culture infectious doses 
(TCID50) assay as described elsewhere (Qiu et al., 2013).  
 
4.2.3.4 Serological assays 
Serum antibody responses were examined in HI, VN and NI assays, as described 
elsewhere (Sandbulte et al., 2009; Van Reeth et al., 2003). All sera collected before 
and at 2 weeks after each inoculation were examined against all 5 viruses in all 3 
assays. At 5, 7 and 10 days after challenge with H1 viruses, additional VN assays 
against the respective challenge viruses were performed. Antibody titers were 
expressed as the reciprocal of the highest serum dilution that showed complete 
inhibition of HA of 4 hemagglutinating units of virus (HI assay), 50% neutralization of 
100 TCID50 of virus in MDCK cells (VN assay), or 50% reduction of NA activity (NI 
assay). Starting dilutions were 1:2 in the VN assay, and 1:10 in HI and NI assays.  
 
4.2.3.5 Statistics 
Nasal virus shedding in each group was quantified by calculation of the area under 
the curve (AUC), which is obtained by plotting viral titers versus each time point of 
sample collection. Mann-Whitney tests were used to compare antibody levels 
between any two experimental groups, and before and after inoculation in each 
group. Differences were considered significant when p < 0.05. GraphPad Prism5 
software (GraphPad Software, San Diego, CA, USA) was used for all statistical 
analyses.  
 
4.2.4 Results 
4.2.4.1 Genetic and antigenic relationships between pH1N1 and European SIVs 
Genetic and antigenic relationships between pH1N1 and European SIVs 
Genetic relationships between viruses were assessed by comparison of the percent 
amino acid homology in the HA1 and NA sequences (Table 2). Antigenic 
relationships between viruses were examined in cross-HI, VN and NI assays, using 
monospecific pig sera (Table 3). The rH1N1 and H1N2 viruses showed 90% amino 
acid sequence identity in their HA1 and cross-reactivity in HI and VN assays, 
reflecting the same human-like HA lineages of the two viruses. The HA1 of H1N1, 
rH1N1 and H1N2 had a similar homology (71-73%) to the classical H1 of pH1N1. 
Alignment of HA1 antigenic sites of pH1N1 with those of H1N1, rH1N1 and H1N2 
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revealed 17, 26 and 27 amino acid differences, respectively. Cross-reactivity 
between pH1N1 and other European H1 SIVs was absent in the HI assay, and rare 
in the VN assay. H3N2 failed to cross-react with any H1 viruses in HI and VN assays. 
The H1N1 and rH1N1 showed 97% amino acid identity in their NA, and were closely 
related to the NA of pH1N1 (91% identity), reflecting the same avian-like N1 lineage 
of the three viruses. The human-like NAs of H1N2 and H3N2 had 84% amino acid 
identity and 10 residue differences in antigenic sites. Consistent with the genetic 
relatedness, cross-reactivity in the NI assay was observed between viruses with the 
same avian-like N1 or human-like N2 lineage. 
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4.2.4.2 protection against challenge with various European H1 SIVs in pigs with 
infection-immunity to pH1N1  
After primary inoculation with pH1N1, pigs from groups A, B, C and D had similar 
mean AUC values (range from 24.9-27.4) and nasal shedding during 6-7 days. The 
mock-inoculated pigs tested negative for virus at all time points.  
Figure 2A shows mean virus titers in nasal swabs after challenge with pH1N1, H1N1, 
rH1N1 or H1N2. The respective challenge control groups (E, F and G) excreted high 
titers of the challenge viruses for 5-6 days (mean AUC=23.7, 25.1 and 23.6, 
respectively). In contrast, pH1N1-immune pigs showed complete protection (AUC=0) 
against challenge with the homologous virus (group A) or with H1N1 (group B), and a 
almost complete protection against challenge with rH1N1 (group C) (mean AUC=0.1). 
Virus excretion was detectable in three out of five pigs, for one day only and at 
minimal virus titers. A slightly weaker protection was observed after challenge with 
H1N2 (group D): four out of five pigs had virus shedding for 1-3 days (mean 
AUC=2.1).  
Prior to the start of the experiment, pigs were seronegative against all tested 
influenza viruses in HI, VN and NI assays. At 2 weeks after primary inoculation with 
pH1N1, pigs from groups A, B, C and D had similar antibody titers (p > 0.05) to the 
homologous virus in all assays. The geometric mean titers (GMTs) are shown in 
Table 3. At 6 weeks post-inoculation (time of challenge with various H1 viruses), the 
HI, VN and NI GMTs to pH1N1 were 39, 106 and 260, respectively. Cross-reactive 
antibodies against H1N1, rH1N1 and H1N2 were undetectable in all pH1N1-immune 
pigs in the HI assay, but most pigs had low cross-reactive VN titers. Higher cross-
reactive NI titers were detected to H1N1 (GMT 36) than to rH1N1 (GMT 17) (p < 
0.05). The challenge control pigs (groups E, F and G) were still seronegative at the 
time of challenge with various H1 viruses, but had developed HI, VN and NI 
antibodies against the respective challenge virus at 14 days post challenge (Table 3).  
Figure 2B illustrates the more rapid development of VN antibodies against the 
challenge virus in challenge control pigs than in pH1N1-immune pigs. Anti-pH1N1 
antibody titers remained at pre-challenge levels in group A, B and C in all assays (p > 
0.05), but increased significantly in group D in HI and VN assays (p < 0.05). 
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Figure 2. Virus titers in nasal swabs (A) and virus-neutralizing (VN) antibody titers in serum (B) 
after H1 virus challenge. Horizontal dotted lines represent the detection limit of the assay: 1.7 log10 
TCID50 for virus titration, 2 for the VN assay. * p < 0.05 and ** p < 0.01, by the Mann-Whitney test.  
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4.2.4.3 protection against challenge with a European H3N2 SIV in pigs with 
infection-immunity to various H1 virus(es)  
Figure 3A shows mean virus titers in nasal swabs after challenge with a European 
H3N2 SIV. All challenge control pigs (group H), pigs immune to pH1N1 (group A) or 
pH1N1 followed by H1N1 (group B) shed high titers of virus for 4-6 days (mean 
AUC=23.2, 18.9 or 16.4, respectively). All H1N1-immune pigs (group E) also shed 
viruses for at least 2-6 days, but the virus titers were reduced (mean AUC=12.3). 
Only one pig with infection-immunity to H1N2 (group G) and two pigs with infection-
immunity to both pH1N1 and H1N2 (group D) had detectable virus excretion (mean 
AUC=0.14 and 1.65, respectively). Figure 3B shows individual virus titers in the 
respiratory tract of two pigs of each group at 4 days post H3N2 challenge. Challenge 
control pigs (group H) were virus-positive in all tissues, except for the olfactory region 
of the nasal mucosa of one pig. Virus isolation rates and virus titers in the other 
groups reflected those in nasal swabs. Pigs immune to pH1N1 (group A) or both 
pH1N1 and H1N1 (group B) showed only a minimal reduction of virus replication. A 
higher reduction of virus titers was observed in the pigs only immune to H1N1 (group 
E), while those immune to H1N2 alone (group G) or pH1N1 followed by H1N2 (group 
D) were almost completely protected against H3N2 replication.  
All pigs lacked HI and VN antibodies against H3N2 before the H3N2 challenge. 
Cross-NI antibodies against H3N2 were only detected in pigs previously exposed to 
H1N2, and titers were higher in group G (GMT 70) than in group D (GMT 17) (p < 
0.05). At 14 days after H3N2 challenge, all pigs developed antibodies or showed an 
increase in pre-existing antibody titers against H3N2 (Table 4). Antibody titers 
against H1 viruses did not change in all assays after H3N2 challenge (p > 0.05). 
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Figure 3. Virus titers in nasal swabs (A) and respiratory tissues (B) after H3N2 challenge. 
Horizontal dotted lines represent the detection limit for virus titration: 1.7 log10 TCID50.  
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Table 4. Geometric mean antibody titers against the H3N2 virus in hemagglutination- inhibition 
(HI), virus-neutralization (VN), and neuraminidase-inhibition (NI) assays at 14 days after H3N2 
challenge 
Group Virus inoculations HI VN NI 
A pH1N1-6w-pH1N1-17w-H3N2 202 116 320 
B pH1N1-6w-H1N1-17w-H3N2 254 266 254 
D pH1N1-6w-H1N2-17w-H3N2 16 26 320 
E Mock-6w-H1N1-17w-H3N2 127 185 320 
G Mock-6w-H1N2-17w-H3N2 20 16 320 
H Mock-6w-mock-17w-H3N2 160 347 381 
 
4.2.5 Discussion 
We have shown a nearly complete cross-protection against replication of European 
H1 SIV lineages in pigs with infection-immunity against pH1N1, but only a weak 
cross-protection against the H3N2 subtype in pigs with infection-immunity against 
various H1N1 viruses. In line with previous studies (Busquets et al., 2010; Kyriakis et 
al., 2010), all three H1 SIVs used in our studies failed to cross-react with pH1N1 in HI 
assays with post-infection swine sera, and there was minimal cross-reactivity in VN 
assays. The VN assay is known to be more sensitive than the HI assay, and the 
former detects does not only detect antibodies that inhibit the attachment of the virus 
to target cells, but also antibodies that can block the fusion of the viral and 
endosomal membranes (Brandenburg et al., 2013). Cross-HI assays with high-titered 
hyperimmune swine sera have also shown low titers of cross-reactivity between 
pH1N1 and European avian-like H1N1 but not human-like H1N2 SIVs (Kyriakis et al., 
2010). The HA1 of the European H1 SIVs had similarly low percentages (69-71%) of 
amino acid homology to pH1N1. However, a detailed analysis of the antigenic sites 
revealed fewer amino acid differences between the classical H1 of pH1N1 and the 
avian-like H1 of H1N1 as compared to the human-like H1 of rH1N1 and H1N2 SIVs. 
Interestingly, the Sa (13 amino acids) site is an immunodominant antigenic site in 
pH1N1 (Manicassamy et al., 2010; Retamal et al., 2014; Strengell et al., 2011), and 
was found to be completely conserved between the first two viruses as previously 
reported (Castrucci et al., 2014), while there were 5-6 amino acid differences 
between pH1N1 and the human-like H1 SIVs. This may explain why the 
pH1N1infection-immune pigs in our study were more optimal protected against the 
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avian-like H1N1 SIV. A complete cross-protection against the pH1N1 after prior 
infection of pigs with the avian-like H1N1 SIV has been demonstrated in a previous 
study (Busquets et al., 2010). Likewise, prior infection or vaccination with 1918 
pandemic or classical swine H1N1 virus, which differ from pH1N1 in only 1 amino 
acid in the Sa antigenic site, resulted in nearly complete protection from the latter 
virus in mice and ferrets (Kash et al., 2010; Manicassamy et al., 2010; O'Donnell et 
al., 2012). Furthermore, there is strong evidence for cross-protection between pH1N1 
and historical human seasonal H1N1 viruses from the 1930-40s in humans and in 
experimental animal models (O'Donnell et al., 2012; Skountzou et al., 2010; 
Skowronski et al., 2011). Yet, these viruses have only 67-76% amino acid homology 
in their HA1 and as many as 5 amino acid differences in the Sa antigenic site 
(O'Donnell et al., 2012). Some of the viruses used for prior infection and challenge in 
the present study also had NAs of the same lineage. This was the case for pH1N1 
and European SIVs of the H1N1 subtype (H1N1 and rH1N1), as well as for the 
European H1N2 and H3N2 SIVs. Unlike antibodies against HA, anti-NA antibodies 
cannot neutralize influenza viruses, but do play a significant secondary role in 
protection against influenza in humans and animals (Kilbourne et al., 2004; Monto & 
Kendal, 1973; Schulman et al., 1968; Sylte et al., 2007). Therefore, it is not surprising 
that pH1N1-immune pigs were better protected against European H1N1 than H1N2 
SIVs, and that H1N2-immune pigs were better protected against H3N2 challenge 
than H1N1-immune pigs.  
Protection between viruses of H1N1 and H3N2 subtype was clearly less robust than 
that between viruses of the same HA and/or NA subtype. Yet, pigs with infection-
immunity to the avian-like H1N1 SIV were better protected against H3N2 than 
pH1N1-immune pigs. This suggests a contribution of immune responses to internal 
proteins, which are shared between avian-like H1N1 and human-like H3N2 SIVs but 
are of different origin in pH1N1, except for the M protein. In pigs that had been 
subsequently exposed to pH1N1 and the avian-like H1N1, protection against H3N2 
was inferior to that in pigs exposed to H1N1 only, and similar to that in pigs exposed 
twice to pH1N1. This is most likely due to the failure of the H1N1 virus to replicate 
and induce specific immune responses in pH1N1-immune pigs, as indicated by the 
nasal virus titers and serological responses. Our data are largely in agreement with 
previous studies on heterosubtypic protection in pigs, ferrets, and mice (Heinen et al., 
2001; Hillaire et al., 2011; Kreijtz et al., 2007; Laurie et al., 2010; Liang et al., 1994; 
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Yetter et al., 1980), none of which showed a complete protection between H1 and H3 
viruses. For example, prior infection of ferrets with pH1N1 or a seasonal H1N1 virus 
resulted in a shorter duration of nasal excretion of seasonal H3N2 virus, i.e. 5 days 
instead of 7 days in unprimed influenza naïve ferrets (Laurie et al., 2010; Yetter et al., 
1980). In mice, prior infection with H1N1 or pH1N1 did not reduce H3N2 virus titers in 
the lungs at 4 dpc, but titers were undetectable or reduced by 104-fold at 7 dpc 
(Hillaire et al., 2011; Kreijtz et al., 2007).  
Although heterosubtypic protection has been frequently studied in mice, the pig 
model has some specific advantages for studying protection between influenza 
viruses. Pigs are natural hosts for a variety of genetically and antigenically diverse 
H1 and H3 viruses. Most SIVs have an HA derived from viruses that once circulated 
in humans and the pH1N1 is a shared virus between humans and swine (Van Reeth 
et al., 2012). Nearly all SIVs are natural reassortants. As a result, the SIVs used in 
this study share 1 to 7 genes with each other, and this allows examination of the 
relative importance of each protein for protection. As pointed out before (Brookes et 
al., 2010; Khatri et al., 2010; Van Reeth et al., 1998), the pathogenesis of influenza is 
very similar in pigs and in humans, and there are also striking similarities in their 
immune responses. In mice, the outcome of infection experiments depends on the 
mouse and virus strain used. For instance, upon infection with PR/8, DBA/2 mice 
showed a greater susceptibility to infection, more rapid weight loss and death, 
elevated cytokine production, and more severe lung histopathology than C57BL/6 
mice (Srivastava et al., 2009). Also, human influenza viruses generally require 
adaptation to be able to replicate and achieve virulence in mice, and the adapted 
virus may be antigenically and phenotypically very different from the initial strain 
(Bouvier & Lowen, 2010). Finally, mice transmit influenza viruses inefficiently and 
nasal virus excretion cannot be evaluated in mice (Lowen et al., 2006). Pigs, in 
contrast, are highly susceptible to a variety of human H1 and H3 viruses in 
experimental settings (Landolt et al., 2003; Qiu et al., 2013), and unlike mice, pigs 
can shed high titer virus in nasal swabs for 4-6 days. 
During the last few years, there have been several serologic investigations for cross-
reactive antibodies against H1 and H3 SIVs in humans of different age categories 
(Hoschler et al., 2013; Krumbholz et al., 2014; Qiu et al., 2015). HI antibodies against 
the avian-like H1N1 SIV were undetectable in approximately 90% of humans in 2009, 
and they showed only a minimal increase in humans with seroconversion to pH1N1 
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(De Marco et al., 2013; Hoschler et al., 2013; Perera et al., 2011). This is in 
agreement with our finding that pH1N1 infection did not induce detectable serum HI 
antibodies against the avian-like H1N1. On the other hand, pH1N1infection-immune 
pigs showed a complete virological protection against the avian-like H1N1 SIV. This 
further supports the notion that infection with wild type live viruses can induce 
heterovariant protection in the absence of cross-reactive serum HI antibodies and 
argues for more in vivo cross-protection studies in animal models. From such studies, 
we conclude that humans will likely have better immune protection against European 
H1 than H3 viruses of swine. This is based on the presence of minimal protection 
against European H3N2 SIVs in pigs with infection immunity to contemporary human 
H3N2 viruses (Qiu et al., 2013) or pH1N1, whereas infection immunity to pH1N1 
seems to offer significant protection against the major H1 SIVs. 
In conclusion, our study shows post-infection immunity may offer substantial cross-
lineage protection against influenza viruses of the same HA and/or NA subtype. 
Heterosubtypic protection between viruses of different HA and NA subtypes, in 
contrast, appears to be weak in pigs. Because they are natural hosts for the same 
influenza virus subtypes as humans, pigs have some unique advantages as a model 
for cross-protection studies with influenza. According to our data, the global spread of 
pH1N1 in humans will enhance their cross-protective immunity to European H1 SIVs, 
making those viruses less likely to cause pandemics in the near future. 
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5.1.1 Abstract  
H3N2 influenza viruses circulating in humans and European pigs originate from the 
pandemic A/Hong Kong/68 virus. Because of slower antigenic drift in swine, the 
antigenic divergence between swine and human viruses has been increasing. It 
remains unknown to what extent this results in a reduced cross-protection between 
recent human and swine H3N2 influenza viruses. 
We examined whether prior infection of pigs with an old [A/Victoria/3/75 (A/Vic/75)] or 
a more recent [A/Wisconsin/67/05 (A/Wis/05)] human H3N2 virus protected against a 
European swine H3N2 virus [sw/Gent/172/08 (sw/Gent/08)]. Genetic and antigenic 
relationships between sw/Gent/08 and a selection of human H3N2 viruses were also 
assessed. 
After challenge with sw/Gent/08, all challenge controls had high virus titers in the 
entire respiratory tract at 3 days post-challenge and nasal virus excretion for 5–
6 days. Prior infection with sw/Gent/08 or A/Vic/75 offered complete virological 
protection against challenge. Pigs previously inoculated with A/Wis/05 showed 
similar virus titers in the respiratory tract as challenge controls, but the mean duration 
of nasal shedding was 1·3 days shorter. Unlike sw/Gent/08- and A/Vic/75-inoculated 
pigs, A/Wis/05-inoculated pigs lacked cross-reactive neutralizing antibodies against 
sw/Gent/08 before challenge, but they showed a more rapid antibody response to 
sw/Gent/08 than challenge controls after challenge. Cross-protection and serological 
responses correlated with genetic and antigenic differences. 
 Infection immunity to a recent human H3N2 virus confers minimal cross-protection 
against a European swine H3N2 virus. We discuss our findings with regard to the 
recent zoonotic infections of humans in the United States with a swine-origin H3N2 
variant virus. 
 
5.1.2 Introduction 
The antigenic and genetic characteristics of swine influenza viruses (SIVs) vary in 
different continents and regions of the world, but most if not all H3N2 SIVs contain 
hemagglutinin (HA) and neuraminidase (NA) genes from early or more recent human 
H3N2 viruses (Van Reeth et al., 2012). In Europe, H3N2 SIVs are derived from 
descendants of the 1968 “Hong Kong” pandemic virus, but they have evolved further 
through genetic reassortment with the endemic avian-like H1N1 SIV in the mid-1980s. 
This has resulted in H3N2 SIVs with human-like HA and NA genes and avian-like 
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internal genes (Campitelli et al., 1997; Castrucci et al., 1993). In North America, 
H3N2 viruses did not become established in the pig population until 1998. These 
viruses are “triple” reassortants with the HA, NA, and PB1 genes of human H3N2 
viruses from the mid-1990s and the remaining genes of classical swine and avian 
origin (Webby et al., 2000). Multiple H3N2 SIV lineages have been found in Asia, and 
all have HA and NA genes derived from human H3N2 viruses from various time 
periods (Nerome et al., 1995; Ngo et al., 2012; Yu et al., 2008). Because of slower 
antigenic drift in the H3 HA in swine than in humans (de Jong et al., 2007; Nerome et 
al., 1995), human-lineage H3N2 viruses in swine over time become increasingly 
divergent from contemporary human H3N2 viruses. As an example, European H3N2 
SIVs from 1983 to 1999 showed a six times slower rate of antigenic drift than their 
human counterparts (de Jong et al., 2007). Consequently, European H3N2 SIVs from 
recent years still show some degree of serological cross-reactivity with human 
viruses from the 1970s to 1980s, but not with human viruses isolated after 1990 (de 
Jong et al., 1999; Kyriakis et al., 2011). 
Swine influenza viruses usually do not infect humans, but sporadic dead-end 
zoonotic infections have been reported with most SIV subtypes or lineages (Myers et 
al., 2007; Shu et al., 2012; Van Reeth, 2007). Such infections are generally mild and 
clinically indistinguishable from infections with human influenza viruses. Most cases 
of swine influenza occur in people with direct or indirect exposure to swine, frequently 
children, or young adults. The European H3N2 SIV has been isolated from a 1-year-
old girl and a 2-year-old boy in the Netherlands in 1993 (Claas et al., 1994). A closely 
related virus was also isolated from a 10-month-old girl in Hong Kong in 1999 
(Gregory et al., 2001). In North America, nine cases of human infection with triple 
reassortant H3N2 SIV have been reported from 2005 to 2010 (Olsen et al., 2006; 
Robinson et al., 2007; Shu et al., 2012). A variant of the original triple reassortant 
H3N2 SIVs, which contains the matrix gene of the pandemic 2009 H1N1 virus, has 
been detected in 13 humans in the United States from July 2011 to April 2012 
(Skowronski et al., 2012), and in 306 cases in 10 US states from July to September 
2012, mainly in children visiting county or state fairs (CDC, 2012b). The increasing 
numbers of human cases may be in part due to heightened awareness and 
surveillance. No H3N2 SIV has so far shown the capacity to spread efficiently 
between humans. 
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Already in 1977, Shortridge et al. suggested that pigs could serve as a reservoir for 
old, A/Hong Kong/68-like human H3N2 viruses and that such viruses might be re-
introduced into humans when their immunity has waned (Shortridge et al., 1977). 
However, it remains unknown to what extent immunity to human H3N2 viruses may 
offer protection against H3N2 SIVs. We have therefore examined the effect of prior 
infection with an old (1975) or a more recent (2005) human H3N2 influenza virus on 
challenge with a recent European H3N2 SIV in the pig model. 
 
5.1.3 Materials and methods 
5.1.3.1 Genetic and antigenic characterization of viruses 
Sw/Gent/172/08 (sw/Gent/08) is representative of H3N2 SIVs that are enzootic in 
Western Europe. The human H3N2 influenza viruses A/Victoria/3/75 (A/Vic/75) and 
A/Wisconsin/67/05 (A/Wis/05) have been WHO vaccine reference strains in 1976–
1978 and 2006–2008, respectively. All viruses were propagated in the allantoic cavity 
of 10-day-old embryonated chicken eggs for less than four passages. 
The HA1, NA, matrix (M), and nucleoprotein (NP) sequences of A/Vic/75, A/Wis/05, 
and sw/Gent/08 were compared at the nucleotide and amino acid (aa) level 
using Megalign program within DNAStar 5.01 software (DNASTAR, Inc., Madison, WI, 
USA). In addition, the HA1 and NA of a selection of human H3N2 viruses circulating 
from 1973 to 2009 (Table 2) were compared with sw/Gent/08. Amino acid differences 
at putative antigenic sites of the HA and NA, as defined by others (Colman et al., 
1983; Underwood, 1982; Wiley et al., 1981), were identified by alignment 
using Mega 5.05 software (http://www.megasoftware.net/) (Tamura et al., 2011). N-
linked glycosylation sites were predicted by the NetNGlyc 1.0 web server 
(http://www.cbs.dtu.dk/services/NetNGlyc) as described elsewhere (Das et al., 2010). 
The HA1, NA, M, and NP of sw/Gent/08 and the HA1 of A/Vic/75 and A/Wis/05 were 
(re-)sequenced for this study (GenBank accession numbers KC142126–32). All other 
sequences used for comparison were downloaded from GenBank. 
A/Vic/75, A/Wis/05, and sw/Gent/08 were characterized in hemagglutination inhibition 
(HI) and neuraminidase inhibition (NI) tests using post-infection ferret or 
hyperimmune swine sera, or both. 
 
5.1.3.2 Experimental design 
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Thirty-two 5-week-old pigs were obtained from an influenza virus-seronegative farm. 
Pigs were randomly assigned to four groups of eight pigs. Each group was housed in 
a separate biosafety level-2 HEPA-filtered isolation unit. Before the start of the 
experiment, all pigs were seronegative to any of the European endemic H1N1, H1N2, 
and H3N2 SIVs, as determined by HI test, immunoperoxidase monolayer assay, and 
a competitive anti-influenza A NP enzyme-linked immunosorbent assay (Idexx 
Laboratories, Hoofddorp, the Netherlands). After acclimation for 1 week, three groups 
were inoculated with A/Vic/75, A/Wis/05, or sw/Gent/08, respectively. One group was 
left uninoculated and served as the challenge control group. Six weeks later, all 
groups were challenged with sw/Gent/08. All inoculations were performed 
intranasally with 7·0 log10 50% egg infective doses (EID50) influenza virus in 3 ml 
(1.5 ml per nostril) as described elsewhere (De Vleeschauwer et al., 2011). Pigs 
were observed daily for clinical signs from 4 days before until 7 days after each 
inoculation, or until euthanasia. To determine virus excretion, nasal swabs were 
collected daily from all pigs from 0–7 days post-primary inoculation (dpi) and from 0–
7 days post-challenge (dpc), or until euthanasia. Four pigs per group were 
euthanized at 3 dpc and gross lung lesions were assessed as described elsewhere 
(Atanasova et al., 2011). To determine the extent of replication of the sw/Gent/08 
challenge virus in the respiratory tract, tissue samples of the upper (nasal mucosa 
respiratory part and olfactory part, tonsil, and trachea) and lower (apical, cardiac, and 
diaphragmatic lobes of the left and right lung) respiratory tract were collected and 
titrated separately. Blood samples for serological examinations were collected at the 
start of the experiment, 14 and 42 dpi, that is, at the time of challenge with 
sw/Gent/08. The remaining pigs were also bled at 5, 7, 10, and 14 dpc. 
 
5.1.3.3 Virus titration 
Cotton swabs were weighed before and after collection to determine virus titers per 
100 mg nasal secretions. Swabs from both nostrils were suspended in 1 ml of 
phosphate-buffered saline supplemented with 10% fetal bovine serum, 100 IU/ml 
penicillin, and 100 µg/ml streptomycin and mixed vigorously at 4°C for 1 hour. Tissue 
samples were weighed and ground in PBS containing 10 IU/ml penicillin and 
10 µg/ml streptomycin to obtain 20% (w/v) tissue homogenates. Nasal swab samples 
and tissue homogenates were clarified by centrifugation (16 000 g for 3 minutes) and 
stored at −70°C until titration. All samples were titrated on Madin–Darby canine 
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kidney (MDCK) cells in serum-free medium with trypsin. Briefly, confluent monolayers 
of cells were inoculated with 10-fold serial dilutions of samples. Cells were washed 
2 hours after inoculation and subsequently observed for development of cytopathic 
effect over 7 days. Virus titers were expressed as log10 50% tissue culture infective 
doses (TCID50) per 100 mg (nasal swabs) or per gram (tissues). 
 
5.1.3.4 Serological assays 
Serum antibody responses were examined by HI, virus neutralization (VN), and NI 
tests. All sera collected at 0, 14 dpi, and 0 and 14 dpc were examined against all 
three viruses in HI and VN tests, while only the sera collected at 0 and 14 dpc were 
tested in NI tests. Additional VN tests against the challenge virus sw/Gent/08 were 
performed on the sera collected at 5, 7, and 10 dpc. All sera were heat inactivated 
(56°C, 30 minutes) before use. The HI test was performed according to standard 
procedures with 0·5% turkey erythrocytes and 4 hemagglutinating units of virus 
(Leuwerke et al., 2008). The VN test was performed in MDCK cells in microplates 
with 100 TCID50 of virus per well as previously described (Van Reeth et al., 2003). 
The NI test was based on the colorimetric analysis of sialic acid release from fetuin 
substrate and conducted in 96-well PCR plates as described elsewhere (Sandbulte 
et al., 2009). Starting dilutions were 1:2 in the VN test and 1:10 in the HI and NI tests. 
 
5.1.3.5 Statistics 
Nasal virus shedding in each group was quantified by calculation of the area under 
the curve (AUC), which is obtained by plotting viral titers versus each time point of 
sample collection. Samples that tested negative for virus were given a numeric value 
of 1·6 log10 TCID50 per 100 mg or gram. Samples that tested negative in the 
serological assays were assigned a value corresponding to half of the minimum 
detectable titer. Mann–Whitney tests were used to compare virus titers and antibody 
levels between any two experimental groups. P < 0.05 was considered statistically 
significant. Graphpad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, 
USA) was used for all analyses. 
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5.1.4 Results 
5.1.4.1 Genetic and antigenic relationships between human and European 
swine H3N2 viruses 
Percentages of nucleotide and aa identity between the HA1, NA, M, and NP of 
A/Vic/75, A/Wis/05, and sw/Gent/08 are summarized in Table 1. The HA1 and NA of 
sw/Gent/08 were more similar to A/Vic/75 than to A/Wis/05 at both levels. The M and 
NP genes of both human viruses were equally similar to those of the swine virus. 
 
Table 1. Percent identity of the nucleotide and amino acid sequences of the hemagglutinin 
(HA1), neuraminidase (NA), matrix (M), and nucleoprotein (NP) genes of sw/Gent/08 with those 
of the human H3N2 viruses A/Vic/75 and A/Wis/05 
 % identity compared to sw/Gent/08 
 HA1  NA  M  NP 
 N aa  N aa  N aa  N aa 
A/Vic/75 88 87  89 91  87 91  84 91 
A/Wis/05 80 80  85 87  86 90  82 91 
N, nucleotide; aa, amino acid. 
 
Amino acid differences at presumed antigenic sites of the HA are shown in Figure 1. 
The HA1 segment of A/Vic/75 contained 42 aa differences compared with 
sw/Gent/08, with 9 of these occurring in each of the 5 recognized antigenic sites: 4 in 
antigenic site A, 1 in B, 2 in C, 1 in D, and 1 in E. The HA1 of A/Wis/05 contained as 
much as 64 aa differences compared with sw/Gent/08. Fourteen differences were 
located in antigenic sites: 2 in antigenic site A, 7 in B, 3 in C, 1 in D, and 1 in E. 
Three additional N-glycosylation sites in the globular head of HA1, at positions 133, 
144, and 246, were found in A/Wis/05 but absent in A/Vic/75 and sw/Gent/08. 
Positions 133 and 144 were located in antigenic site A and position 133 was in the 
receptor binding site. The NA gene of A/Vic/75 was also more closely related to 
sw/Gent/08 (44 aa differences, with 10 in putative antigenic sites) than that of 
A/Wis/05 (62 aa differences, 15 in antigenic sites). Compared with sw/Gent/08, one 
additional N-glycosylation site was predicted for A/Vic/75 (position 234) and two for 
A/Wis/05 (positions 93 and 234). 
Table 2 compares the HA1 and NA protein sequences and presumed antigenic sites 
of sw/Gent/08 with those of additional human H3N2 viruses collected over time. The 
HA1 of sw/Gent/08 was most similar to that of A/Vic/75. Starting in 1989, all human 
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strains showed less than 85% aa homology with the swine virus, and 14–17 aa 
differences in antigenic sites of the HA. N-glycosylation site 246 and 133 were 
consistently present in the globular head of the HA1 of all human H3N2 viruses 
examined since 1987 and 1997, respectively. The NA of sw/Gent/08 was most 
similar to that of A/Port Chalmers/1/73. Human viruses from 1989 or later showed 
<89% aa homology with the swine virus and 13–15 aa differences in antigenic sites 
of the NA. 
 
 
 
Figure 1. Alignment of deduced amino acid sequences in the HA1 of sw/Gent/08, A/Vic/75, and 
A/Wis/05. Residues in the open boxes represent previously identified antigenic sites (A, B, C, D, and 
E) of H3. Underlined residues represent potential N-glycosylation sites in the globular head of the HA1. 
Only amino acids different from those in the sw/Gent/08 sequence are shown, conserved residues are 
shown as dots. 
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Table 2. Comparison of hemagglutinin (HA1) and neuraminidase (NA) protein sequences of 
epidemic human H3N2 influenza viruses from 1973 to 2009 and their antigenic sites with those 
of sw/Gent/08 
 HA1  NA 
Virus strain 
Genbank 
accession no. 
% aa 
identity 
No. of aa 
differences in 
antigenic sites 
 
Genbank 
accession no. 
% aa 
identity 
No. of aa 
differences in 
antigenic sites 
A/Port Chalmers/1/73 ABE12532 86.9 11  ABE12548 91.6 6 
A/Victoria/3/75 AFY08275 87.2 9  AAB03361 90.5 10 
A/Texas/1/77 ABQ58940 86.9 11  AFM68968 90.7 9 
A/Bangkok/01/79 ABF21268 85.4 13  ABF21324 90.3 9 
A/Philippines/2/82 ADJ41805 85.4 11  ADJ41808 89.7 10 
A/Leningrad/360/86 AAB69845 85.1 13  AFN11845 89.7 11 
A/Sichuan/02/87 D10161 85.1 15  - - - 
A/Beijing/353/89 AAB58297 83.9 16  AAB06969 88.6 14 
A/Shangdong/9/93 ACL12129 82.4 16  ACL12132 88.6 13 
A/Wuhan/359/95 AFR42694 83.0 16  AAB06998 87.7 13 
A/Sydney/5/97 ACO95259 81.8 17  ACO95262 88.1 13 
A/Moscow/10/99 ABE73115 82.7 16  ABE73101 86.4 15 
A/California/7/04 ABO37490 81.2 14  ABV24038 86.9 15 
A/Wisconsin/67/05 AFY08274 80.2 14  ABW80983 86.6 15 
A/Brisbane/10/07 ABW23353 81.2 15  ACO95273 86.2 14 
A/Perth/16/09 ACS71642 80.9 16  ADW80519 86.0 14 
-: not available in Genbank. 
 
Table 3 shows the antigenic relationship in the HA and NA of the three viruses used 
in infection-challenge studies. Low to moderate cross-reactivity between A/Vic/75 
and sw/Gent/08 was observed in both HI and NI tests, whereas antisera against the 
two viruses lacked cross-reactivity with A/Wis/05 in both tests. For an unknown 
reason, ferret serum against A/Wis/05 showed similar NI antibody titers to all three 
viruses, while the swine serum showed minimal reaction with sw/Gent/08 or A/Vic/75. 
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Table 3. Cross-reactivity between the human H3N2 viruses A/Vic/75 and A/Wis/05 and the 
swine H3N2 virus sw/Gent/08 in hemagglutination inhibition (HI) and neuraminidase inhibition 
(NI) assays 
  Antibody titers with serum to… 
  A/Vic/75 
(F)* 
A/Wis/05  
(F) 
A/Wis/05  
(S)* 
sw/Gent/08 
(S) 
A/Vic/75 HI 160 < 10 < 10 40 
 NI 2560 40 < 10 320 
A/Wis/05 HI < 10 2560 2560 < 10 
 NI < 10 80 640 < 10 
sw/Gent/08 HI 40 < 10 <10 1280 
 NI 320 40 20 5120 
* (F): post-infection ferret serum, (S): hyperimmune swine serum. 
 
5.1.4.2 Virus excretion and serological response after primary inoculation 
As expected after intranasal inoculation of pigs with influenza virus,[1] clinical 
symptoms were absent in most pigs except for two sw/Gent/08-inoculated pigs with 
dyspnea at 3 dpi. All pigs excreted virus in nasal swabs. Virus shedding was 
detected for 5–6 consecutive dpi with sw/Gent/08 or A/Vic/75 and for 4–5 dpi with 
A/Wis/05. Mean virus titers in nasal swabs are shown in Figure 2. The average AUC 
value was highest for sw/Gent/08 (21.8), followed by A/Vic/75 (16.6) and A/Wis/05 
(12.1). 
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Figure 2. Nasal virus excretion after primary inoculation with human or swine H3N2 influenza 
virus and after challenge with sw/Gent/08. Mean virus titers in nasal swabs of each group are given. 
The horizontal broken line represents the detection limit (<1.7 log10 TCID50/100 mg). 
 
All pigs were seronegative against the three viruses prior to the start of the 
experiment. Antibody titers at 2 and 6 weeks after the primary inoculation are shown 
in Table 4. All challenge controls remained seronegative until the time of challenge, 
whereas the other pigs developed HI, VN, and NI antibodies to the influenza virus 
used for inoculation. These homologous antibody titers were significantly higher in 
sw/Gent/08-inoculated pigs than in the pigs inoculated with human H3N2 viruses 
(P < 0.05), except for the HI titers at 14 dpi (P > 0.05). Inoculation with A/Vic/75 
induced cross-reactive VN antibodies against sw/Gent/08 in all pigs. Cross-reactive 
HI antibodies were detected in only 3 of 8 pigs, at 14 dpi only, and cross-reactive NI 
antibodies in 6 pigs. In A/Wis/05-inoculated pigs, serological cross-reaction with 
sw/Gent/08 was negligible in the VN test and undetectable in the HI or NI test. 
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5.1.4.2 Virological protection after challenge with sw/Gent/08 
No clinical signs were observed in any pigs after challenge infection. Mean 
sw/Gent/08 titers in nasal swabs are shown in Figure 2. Virus shedding was 
detectable in all challenge controls during 5–6 consecutive days or until euthanasia. 
All pigs of the sw/Gent/08-sw/Gent/08 and A/Vic/75-sw/Gent/08 groups tested 
negative for virus excretion. Pre-infection with A/Wis/05 failed to prevent challenge 
infection or to reduce peak virus titers in nasal swabs. However, the mean duration of 
nasal shedding was 1·3 days shorter than in the challenge control group. 
Sw/Gent/08 virus titers in the respiratory tract of the pigs euthanized at 3 dpc are 
shown in Table 5. Sw/Gent/08 was isolated from the nasal mucosa, tonsil, trachea, 
left lung, and right lung of all challenge control pigs. In contrast, all pigs of the 
sw/Gent/08-sw/Gent/08 and A/Vic/75-sw/Gent/08 groups were completely virus 
negative. In the A/Wis/05-sw/Gent/08 group, virus isolation rates and virus titers were 
similar as in the challenge control group (P > 0.05). Lung lesions characterized by 
dark-red consolidated areas, involving only 1–2% of the lung surface, were present in 
two challenge control pigs and two A/Wis/05-sw/Gent/08 pigs, but absent in both 
other groups. 
 
5.1.4.3 Serological profile after challenge with sw/Gent/08 
All pigs of the challenge control group had developed HI, VN, and NI antibodies to 
sw/Gent/08 at 14 dpc (Table 4), whereas anti-sw/Gent/08 antibody titers remained at 
pre-challenge levels in the sw/Gent/08-sw/Gent/08 group (P > 0.05). Pigs of the 
A/Vic/75-sw/Gent/08 and A/Wis/05-sw/Gent/08 groups developed antibodies to 
sw/Gent/08 or showed a considerable increase in pre-existing antibody titers. As 
shown in Figure 3, VN antibodies to the challenge virus developed more rapidly in 
the A/Wis/05-sw/Gent/08 group than in the challenge control group, but all 4 groups 
had similar antibody titers at 10 dpc. Homologous antibody titers to the human H3N2 
viruses also increased after challenge with sw/Gent/08. Many pigs showed low cross-
reactive antibody titers to A/Vic/75 without being exposed to it, but cross-reaction 
with A/Wis/05 was rare. 
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Table 5. Virus titers in the respiratory tract 3 days after challenge with sw/Gent/08 in challenge 
controls and pigs first infected with human or swine H3N2 influenza virus 
 Mean virus titers (log10 TCID50/g) ± SEM* 
Group 
Nasal mucosa 
respiratory part 
Nasal mucosa 
olfactory  part Tonsil Trachea Left lung Right lung 
Challenge control 6.4 ± 0.1 5.4 ± 0.5 4.1 ± 0.7 7.1 ± 0.1 6.2 ± 0.1 6.7 ± 0.3 
sw/Gent/08-sw/Gent/08 <† < < < < < 
A/Vic/75-sw/Gent/08 < < < < < < 
A/Wis/05-sw/Gent/08 7.6 ± 0.4 4.6 ± 1.1 4.6 ± 0.7 7.3 ± 0.2 6.2 ± 0.3 6.1 ± 0.3 
* Standard error of the mean; † Virus titers below the detection limit (<1.7 log10 TCID50/g)  
 
 
 
Figure 3. Evolution of virus-neutralizing (VN) antibody titers against the challenge virus 
sw/Gent/08 during the first 10 days post challenge. Bars represent group geometric mean VN 
antibody titers with standard error of the mean (SEM); the asterisk denotes a statistically significant 
difference (P < 0.05) with the challenge control group. The horizontal broken line represents the 
detection limit of the assay (<2). 
 
5.1.5 Discussion 
The increasing antigenic divergence between H3N2 viruses from swine and humans 
may have important implications for zoonotic transmission of H3N2 SIVs. This is the 
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first study to evaluate cross-protection between human and swine H3N2 viruses in 
pigs. It shows a complete virological protection against infection with a contemporary 
European H3N2 SIV in pigs infected with A/Vic/75 6 weeks earlier, but only a minimal 
protection in pigs pre-infected with the more recent human H3N2 virus A/Wis/05. We 
did not identify the immune mechanisms underlying the observed cross-protection, 
but several findings point toward a role for cross-reactive antibodies against the HA 
and/or NA of the swine virus. Indeed, the difference in protective immune response 
induced by the two human viruses was in line with the genetic and antigenic 
differences in their HA and NA. Antigenic sites A and B are located on the tip of the 
HA molecule, and they are supposed to be the primary targets for neutralizing 
antibodies (Underwood, 1982; Wiley et al., 1981). A/Wis/05 differed from sw/Gent/08 
in as much as seven of the total nine amino acids of site B, and it had two additional 
N-glycosylations in site A, which make it more distinct from sw/Gent/08 than A/Vic/75. 
In addition, low-titered cross-reactive VN antibodies against sw/Gent/08 were found 
in all pigs previously infected with A/Vic/75, but they were rare after infection with 
A/Wis/05. Post-challenge, however, such antibodies developed more rapidly in 
A/Wis/05 pre-infected pigs than in challenge controls, and this coincided with the 
enhanced clearance of the challenge virus. The HI test, as well as the NI test, is less 
sensitive than the VN test (De Vleeschauwer et al., 2011). This can explain the lack 
of cross-reactive HI and NI antibodies in most A/Vic/75-inoculated pigs. Given the 
low cross-reactive serum antibody titers in A/Vic/75-inoculated pigs, it is likely that 
local antibodies in the respiratory tract and cell-mediated immunity, which are more 
cross-reactive (Tamura & Kurata, 2004), also contribute to the cross-protection. 
Previous studies by Kyriakis et al. (Kyriakis et al., 2011) have shown that H3N2 SIVs 
from 2007 to 2008 cross-react in the HI test with hyperimmune sera against the 
human viruses A/Vic/75 and A/Philippines/2/82, but not with sera against 
A/Sydney/5/97 or A/Wis/05. The present comparison of sw/Gent/08 with human 
H3N2 viruses showed increased genetic differences since 1987–1989, as reflected 
by an increased number of aa differences in the HA (≥14) and NA (≥13), and 
additional N-glycosylations in the HA1 globular head. This suggests that especially 
people born after the mid-1980s are at a higher risk for infection with European H3N2 
SIVs. Additional in vivo cross-protection studies with more, antigenically distinct 
human viruses would be required for a better understanding of the nature of the 
human viruses that could offer cross-protection against swine viruses. Still, genetic 
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and antigenic analyses should be interpreted with caution. Our cross-NI test results 
with A/Wis/05 serum from ferrets versus swine, for example, illustrate that sera from 
different animal species may yield discrepant results. As for the definition of antigenic 
sites, this is based on studies of the oldest human viruses and their reaction with 
mouse monoclonal antibodies. It is questionable whether the antigenic sites of such 
historical viruses will overlap exactly with those of recent human or swine H3N2 
viruses. Furthermore, different animal species will likely mount antibodies recognizing 
different epitopes. Finally, some amino acids will be more important for antigenic drift 
than others. According to recent studies, only 7 aa positions in the HA were largely 
responsible for the antigenic evolution of human H3N2 viruses over a period of 
35 years (Koel et al., 2013). It is of great interest to identify the immunodominant 
amino acids in the HA of SIVs and those that are cross-reactive with human H3N2 
viruses. 
Virus titers in nasal swabs and antibody titers in serum were lower in pigs inoculated 
with human H3N2 virus than in pigs inoculated with sw/Gent/08. A/Wis/05 also 
seemed to replicate less efficiently in pigs than A/Vic/75, which is more closely 
related to swine-adapted H3N2 viruses. Similar findings were made in a comparative 
pig infection study with a triple reassortant H3N2 SIV from North America and a non-
reassortant wholly human H3N2 virus (Landolt et al., 2003). Like the authors of that 
study, we suspect that the lower antibody responses to human influenza viruses in 
pigs are in part due to their lower replication efficiencies. Virus titers in the ferret 
model also differ for different H3N2 virus strains (Svitek et al., 2008; van den Brand 
et al., 2012). Comparative studies of the pathogenesis of human and swine H3N2 
viruses in pigs and ferrets would help to select the best animal models and 
experimental conditions for cross-protection studies with such viruses. On the other 
hand, a separate experiment in our laboratory has demonstrated complete protection 
against A/Wis/05 in pigs that had been previously infected with the homologous virus 
under the same conditions as in the present study, and with similar antibody titers. 
Thus, human H3N2 viruses can elicit an efficient protective immune response in pigs. 
The recent infections of over 300 humans in the United States, mainly children in a 
fair setting, with a H3N2 variant virus (H3N2v) of swine origin have raised concerns 
about the extent of pre-existing immunity against this virus in the human population. 
Serological studies have shown cross-reactive HI antibodies in ≥50% of late 
adolescents and young adults, whereas such antibodies were generally lacking in 
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children under 10 (CDC, 2012a; Skowronski et al., 2012; Waalen et al., 2012). 
Overall, these serological findings and the present study support the idea that various 
H3N2 SIV lineages could cause epi- or pandemics in the younger population, should 
they acquire the capacity to spread efficiently between people. The H3 of H3N2v is 
phylogenetically most closely related to human H3N2 viruses from the 1995 to 1997 
era and slightly more related to human H3N2 viruses from the 21st century than 
European H3N2 SIVs (Lina et al., 2011). We therefore assume that the immune 
status of young people may be even lower for the European H3N2 SIV than for 
H3N2v. Both serological investigation of humans and experimental cross-protection 
studies, as well as studies of the host barriers, are needed to further explore the 
susceptibility of humans to various H3N2 SIVs. Experimental cross-protection studies 
are performed under artificial conditions, but they will assess all arms of the immune 
response and true protection. Many serological studies only consider subjects with HI 
titers ≥40 as protected, and they may therefore underestimate protection against 
SIVs in the human population. 
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5.2.1 Abstract:  
Seroreactivity to H3N2 swine influenza viruses (SIVs) was evaluated in serum 
samples collected from 843 people aged 0 to 100 years in 2010 in Luxembourg. Sera 
were analyzed by hemagglutination inhibition (HI) and virus neutralization (VN) 
assays targeting a European H3N2 SIV, a North American H3N2 variant of swine 
origin (H3N2v) and human seasonal H3N2 viruses isolated in 1975, 1995 and 2005. 
HI antibodies (titer  ≥  10) against European H3N2 SIV were almost exclusively 
detected in those born before 1990, of whom 70% were seropositive. HI antibodies 
against H3N2v were predominantly found in those born before 2000, with 86% 
seropositive. Titres against the North American H3N2v were higher than against the 
European H3N2 SIV. VN patterns were similar, but with higher rates and titers. We 
also demonstrated lower seroreactivity to European H3N2 SIV than to North 
American H3N2v virus. Finally, we found a strong correlation between HI titers 
against the European H3N2 SIV and H3N2v and their respective human ancestors, 
A/Victoria/3/75 and A/Nanchang/933/95. This finding and the minimal contacts 
between humans and pigs in Luxembourg suggest that anti-SIV antibodies in human 
serum samples reflect serological cross-reactivity with historical human H3N2 
viruses. Our findings help assess the pandemic risk of H3N2 SIV. 
 
5.2.2 Introduction 
Three swine influenza virus (SIV) subtypes, H1N1, H1N2 and H3N2, are enzootic 
throughout the world in regions with a high density of pigs. The hemagglutinin (HA) 
and neuraminidase (NA) genes of most, if not all, H3N2 SIVs have been derived from 
human seasonal influenza A(H3N2) viruses. In Europe, H3N2 SIVs are derived from 
descendants of the A/Hong Kong/1/68 pandemic influenza A(H3N2) virus, but they 
have evolved further through genetic reassortment with the endemic avian-like H1N1 
SIVs present in western Europe since the late 1970s. This has resulted in H3N2 SIVs 
with human-like HA and NA genes and avian-like internal genes (Campitelli et al., 
1997; Castrucci et al., 1993). In North America, H3N2 viruses have become 
established in swine since 1998. They are known as ‘triple-reassortant’ viruses 
because their HA, NA and polymerase B1 genes stem from human seasonal H3N2 
viruses and the remaining internal genes from avian influenza virus and classical 
H1N1 SIV (Webby et al., 2000). Since 2009, novel reassortant H3N2 viruses with 
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variable numbers of internal genes derived from the 2009 pandemic influenza pH1N1 
virus have been reported frequently and this has further complicated the 
epidemiology of swine influenza in the United States (US) (Kitikoon et al., 2013). 
From 2009 to 2012, these novel influenza pH1N1 reassortants accounted for 54% of 
H3N2 SIVs isolated (Kitikoon et al., 2013). Reassortant viruses with seven genes 
from the triple-reassortant H3N2 SIVs and only the matrix (M) gene from the pH1N1 
virus have become the dominant genotype. These viruses, called H3N2 variant or 
H3N2v when isolated from humans, have caused many zoonotic infections since 
2011 (Lindstrom et al., 2012). 
Antigenic drift in the HA is generally slower in SIVs than in human influenza viruses, 
and pigs can therefore serve as reservoirs of older human HAs (de Jong et al., 2007; 
Kyriakis et al., 2011; Shortridge et al., 1977). Swine-adapted viruses with an HA of 
human origin could initiate a pandemic once immunity within the human population 
has waned sufficiently to allow widespread infection, provided that the viruses also 
have the ability to spread efficiently from person to person. This was observed for the 
pH1N1 virus that contains the classical swine H1. Evolutionarily, the 1918 H1N1 
pandemic influenza virus was the common ancestor of human seasonal and classical 
swine H1N1 influenza viruses; it has undergone significant antigenic drift in humans 
but remained largely in antigenic stasis in swine (Kash et al., 2010; Skountzou et al., 
2010). Consequently, only people born before the 1940s had been previously 
exposed to human seasonal H1N1 viruses with an H1 related to that of pH1N1, and a 
pandemic was possible because younger people lacked cross-reactive anti-H1 
antibodies (CDC, 2009; Hancock et al., 2009; Ikonen et al., 2010a; Skowronski et al., 
2011). A similar situation could occur with human-adapted H3N2 SIVs in the future if 
they carry the HA of seasonal H3N2 viruses that have not circulated in decades. 
Before 2011, only sporadic dead-end zoonotic infections with H3N2 SIVs had been 
reported, in humans in close contact with pigs. Recently, the H3N2v virus has caused 
343 human infections in the US from August 2011 through October 2014 (CDC, 
2015). These infections occurred primarily in young children visiting agricultural fairs, 
and the H3N2v virus did not spread widely through the human population (Jhung et 
al., 2013). These zoonotic infections prompted serological investigations for cross-
reactive antibodies against H3N2v in people of various ages in the US, Canada, 
Norway and England. These studies found that more than half of the adolescents 
and young adults tested had hemagglutination inhibition (HI) antibody titers  ≥  40, 
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which is considered as seroprotective (Potter & Oxford, 1979). In contrast, younger 
children and older adults typically exhibited lower or negative antibody titers (CDC, 
2012; Hoschler et al., 2013; Skowronski et al., 2012a; Skowronski et al., 2012b; 
Waalen et al., 2012). 
Antibodies against the antigenically distinct European H3N2 SIV have been reported 
in ca 50% of humans in studies in Italy and Germany between 2008 and 2010 (De 
Marco et al., 2013; Krumbholz et al., 2010). However, these studies sought to 
compare antibody prevalences in swine workers and non-swine workers with a mean 
age of 45 years, rather than using an age-stratified design to assess seropositivity in 
the general population. In this study, we primarily sought to compare the 
seroreactivity to a European H3N2 SIV with that to a North American H3N2v virus in 
people in various age groups in Luxembourg who were very unlikely to have been 
exposed to pigs. Importantly, we also examined the association between antibody 
titers against swine-origin and those against human seasonal H3N2 influenza 
viruses. 
 
5.2.3 Material and methods 
5.2.3.1 Serum samples 
A total of 843 anonymised human serum samples were randomly selected from the 
Serum Bank of the Laboratoire National de Santé, Luxembourg. The sera were 
collected from patients admitted to hospital for various reasons in April or May 2010. 
The sera were from people born between 1910 and 2010 and were divided into 10 
groups by birth decade. As an example, 1910s refers to people born between 1910 
and 1919. Ca 10 sera per year of birth and 100 sera per birth decade were tested. 
Only the youngest (n  =  40 samples) and oldest age group (n  =  9 samples) had fewer 
samples. The sex ratio in each age group was ca 50:50, except for the participants 
born in the 1910s (two male vs seven females). No further personal data were 
collected due to ethical constraints. 
 
5.2.3.2 H3N2 influenza viruses 
We measured serum antibody titers against human seasonal H3N2 influenza viruses 
A/Victoria/3/75, A/Nanchang/933/95 and A/Wisconsin/67/05. These viruses were 
circulating worldwide during 1976–78, 1996–98 and 2006–08, respectively, and were 
recommended as the influenza vaccine strains by the World Health Organization 
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during their time of circulation. We also measured antibody titers against 
sw/Gent/172/08, a virus representative of H3N2 SIVs that are currently circulating in 
western Europe, and against A/Indiana/08/11, which represents swine-origin H3N2v 
viruses isolated from humans in the US since 2011. 
The HA1 amino acid sequences of these five viruses, a selection of human seasonal 
influenza A(H3N2) viruses (1968–2012), and European and North American H3N2 
SIVs (1984–2012) were downloaded from GenBank. The sequences were compared 
using the MegAlign programme with DNASTAR 5.01 software (DNASTAR, Inc., 
Madison, WI, US). A neighbour-joining phylogenetic tree was constructed to compare 
amino acid sequences with MEGA 5.05 software (http://www.megasoftware.net/). 
The tree was drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances 
were computed using the Poisson correction method and are expressed as the 
number of amino acid substitutions per site.  
Antigenic characterisation of the five viruses used for serology was performed by HI 
and virus neutralization (VN) assays with hyperimmune swine serum (for 
sw/Gent/172/08) or post-infection ferret sera (for all other viruses). We used ferret 
serum against A/Wuhan/359/95 instead of A/Nanchang/933/95 because a ferret 
serum against the latter virus was not available. The two viruses have only two amino 
acid differences in the HA1, outside the antigenic region. Viruses used in HI assays 
were propagated in 10 day-old embryonated chicken eggs (≤  4 passages); viruses 
used in VN assays underwent an additional passage in Madin-Darby canine kidney 
(MDCK) cells. 
 
5.2.3.3 Serological assays 
All sera were examined in HI assays against the three human seasonal H3N2 viruses 
and the two swine-origin H3N2 viruses. Since the VN assay is more sensitive than 
the HI assay and highly relevant for protection, sera from people born after 1940 
were also tested in VN assays against the swine-origin viruses. HI and VN assays 
were performed following standard procedures (Leuwerke et al., 2008; Van Reeth et 
al., 2003). Antibody titers were expressed as the reciprocal of the highest serum 
dilution that showed complete inhibition of HA of 4 hemagglutinating units of virus (HI 
assay), or 50% neutralization of 102 50% tissue culture infectious doses (TCID50) of 
virus in MDCK cells (VN assay). The starting serum dilution was 1:10 for both 
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assays. Sera with titers  ≥  10 were considered as seropositive. HI titers  ≥  40 were 
considered as seroprotective. 
 
5.2.3.4 Statistical analysis 
Geometric mean titers (GMTs) of antibody with 95% confidence intervals (CI) were 
calculated for each age group against each of the five influenza viruses. A numeric 
value of 5 was assigned to samples with antibody titers  <  10. Antibody titers between 
age groups were compared using the nonparametric Wilcoxon signed-rank test, and 
differences in the proportion of sera with HI titers  ≥  40 were analyzed using Fisher’s 
exact test. A p value  <  0.05 was considered statistically significant. Pearson 
correlation tests were used to compare HI antibody titers against human and swine-
origin viruses. All analyses were performed with Graphpad Prism 5.0 (GraphPad 
Software, Inc., San Diego, CA, US). 
 
5.2.4 Results 
5.2.4.1 Relationships between human seasonal and swine-origin influenza 
A(H3N2) viruses 
Phylogenetic relationships between the HA1 amino acid sequences of human 
seasonal H3N2 viruses and H3N2 SIVs from Europe and North America are shown 
in Figure 1. European and North American H3N2 SIVs formed separate clusters, and 
branched off from human viruses at different apparent time points. The HA1 of the 
human A/Victoria/3/75 virus was most closely related to the European H3N2 SIVs 
(87.0% identity to sw/Gent/172/08). The HA1 of the human A/Nanchang/933/95 virus 
was most closely related to North American H3N2 SIVs (89.7% identity to 
A/Indiana/08/11). 
Antigenic relationships between human seasonal and swine-origin H3N2 viruses are 
shown in Table 1. All viruses reacted with their homologous antisera at HI and VN 
titers  ≥  160. There was minimal cross-reactivity between the H3N2v virus 
A/Indiana/08/11 and the European H3N2 SIV sw/Gent/172/08 using hyperimmune 
swine serum against sw/Gent/172/08, and ferret serum against A/Indiana/08/11 failed 
to cross-react with sw/Gent/172/08. Sw/Gent/172/08 showed cross-reaction with 
antiserum against the human A/Victoria/3/75 virus in both HI and VN assays 
(titer  =  80). A/Indiana/08/11, on the other hand, reacted with antiserum against the 
human A/Wuhan/359/95 virus, which is similar to A/Nanchang/933/95, in the VN 
Chapter 5.2 
150 
assay (titer  =  240), but not in the HI assay. Both swine-origin viruses had negligible 
cross-reactivity with A/Wisconsin/67/05. 
 
Table 1. Cross-reactivity between human seasonal A(H3N2) viruses (A/Victoria/3/75, 
A/Nanchang/933/95 and A/Wisconsin/67/05) and swine-origin A(H3N2) viruses (sw/Gent/172/08 
and A/Indiana/08/11) in hemagglutination inhibition and virus neutralization assays, 
Luxembourg, 2010 (n  =  843) 
Virus strain 
Antibody titers with serum to ... 
A/Victoria/3/75 A/Wuhan/359/95b A/Wisconsin/67/05 sw/Gent/172/08a A/Indiana/08/11 
HI VN HI VN HI VN HI VN HI VN 
A/Victoria/3/75 160 960 < 10 < 10 < 10 15 20 120 10 < 10 
A/Nanchang/933/95 < 10 20 320 1280 < 10 15 < 10 10 < 10 80 
A/Wisconsin/67/05 < 10 10 < 10 20 160 160 < 10 10 < 10 < 10 
sw/Gent/172/08 80 80 < 10 < 10 < 10 15 2560 5120 < 10 < 10 
A/Indiana/08/11 20 30 < 10 240 < 10 15 10 40 320 2560 
HI: hemagglutination-inhibition; VN: virus-neutralization. 
a Serum against sw/Gent/172/08 was obtained by hyper-immunisation of swine; the other sera were post-infection ferret sera. 
b Ferret serum to A/Wuhan/359/95 was used, because ferret serum to A/Nanchang/933/95 was not available. The two viruses 
are antigenically identical. 
 
5.2.4.2 Serological status to human seasonal influenza A(H3N2) viruses 
HI antibody titers  ≥  10 against the A/Victoria/3/75 virus were detected in 78% of 
individuals born before 1990 (Figure 2). In contrast, only 10% of those born in the 
1990s and none of the children born after 2000 had detectable antibodies. HI 
titers  ≥  40 were most common in persons born in the 1950s, 1960s and 1970s. A 
larger proportion of people had detectable HI antibodies and titers  ≥  40 against the 
A/Nanchang/933/95 virus. Detectable HI antibodies against the latter virus were 
observed in 85% of individuals born before 2000, but only in 20% of the children born 
after 2000. More than half of those born in the 1970s, 1980s and 1990s had HI 
titers  ≥  40. Seroprevalence rates against the A/Wisconsin/67/05 strain had the least 
variation across different age groups. More than half of the people in each age 
category had detectable antibodies, except for those born in the 1960s (42%). HI 
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The viruses used for the present serological studies are indicated in bold.  
 
Figure 1. Neighbour-joining phylogenetic 
tree of HA1 amino acid sequences from 
human seasonal influenza A(H3N2) 
viruses and European and North American 
swine influenza A(H3N2) viruses. 
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HI: hemagglutination inhibition. 
The percentage of individuals with detectable (white bars) and  high (black bars) antibody titers are shown. Numbers above the 
bars represent the percent of positive sera at each cut-off value.  
 
Figure 2. Prevalence of hemagglutination inhibition antibodies against three human seasonal 
influenza A(H3N2) viruses, an endemic European H3N2 swine influenza virus and a North 
American H3N2v virus, by decade of birth, Luxembourg, 2010 (n  =  843).  
 
titers  ≥  40 were most common in those born after 1990.  
GMTs of HI antibodies against the three human seasonal H3N2 viruses showed 
similar age-dependent trends as the seroprevalence rates (Table 2). Antibody titers 
against A/Victoria/3/75 were highest in people born in the 1950s, 1960s and 1970s. 
Antibody titers against A/Nanchang/933/95 and A/Wisconsin/67/05, on the other 
hand, were highest in people born in the 1980s and 1990s and those born in the 
1990s, respectively. Peak antibody titers against A/Nanchang/933/95 were higher 
than those against either of the other viruses. 
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Table 2. Haemagglutination inhibition antibody titers against human and swine-origin influenza 
A(H3N2) viruses, by age group, Luxembourg, 2010 (n  =  843)  
Birth decade  n 
GMT (95% CI) 
A/Victoria/3/75 A/Nanchang/933/95 A/Wisconsin/67/05 sw/Gent/172/08 A/Indiana/08/11 
1910s  9 13.6 (6.4-29.1) 20.0 (7.9-50.3) 25.2 (7.0-90.4) 12.6 (4.3-36.6) 29.4 (10.1-85.6) 
1920s  91 13.8 (11.5-16.5) 21.4 (17.1-26.8) 18.0 (14.5-22.3) 12.1 (10.2-14.4) 28.2 (21.8-36.5) 
1930s 100 12.7 (10.9-14.8) 22.4 (18.3-27.3) 16.1 (13.0-20.0) 11.2 (9.5-13.2) 22.1 (17.4-28.0) 
1940s  100 12.4 (10.5-14.7) 14.9 (12.4-17.8) 12.0 (9.7-14.9) 11.1 (9.2-13.4) 17.6 (14.3-21.6) 
1950s  100 25.0 (20.2-30.9) 19.2 (15.6-23.5) 12.8 (10.3-16.0) 16.8 (13.7-20.7) 22.0 (17.3-28.1) 
1960s 100 30.1 (24.9-36.5) 24.0 (19.2-29.9) 9.7 (7.9-11.8) 24.1 (19.3-30.1) 28.7 (22.8-36.1) 
1970s  100 28.7 (23.5-35.0) 29.1 (23.8-35.6) 10.8 (8.9-13.1) 23.1 (19.1-28.0) 69.6 (58.0-83.7) 
1980s  104 10.0 (8.7-11.5) 71.0 (59.1-85.3) 18.2 (14.8-22.4) 10.9 (9.4-12.7) 117.8 (97.5-142.2) 
1990s 99 5.5 (5.2-5.8) 77.8 (59.5-101.6) 34.3 (26.9-43.7) 6.2 (5.5-7.0) 58.8 (44.6-77.5) 
2000s 40 5.0 (5.0-5.0) 6.5 (5.4-7.8) 20.4 (14.6-28.3) 5.2 (4.9-5.4) 7.7 (6.1-9.7) 
GMT: geometric mean titer; CI: confidence interval. 
 
5.2.4.3 Serological status to European and North American swine-origin 
influenza A(H3N2) viruses 
Rates of seroprevalence against the European H3N2 SIV sw/Gent/172/08 and North 
American H3N2v virus A/Indiana/08/11 were similar to those against the human 
seasonal viruses A/Victoria/3/75 and A/Nanchang/933/95, respectively (Figure 2). HI 
antibodies (titers  ≥  10) against sw/Gent/172/08 were almost exclusively found in 
those born before 1990, of whom 70% were seropositive. HI antibodies against 
A/Indiana/08/11 were mainly detected in people born before 2000, of whom 86% 
were seropositive. In contrast, fewer than 20% of those born after 1990 had 
antibodies against sw/Gent/172/08, and only 33% of children born after 2000 showed 
antibodies against A/Indiana/08/11. Seroprevalences and HI antibody GMTs followed 
similar age-specific patterns for both viruses (Figure 2, Table 2). The highest 
proportions of HI titers  ≥  40 and the highest GMTs were observed in individuals born 
in the 1950s to 1970s for sw/Gent/172/08, and in those born in the 1970s to 1990s 
for A/Indiana/08/11. Nonetheless, the prevalence of titers  ≥  40 and the GMTs were 
higher for A/Indiana/08/11 than for sw/Gent/172/08 in all age categories (p  <  0.05), 
except for those born in 1950s and 1960s (p  >  0.05). 
Sera from individuals born after 1940 were also examined for antibodies against the 
two swine-origin H3N2 viruses with the VN assay (Table 3). For both viruses, VN 
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titers were higher than HI titers (p  <  0.05), except for antibodies against 
sw/Gent/172/08 in children born after 2000 (p  >  0.05). Higher VN antibody titers were 
detected against A/Indiana/08/11 than against sw/Gent/172/08 (p  <  0.05). 
 
Table 3. Virus-neutralizing antibody titers against swine-origin influenza A(H3N2) viruses 
sw/Gent/172/08 and A/Indiana/08/11 in people born after 1940, Luxembourg, 2010 (n  =  643)  
Birth decade n  
sw/Gent/172/08 
 
A/Indiana/08/11 
% sera with titer 
GMT (95% CI) 
% sera with titer 
GMT (95% CI) ≥10 ≥40 ≥10 ≥40 
1940s  100 
 
77 36 24.0 (18.6-31.0)* 
 
98 71 80.6 (62.6-103.6)* 
1950s  100 94 68 76.4 (56.8-102.7)* 96 69 90.1 (67.3-120.6)* 
1960s 100 93 62 62.6 (46.6-84.0)* 100 82 112.4 (87.7-144.2)* 
1970s 100 99 79 90.4 (70.9-115.1)* 100 94 247.2 (199.7-306.0)* 
1980s 104 79 30 22.7 (18.4-28.1)* 100 99 488.1 (410.4-580.5)* 
1990s  99 30 9 8.0 (6.7-9.7)* 97 89 235.4 (172.3-321.7)* 
2000s 40 10 0 5.4 (5.0-5.7) 58 15 13.3 (9.2-19.2)* 
GMT: geometric mean titer; CI: confidence interval. 
* GMTs significantly higher (p<0.05, by Wilcoxon signed-rank test) in the virus-neutralizing than in the hemagglutination-
inhibition assay. 
 
5.2.4.4 Correlations between antibody titers against human seasonal and 
swine-origin influenza A (H3N2) viruses 
There was a strong correlation between HI antibody titers against sw/Gent/172/08 
and A/Victoria/3/75 viruses (r  =  0.71), and between those against A/Indiana/08/11 
and A/Nanchang/933/95 viruses (r  =  0.69) (Table 4). Correlations were low between 
HI titers against A/Wisconsin/67/05 and sw/Gent/172/08 (r  =  0.25), as well as 
between those against A/Wisconsin/67/05 and A/Indiana/08/11 (r  =  0.42) (all 
p  <  0.01). 
 
Table 4. Pearson correlation coefficients between hemagglutination inhibition antibody titers 
against human and swine-origin influenza A(H3N2) viruses, Luxembourg, 2010 (n  =  843)  
 A/Victoria/3/75 A/Nanchang/933/95 A/Wisconsin/67/05 sw/Gent/172/08 A/Indiana/08/11 
A/Victoria/3/75 1 0.17 0.24 0.71 0.09 
A/Nanchang/933/95  1 0.48 0.26 0.69 
A/Wisconsin/67/05   1 0.25 0.42 
sw/Gent/172/08    1 0.31 
A/Indiana/08/11     1 
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All p<0.01. 
 
5.2.5 Discussion 
The present study was designed to investigate the extent to which prior exposure, 
through infection or vaccination, to earlier antigenic variants of seasonal influenza 
A(H3N2) viruses was associated with the presence of antibodies against swine-origin 
H3N2 viruses from Europe and North America in people in Luxembourg born 
between 1910 and 2010. Our results demonstrate that as many as 70% of people in 
the study born before 1990 had detectable HI antibodies against the European H3N2 
SIV, whereas such antibodies were generally lacking in those born after 1990. The 
prevalence of antibodies against the antigenically distinct H3N2v swine-origin virus 
was also age-dependent: antibodies were predominantly found in people born before 
2000, of whom 86% were seropositive. Our data are consistent with previous studies 
(CDC, 2012; De Marco et al., 2013; Hoschler et al., 2013; Krumbholz et al., 2014; 
Skowronski et al., 2012a; Skowronski et al., 2012b; Waalen et al., 2012), but we 
have for the first time demonstrated a lower level of seroreactivity to the European 
H3N2 SIV than to the H3N2v virus. Although HI titers of  ≥  40 are generally 
considered as seroprotective, people with lower antibody titers may also have some 
protection against H3N2 viruses from swine. Indeed, HI assays do not measure 
mucosal antibodies, antibodies against NA and cell-mediated immunity, which will 
also contribute to protection (Tamura et al., 2005). The VN assay yielded higher 
seroprevalence rates and antibody titers against both swine-origin influenza viruses 
than the HI assay. This is not surprising, because the VN assay detects a broader 
range of antibodies than the HI assay (Sui et al., 2009). 
We have several reasons to believe that antibodies against current swine-origin 
H3N2 viruses result from exposure to historical human H3N2 strains rather than from 
infection with SIVs. Firstly, Luxembourg has a low pig density compared with other 
European regions and only 0.07% of the population are employed in the swine 
industry. Furthermore, only 0.99% of the Luxembourg swine population tested 
seropositive against H3N2 SIV in 2013 (Lutteke et al., 2014). Secondly, H3N2 SIVs 
from North America have never been detected in swine in Europe. Finally, we found 
a strong correlation between antibody titers against swine-origin viruses 
sw/Gent/172/08 and A/Indiana/08/11 and their respective human ancestor 
A/Victoria/3/75 and A/Nanchang/933/95. Similar correlations have previously been 
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reported between antibody titers against the European H3N2 SIV and A/Port 
Chalmers/1/73 (Krumbholz et al., 2014), and between the H3N2v virus and 
A/Wuhan/359/95 and A/Sydney/5/97 viruses (Hoschler et al., 2013; Skowronski et 
al., 2012b). In contrast, younger people who had not been exposed to these human 
H3N2 strains in past decades, were generally seronegative against the swine-origin 
viruses. In addition, our phylogenetic and antigenic analyses, in agreement with 
previous studies (Lina et al., 2011; Qiu et al., 2013), confirm the close relationship 
between these swine-origin viruses and their human H3N2 ancestors. 
Despite lower seroreactivity to the European H3N2 SIV than to the North American 
H3N2v virus, only three human infections with the European H3N2 SIV have been 
reported between 1993 and 2014 (Claas et al., 1994; Gregory et al., 2001). The 
H3N2v viruses, in contrast, have caused 343 human infections in the US between 
2011 and 2014. It is possible that the H3N2v virus is more infectious for humans than 
other H3N2 lineages from swine or that more people in the US may have 
opportunities for exposure to pigs. The H3N2v is the only North American H3N2 SIV 
genotype that has caused widespread infections in humans, and although some 
believe this is due to the presence of the pandemic M gene segment, this has not 
been firmly proven (Van Reeth, 2013). Most H3N2v cases reported exposure to pigs 
at agricultural fairs (Jhung et al., 2013; Wong et al., 2012). Thousands of fairs are 
held in summer and autumn in North America, and these fairs provide unique 
settings where pigs from numerous sources can come into contact with millions of 
persons, which may facilitate interspecies transmission of influenza viruses. Such 
large-scale pig shows are rare in Europe. Furthermore, human cases of animal 
influenza have been notifiable in the US since 2007, which is not the case in Europe, 
and there is much more extensive surveillance for influenza in humans and swine in 
the US than in Europe. 
Our data further support the notion that pigs serve as reservoirs for older human H3 
HAs against which immunity in the human population will gradually decrease over 
time. Experimental infection studies in pigs and in ferrets have shown that prior 
infection with recent seasonal H3N2 viruses offers limited or no protection against 
challenge with the European H3N2 SIV or H3N2v (Houser et al., 2013; Qiu et al., 
2013). As such, H3N2 SIVs, and the European strains in particular, could potentially 
contribute to pandemic viruses in the future as seroreactivity to the respective HAs 
wanes over time in the human population. Yet, it is highly likely that the current 
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substantial immunity in people born before 1990 would prevent extensive spread of 
H3N2 SIVs. As for the swine-origin pH1N1 virus, pre-pandemic antibodies against 
pH1N1 were present in most individuals born before 1944, but were low or absent in 
younger people (CDC, 2009; Hancock et al., 2009; Ikonen et al., 2010b; Skowronski 
et al., 2011). It may take nearly 50 years before a substantial proportion of the human 
population would be fully susceptible to swine-origin H3N2 viruses. To assure the 
best preparation for swine-origin influenza virus pandemics, surveillance of influenza 
in pigs should be expanded and integrated with human public health surveillance 
efforts, and additional studies on the cross-reactivity between human and swine 
influenza viruses are warranted. 
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Heterovariant and heterosubtypic protection between influenza viruses 
Our research shows that cross-protection between influenza viruses correlates with 
the genetic similarities of the viral HA and NA genes. That is, protection is usually 
stronger against challenge viruses with HA and/or NA proteins of the same origin as 
the viruses used for primary infection. This is seen in the complete cross-protection 
between pH1N1 and the European SIV H1avN1 as well as H1huN1, reflecting the 
same N1 origin of these viruses. Likewise, full cross-protection also occurred 
between the historic human seasonal H3N2 virus (A/Victoria/3/75) and the European 
H3N2 SIV, which share both the origin of their H3 and N2. This strong protection can 
be induced independently by either HA or NA, and it can explain why there may be 
stronger cross-protection between viruses with a different HA subtype but a closely 
related NA (heterosubtypic protection, i.e. between H3N2 and H1N2) than between 
viruses of the same HA and NA subtype (heterovariant protection, i.e. between 
different H3N2 viruses). As an illustration, after challenge with a European H3N2 SIV, 
nasal virus shedding and virus replication in respiratory tissues were almost 
undetectable in pigs previously infected with a European H1huN2 SIV, but they were 
only minimally reduced in pigs previously infected with a contemporary human 
seasonal H3N2 virus A/Wisconsin/67/05. 
Our results show substantial heterovariant-protection can even occur between two 
viruses having a significant number of amino acid differences in the HA antigenic 
sites. For example, 17 and 9 amino acid differences in atnigenic sties were observed 
between pH1N1 and European H1avN1 SIV, and between A/Victoria/3/75 and 
European H3N2, respectively. Still, a complete cross-protection occurred in both 
cases. While the related NA of these viruses has likely contributed to the protection, 
a closer look at the HA1 genetic sequences revealed that the immunodominant 
antigenic sites (site A and B in H3, and site Sa in H1) were largely conserved in both 
cases. We found minimal cross-reactive virus-neutralizing (VN) antibodies to both 
challenge viruses in serum, but we hypothesize that VN antibodies in the respiratory 
mucosa may be of high affinity and thereby contribute to a rapid and efficient control 
of virus replication. This critical protective role of immunodominant antigenic sites has 
been demonstrated at the time of the 2009 pandemic in humans. The 2009 pH1N1 
differs from the 1918 Spanish H1N1 pandemic virus by 10 amino acids in all 4 
antigenic sites, but the Sa antigenic site is extremely conserved (only 1 amino acid 
difference) (Xu et al., 2010). This correlates well with the observation that humans 
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who have experienced the 1918 Spanish flu carry the highest titers of VN antibodies 
against the 2009 pH1N1 viruses and have lowest infection rates amongst all age 
groups (CDC, 2009; Hancock et al., 2009; Skowronski et al., 2011). 
In 1990, Wilson and Cox proposed that a drift variant of human seasonal influenza 
viruses with ≥4 amino acid changes at ≥2 of the 5 antigenic sites would be of 
epidemiologic importance (Wilson & Cox, 1990). According to more recent studies 
with H3N2 viruses of humans and of North American swine, 6 or 7 amino acid 
positions in the HA1 are critical for the viral antigencity. These amino acid positions 
are identical in both species and 1 or 2 changes of them are believed to result in 
significant antigenic drift, as determined by cross-HI assays with post-infection ferret 
sera or hyperimmune swine sera  (Koel et al., 2013; Lewis et al., 2014). It is unknown 
whether those key amino acid positions are also applicable to other H3N2 lineages 
such as European H3N2 SIVs, and to what extent they really matter in cross-
protection in the field. The A/Victoria/3/75 and European H3N2 SIV used in our 
cross-protection study in pigs have 4 residue differences in those identified positions, 
and cross-reactivity between them was undetectable in the HI assay, and only 
minimal in the VN assay. Still, a complete protection against the European H3N2 SIV 
occurred in pigs previously infected with A/Victoria/3/75. Several studies have shown 
that 1-3 amino acid changes in the HA1 molecule of H1N1 and H3N2 viruses could 
possibly reduce the cross reactivity and the efficacy of inactivated vaccine in an 
animal model (Katz & Webster, 1989; Kodihalli et al., 1995; Newman et al., 1993; 
Wood et al., 1989). This disagrees with the “high” threshold observed in our 
experimental pig infection studies. One possible explanation is that experimental 
inoculation with a high dose of influenza viruses can provoke a broader immune 
response, i.e. local antibody responses in the respiratory tract, than whole inactivated 
virus vaccines (Van Reeth & Ma, 2013). However, we have also performed 
vaccination-challenge experiments with a commercial vaccine based on A/Port 
Chalmers/1/73 vaccine and challenge with a European H3N2 SIV. The two viruses 
had 11 amino acid differences in all antigenic sites of which 6 occurred in site A and 
B. Still, challenge virus titers in the lungs, trachea and nasal mucosa of the 
vaccinated pigs were significantly reduced after challenge (De Vleeschauwer et al., 
2015). We believe that more differences in critical amino acid positions are required 
for a loss of cross-protection in infection-immune pigs or pigs vaccinated with some 
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commercial vaccines. Further studies into the most important amino acids for various 
strains are required. 
Traditionally, HA and NA mediated immunity is examined by HI, VN and 
neuraminidase-inhibition (NI) assays on serum. However, the respiratory tract is the 
site where influenza virus infection occurs, and is the front line where host immunity 
clear viruses. Our findings are in accordance with previous reports that the porcine 
nasal mucosa is the predominant location of both IgG and IgA producing cells after 
infection with a North American H1N1 SIV (Larsen et al., 2000). In addition, we have 
shown that protection between two genetically and antigenically distinct swine-origin 
H3N2 viruses was associated with a rapid boost of antibody-secreting cell responses 
in the nasal mucosa after challenge. Likewise, human nasal-associated lymphoid 
tissue is considered the important induction site for both mucosal and systemic 
immunity to upper respiratory pathogens, including influenza virus (Guthrie et al., 
2004; Wiley et al., 2001; Zuercher et al., 2002). All these data spur more studies 
focusing on the immune responses at the respiratory mucosae. The markedly similar 
pathogenesis and immune responses to influenza viruses in the respiratory tract in 
pigs and in humans make the pig an interesting animal model for humans to study 
this issue.  
The ELISpot assays developed in our study were shown to be a valuable tool to 
quantify local and systematic influenza virus specific immune responses. We have 
performed basic assays using whole virus preparations to detect the responses of 
immune cells. The use of split proteins, or synthesized peptides in future studies will 
allow to get insights into the major viral targets of the immune responses.   
In our research, we used the a miniaturization of the thiobarbituric acid (TBA) method 
to quantify NI antibodies (Sandbulte et al., 2009). We used natural, whole influenza 
virus as antigen and fetuin, a highly glycosylated protein, as substrate to measure the 
amount of free sialic acid, the soluble product of NA activity. Other researchers 
frequently use reassortant viruses that are produced by reverse genetics to contain 
the relevant NA gene but a novel subtype of HA. This is because sometimes HA-
specific antibodies in polyclonal serum may block access of substrate to the NA 
catalytic site, leading to an overestimated NI titer (Gerentes et al., 1999). However, 
this unspecific interference role of HA-specific antibodies has not been observed so 
far in all our studies with post-infection swine sera. As an example, we did not 
observe any cross-reactivity in the NI assay between H1huN1 and H1huN2 SIVs, in 
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spite of the two viruses having very similar HAs and cross-reactivity in the HI assay. 
Considering that cross-reactive HI antibodies against the challenge virus were absent 
in all our cross-protection studies in this thesis, we believe that the detected cross-
reactive NI antibodies were specific to the NA of the challenge virus, and that the 
association with the observed cross-protection was valid. 
Our experimental cross-protection data may explain recent changes in the 
epidemiology of SIVs in Europe. For instance, pH1N1 is found to be the dominant 
H1N1 virus in the United Kingdom, where there is a low prevalence of H1avN1. The 
other way round, pH1N1 is hardly detected in Belgium and the Netherlands where 
H1avN1 is very widespread (Simon et al., 2014). Furthermore, H3N2 is rare in pigs in 
Brittany, France, whereas the prevalence of H1huN2 is high in this region (Simon et 
al., 2014). But there are also some exceptions: Denmark has a similarly high 
prevalence of H1avN1 and pH1N1, while Germany and Italy have similarly high 
prevalences of H3N2 and H1huN2.  
The geographic diversity of endemic SIV strains, and the dramatic increase in the 
numbers of novel SIV lineages highlight the need for more broadly protective or 
universal vaccines. In this respect, live attenuated influenza vaccines (LAIVs) are 
considered to have some advantages over whole inactivated influenza vaccines 
(WIVs), which include the stimulation of mucosal antibodies, a cytotoxic T cell 
response, and longer-lasting immunity (Ambrose et al., 2012; Boyce et al., 1999; Cox 
et al., 2004). However, studies show that LAIV does not always provide superior 
protection from heterologous infection compared to WIV. In comparative studies with 
LAIV and WIV based on a North American cluster I H3N2 SIV, the WIV frequently 
show a similar reduction in nasal virus shedding and viral titers in lung tissues and 
bronchoalveolar lavage fluid after challenge with a H3N2 SIV of cluster II or IV 
(Kitikoon et al., 2013; Loving et al., 2013; Vincent et al., 2012). After intranasal 
administration of LAIV, researchers have detected mucosal antibodies in nasal 
mucosa and bronchoalveolar lavage fluid, but the cell-mediated immune responses 
were inferior in magnitude compared to those observed after infection with wild type 
virus (Kappes et al., 2012). This can be explained by the minimal replication of the 
LAIV in the respiratory tract as compared to the wild type virus. Also, in the field, 
vaccines are usually administered in the context of pre-existing infection immunity, 
and this raises the question as to how well the LAIV could replicate and induce 
immunity in an infection-immune host. Our studies indicate that prior infection 
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immunity impairs the replication of a second virus in spite of inoculation with a dose 
up to 107 50% infection dose (ID50). It is therefore doubtful whether the LAIV, which is 
usually administrated at a dose of 103 ID50 will be able to replicate sufficiently to 
induce a robust immunity against influenza. 
 
Zoonotic potential of European SIVs 
All three influenza pandemics of the 20th century were initiated by antigenic shift: the 
introduction of a new HA subtype from an avian reservoir in the human population. 
The 2009 H1N1 pandemic was different because for the first time a distinct variant of 
a currently circulating HA subtype in humans triggered a new pandemic (Garten et al., 
2009; Itoh et al., 2009). It also highlights the importance of swine as reservoir for 
pandemic viruses.  
Our study in pigs has demonstrated that prior infection with pH1N1 can induce robust 
protection against European H1avN1, H1huN1, and H1huN2 SIVs, but had little 
impact on the European H3N2 SIV. It is likely that the current high population 
immunity against pH1N1 in humans will enhance their cross-protective immunity to 
European H1 SIVs, making those viruses less likely to cause pandemics in the near 
future. The public health importance of H3N2 SIVs has been highlighted after >350 
human infections with H3N2v during 2011-14 in the United States (US). Similar to 
pH1N1 virus, most if not all H3N2 SIVs have their HA derived from human seasonal 
H3N2 viruses of different years. Due to the much slower antigenic drift rate of H3N2 
viruses in swine than in humans, seasonal human H3 HAs gradually diverged from 
the swine lineage (de Jong et al., 2007; Lewis et al., 2014). As a result, the young 
population has only been exposed to the contemporary seasonal viruses and they 
may lack protective immunity against H3N2 SIVs. This hypothesis is supported by 
our study showing a complete virological protection against infection with a European 
H3N2 SIV in pigs infected with an old human seasonal H3N2 virus (A/Victoria/3/75), 
but only a minimal protection in pigs pre-infected with the more recent human 
seasonal H3N2 virus (A/Wisconsin/67/05). Our serological study further shows that 
the prevalence of HI antibodies against the European H3N2 SIV and H3N2v were 
age-dependent, and strongly correlated with the prevalence of HI antibodies against 
their ancestor human viruses A/Victoria/3/75 and A/Nanchang/933/95, respectively. 
Individuals born after 1990 and 2000 generally lacked detectable HI antibodies (titer 
≥10) against the European H3N2 SIV and H3N2v, respectively.  
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Our findings fit with previous H3N2v serological studies (Hoschler et al., 2013; 
Skowronski et al., 2012a; Skowronski et al., 2012b), and with the epidemiological fact 
that H3N2v mainly infected children born after 2000 (Epperson et al., 2013; Jhung et 
al., 2013). Though the prevalence of antibodies against the European H3N2 SIV was 
lower compared to that against H3N2v, only three infant infections with the former 
virus have been documented since 1993 (Claas et al., 1994; Gregory et al., 2001). 
But due to the lack of routine surveillance in people in contact with swine in Europe, 
the real zoonotic infection rates are likely to be higher. Still, Europe does not have 
agricultural fairs with swine exhibition as in the US, which has proven to be an 
important site for the interspecies infections of influenza viruses across the US 
(Bowman et al., 2014; CDC, 2012; Killian et al., 2013; Wong et al., 2012). The history 
of influenza pandemics and epidemics, as well as the emergence of H3N2v, 
repeatedly demonstrate viral evolution through genetic reassortment may aid viral 
invasion and persistence in the new host. Thus, continued surveillance of virus 
epidemiology and human population immunity is required to ensure a timely 
response in case of H3N2 SIV outbreaks in humans. 
The zoonotic potential of H3N2 SIVs of European and North American lineages has 
been discussed by our and others’ studies, but H3 viruses from other animal 
reservoirs should not be ignored. Identifying such strains is of paramount value for 
pandemic surveillance and preparedness. Similar to H3N2 SIVs, the HA genes of the 
H3 subtype isolated from ducks are conserved antigenically and genetically with a 
markedly lower rate of silent and coding nucleotide substitution than for human H3 
strains, with amino acid substitutions occurring outside recognized antibody binding 
sites (Kida et al., 1987). Also, sequencing studies of equine viruses of the H3 
subtype have shown that the HA of these viruses evolved genetically in a pattern 
very similar to that for human H3N2 viruses (Kawaoka et al., 1989; Murcia et al., 
2011), albeit at a slower rate of antigenic drift (Lewis et al., 2011). The antigenic gap 
between those animal H3 viruses and human seasonal viruses may pose a threat to 
public health. Similar cross-protection and serosurveillance studies in both species 
as for H3N2 SIVs are required to evaluate their potential zoonotic risks. 
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Summary 
Swine influenza viruses (SIVs) of H1avN1, H1huN2, and H3N2 lineages, as well as 
the more recently established 2009 pandemic H1N1 (pH1N1) lineage are endemic in 
the European swine population. The H1huN2 and H3N2 SIVs have HAs and NAs 
from historical human seasonal viruses that have already disappeared from humans 
for decades. The pH1N1 is circulating in humans and swine worldwide, whereas all 
other three lineages have a different genetic make-up and antigenic properties from 
the influenza A viruses currently circulating in humans as well as in pigs of other 
continents. Therefore, SIVs from other continents may pose a substantial threat to 
the European swine population. Similarly, European SIVs may also pose a threat for 
introduction/re-introduction into the human population, with associated outbreaks and 
pandemic implications.  
In chapter 1, a general introduction to influenza A virus classification, virion structure 
and viral evolution is given. The second section presents the epidemiology of SIVs in 
Europe and North America, with an emphasis on the H3N2 SIVs. The antigenic 
differences between human and swine H3N2 viruses, and human infections with 
H3N2 SIVs are also reviewed. The third section presents a summary of the current 
knowledge of the pathogenesis and immune responses to influenza viruses, 
especially cross-protection between antigenically distinct viruses. In the fourth 
section, pros and cons of the pig model for influenza research are summarized and 
compared with other laboratory animal models.  
Chapter 2 presents the aims of the thesis. The main aim was to contribute to the 
general understanding of cross-protective immunity between influenza viruses, and 
to evaluate the zoonotic potential of European SIVs.  
Chapter 3 characterizes the genetic and antigenic evolution of European H3N2 SIVs 
from 1998-2012. The European H3N2 SIVs had a similar nucleotide substitution rate 
as compared to their human and North American swine counterparts in both HA and 
NA segments. But in contrast to their human and North American swine counterparts, 
European SIVs showed little changes in antigenic sites and antigenic properties of 
HA and NA. The results are presented as a report because the study still needs to be 
completed.  
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Chapter 4 deals with cross-protection between SIVs of the same HA and NA 
subtypes (heterovariant protection), or between SIVs of different HA and/or NA 
subtypes (heterosubtypic protection). In chapter 4.1., we assessed whether pigs 
after infection with a European H3N2 SIVs would be protected against infection with 
an antigenically distinct North American H3N2 variant virus (H3N2v). The latter virus 
has so far never been isolated in Europe, but it may be introduced by export of pigs 
from the United States (US) to other continents. The H3N2v, is a swine-origin virus 
and it has all but the matrix gene segments of a phylogenetically distinct origin from 
the European H3N2 SIV. Influenza naïve pigs were first inoculated intranasally with 
a European H3N2 SIV and 8 weeks later challenged with a H3N2v virus. Infection 
with the European H3N2 SIV induced minimal H3N2v virus-neutralization (VN) 
antibodies, and no hemagglutination-inhibition (HI) and neuraminidase-inhibition (NI) 
antibodies in serum. Cross-reactive IgA and IgG antibody secreting cells (ASCs) and 
IFN-γ secreting cells (SCs) specific to H3N2v were also demonstrated, especially in 
nasal mucosa. Post H3N2v challenge, the magnitude and duration of virus excretion 
and virus titers in respiratory tissues at day 3 post-challenge were significantly 
reduced in European H3N2 SIV-inoculated pigs. This was associated with vigorous 
early IgG and IgA ASC boost responses to H3N2v, which were by far most 
pronounced in the nasal mucosa. Our data shows a partial protection between H3N2 
viruses of two distinct lineages, and supports the notion that pig is a valuable model 
to study mucosal immune responses and to improve our understanding of broad-
spectrum immunity to influenza. 
In chapter 4.2., we examined the extent of virological protection between a) the 
pH1N1 virus and three different European H1 lineages (H1avN1, H1huN1, and 
H1huN2), and b) these H1 viruses and a European H3N2 SIV. The increasing 
number of novel influenza subtypes and genetic variants isolated from pigs has 
spurred an interest into the extent of cross-protective immunity between them. Also, 
such study may give us some indications as to whether the high human population 
immunity to pH1N1 may enhance cross-protection against other European H1 SIVs. 
The NA of pH1N1 is of European N1 lineage, and the classical HA of pH1N1 has 
shown to be more closely related to the avian-like H1 than to the human-like H1. Pigs 
were inoculated intranasally with representative strains of each virus lineage with 6- 
and 17-week intervals between H1 inoculations and between H1 and H3 inoculations, 
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respectively. Prior infection of pH1N1 conferred complete protection against H1avN1, 
a nearly full protection against H1huN1, and a partial but still substantial protection 
against H1huN2. Protection against H3N2 was weak in pH1N1- or H1N1-immune 
pigs, but much more solid in those with immunity to H1N2, reflecting the same N2 
origin of those two viruses.  
Our data suggest post-infection immunity may offer substantial cross- protection 
against viruses of the same HA and/or NA subtype. Heterosubtypic protection 
between viruses with both HA and NA of different subtypes, in contrast, appears to 
be minimal in pigs. Based on our data, we assumed that, the global spread of pH1N1 
in humans may also induce enhanced immunity to European H1 SIVs, but have 
limited impact on the European H3N2 SIV.  
In chapter 5, the zoonotic potential of European H3N2 SIVs was assessed. In 
chapter 5.1., the extent of cross-protection between human and swine H3N2 viruses 
was investigated. H3N2 influenza viruses circulating in humans and European pigs 
originate from the pandemic A/Hong Kong/68 virus. Because of slower antigenic drift 
in swine, the antigenic divergence between swine and human viruses has been 
increasing. It remains unknown to what extent this results in a reduced cross-
protection between recent human and swine H3N2 influenza viruses. Using the pig 
model of influenza, we examined the effect of prior infection with an old (1975) or 
more recent (2005) human H3N2 virus on protection against challenge with a 
contemporary European H3N2 SIV. Prior infection with the old human virus offered 
complete virological protection against challenge. Pigs previously infected with the 
recent human virus had similar virus titers in the respiratory tract as the previously 
uninfected challenge controls, but the mean duration of nasal virus excretion was 
shortened by 1.2 day. This rapid viral clearance was associated with a more rapid 
development of VN antibodies to the challenge virus than in challenge controls. Our 
study suggests that European H3N2 SIVs may pose a threat to young people who 
have only been exposed to the recent human seasonal H3N2 viruses. The older 
population may have some residual immunity resulting from previous exposure to 
historical seasonal H3N2 viruses that are related to European H3N2 SIVs. 
In chapter 5.2. we studied the prevalence of antibodies against H3N2 SIVs in the 
human population. This study served to further confirm the age-dependent immunity 
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to H3N2 SIVs in humans. Serum samples, which were collected from humans 
(n=843) aged 0 to 100 years in 2010 in Luxembourg, were analyzed by HI and VN 
assays against a European H3N2 SIV, a North American H3N2v virus, and human 
seasonal H3N2 viruses isolated in 1975, 1995 and 2005. HI antibodies (titer ≥10) to 
the European H3N2 SIV were almost exclusively detected in those born before 1990, 
of which 70% were seropositive. HI antibodies to H3N2v were predominantly found 
in those born before 2000, of which 86% were seropositive. The same pattern was 
reflected in the VN assay. A strong correlation between HI titers to the European 
H3N2 SIV and H3N2v and their respective human ancestors, A/Victoria/3/75 and 
A/Nanchang/933/95 was observed. This finding and the minimal contacts between 
humans and pigs in Luxembourg suggests that the anti-SIV antibodies detected in 
the human sera are due to serologic cross-reactivity with historical human H3N2 
viruses. The higher prevalence of antibodies to H3N2v than to the European H3N2 
SIV suggests that a larger proportion of human population is immunologically 
susceptible to the latter virus, which would be potentially more damaging than 
H3N2v if it would jump to humans and acquire the capacity to spread between 
humans. 
In chapter 6, all experimental studies are discussed. In general, our study indicates 
cross-protection between influenza viruses in pigs correlates well with viral genetic 
and antigenic differences. Although we found mucosal immune B cell responses 
were associated with broad protection, it remains questionable which immune 
components best correlate with protection. Prior infection with pH1N1 can generate 
cross-protective immunity against European H1N1 and H1N2 SIVs, making them 
less likely to be the candidates for the next pandemic. In comparison, susceptibility to 
European H3N2 SIVs exists in humans born after 1990, who have never been 
exposed to H3N2 SIVs or antigenically related viruses. The recent outbreaks of the 
swine-origin H3N2v in young people in the US also highlights the zoonotic potential 
of European H3N2 SIVs. Further studies are required to identify the conserved 
epitopes between human and swine H3N2 viruses, as well as the strategies to 
enhance human immunity against H3N2 SIVs. 
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Samenvatting  
Varkensinfluenzavirussen (swine influenza viruses, SIV) van de H1avN1, H1huN2 en 
H3N2 lijnen én de recent ontstane 2009 pandemische H1N1 (pH1N1) lijn komen 
endemisch voor in de Europese varkenspopulatie. De H1huN2 en H3N2 SIV’s 
beschikken nog steeds over de HA’s en NA’s van historische humane 
seizoensgebonden virussen die bij de mens sedert enkele decennia niet meer 
teruggevonden worden. De pH1N1 circuleert zowel bij mens en varken over de hele 
wereld, terwijl de andere drie types, die momenteel circuleren op andere continenten, 
andere genetische en antigene eigenschappen van het influenza A-virus vertonen 
tussen mens en varken. Daarom kunnen SIV's van andere continenten een gevaar 
voor de Europese varkenspopulatie vormen. Bovendien kunnen de Europese SIV's 
ook een bedreiging vormen voor de (her)introductie in de humane populatie, met 
bijbehorende uitbraken en pandemische implicaties.  
Hoofdstuk 1 is een algemene inleiding met weergave van de klassificatie, de virion 
structuur en evolutie over influenza A virussen. In het tweede deel wordt er uitgebreid 
over de epidemiologie van SIV’s en voornamelijk H3N2 SIV. De antigene verschillen 
tussen humane en porciene H3N2 virussen, en humane infecties met H3N2 SIV 
komen alsook aan bod. Het derde deel vat de huidige kennis over de pathogenese 
en de immuunreacties tegenover influenzavirussen samen, waarbij de nadruk gelegd 
wordt op de kruisbescherming tussen antigenisch verschillende virussen. In het 
vierde deel worden de voor-en nadelen van het varken als model voor influenza-
onderzoek opgesomd en wordt het varken vergeleken met andere proefdieren.  
In hoofdstuk 2 worden de doelstellingen van de thesis uiteengezet. Het bijdragen 
aan de algemene kennis over kruisbeschermende immuniteit van influenzavirussen 
en de evaluatie van het zoönotisch karakter van Europese SIV’s waren de 
hoofddoelstellingen van dit proefschrift.  
Hoofdstuk 3 wordt gekenmerkt door de genetische en antigene evolutie van de 
Europese H3N2 SIV's van 1998-2012. De Europese H3N2 SIV’s hadden een 
vergelijkbare nucleotide substitutiegraad met humane en Noord-Amerikaanse 
varkenstegenhangers in zowel HA als NA segmenten. In tegenstelling tot humane en 
Noord-Amerikaanse porciene tegenhangers, toonden Europese SIV’s weinig 
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veranderingen in antigene plaatsen en eigenschappen van HA en NA. De resultaten 
worden weergegeven als een verslag, aangezien de studie nog afgerond moet 
worden. 
De kruisbescherming tussen SIV’s van dezelfde HA en NA subtypes (“heterovariant 
bescherming”) of tussen SIV’s met verschillende HA en/of NA subtypes 
(“heterosubtypische bescherming”) wordt beschreven in hoofdstuk 4. In hoofdstuk 
4.1. wordt de eventuele bescherming van varkens na infectie met een Europees 
H3N2 SIV tegenover een antigenisch verschillend Noord-Amerikaans H3N2 variant 
virus (H3N2v) nagegaan. Dit laatst vernoemde virus is tot nu toe nog nooit geïsoleerd 
in Europa, maar het kan door de export van varkens uit de Verenigde Staten (VS) 
naar andere continenten worden ingevoerd. 
Het H3N2v-virus, afkomstig van varkens, heeft enkel de matrix-gen segmenten 
gemeenschappelijk met een fylogenetisch verschillende Europese H3N2 SIV. 
Influenza naïeve varkens werden eerst intranasaal geïnoculeerd met een Europees 
H3N2 SIV 8 weken voor challenge met een H3N2v virus. Infectie met het Europese 
H3N2 SIV leidde tot een minimale opbouw van H3N2v virus-neutraliserende (VN) 
antistoffen, en geen hemagglutinatie-inhibitie (HI) en neuraminidase-inhibitie (NI) 
antistoffen in serum. Kruisreactieve IgA en IgG-antistof uitscheidende cellen 
(antibody secreting cells, ASC) en IFN-γ uitscheidende cellen (secreting cells, SC's) 
specifiek voor H3N2v werden eveneens aangetoond, voornamelijk ter hoogte van het 
neusslijmvlies. De omvang en duur van virusuitscheiding en virustiters in respiratoire 
weefsels waren aanzienlijk verminderd in Europees H3N2 SIV-immune dieren drie 
dagen na H3N2v challenge. Dit ging gepaard met sterke vroege “IgG en IgA ASC 
recall reacties” op H3N2v, die verreweg het meest uitgesproken waren in de nasale 
mucosa. Onze gegevens tonen een gedeeltelijke bescherming tussen H3N2 virussen 
van twee verschillende lijnen, en toont aan dat het varken een waardevol model is 
om mucosale immuunreacties te bestuderen en onze kennis over breed-spectrum 
immuniteit tegen influenza te verbeteren. In hoofdstuk 4.2. wordt de mate van 
virologische bescherming tussen a) het pH1N1 virus en drie verschillende Europese 
H1 lijnen (H1avN1, H1huN1 en H1huN2), en b) deze H1 virussen en het Europees 
H3N2 SIV bestudeerd. Het toenemend aantal nieuwe influenza subtypes en 
genetische varianten bij varkens wakkerde de interesse in kruisbeschermende 
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immuniteit aan. Dergelijke studie geeft bovendien een indicatie over of de hoge 
humane populatieimmuniteit tegenover pH1N1 kan bijdragen tot een 
kruisbescherming tegen andere Europese H1 SIV’s. De NA van pH1N1 is van 
Europese afkomst en de klassieke HA pH1N1 blijkt nauwer verwant te zijn met de 
aviaire H1 dan met de humane H1. De varkens werden intranasaal geïnoculeerd met 
representatieve stammen van elke lijn met een interval van 6 en 17 weken tussen H1 
inoculaties respectievelijk tussen H1 en H3 inoculaties. Voorafgaande infectie met 
pH1N1 resulteerde in volledige bescherming tegen H1avN1, een bijna volledige 
bescherming tegen H1huN1, en een gedeeltelijke, maar nog steeds aanzienlijke 
bescherming tegen H1huN2. Bescherming tegenover H3N2 was zwak in pH1N1- of 
H1N1-immune varkens, en matige bescherming werd gevonden in H1N2-immune 
dieren, als gevolg van dezelfde N2 oorsprong van die twee virussen. 
Onze gegevens suggereren dat immuniteit ontstaan na infectie een aanzienlijke 
bijdrage kan leveren in kruisbescherming tegen virussen van dezelfde HA en/of NA 
subtype. Heterosubtypische bescherming tussen virussen met zowel HA en NA van 
verschillende subtypen blijkt daarentegen bij varkens minimaal te zijn. Op basis van 
onze gegevens, veronderstellen we dat de wereldwijde spreiding van pH1N1 bij de 
mens zal bijdragen tot een sterkere immuniteit tegen Europese H1 SIV's, maar een 
beperkte impact op de Europese H3N2 SIV immuniteit zal hebben. 
In hoofdstuk 5 werd het zoönotische karakter van de Europese H3N2 SIV’s 
beoordeeld. De mate van kruisbescherming tussen humane en porciene H3N2 
virussen werd onderzocht in hoofdstuk 5.1.. H3N2 influenza virussen, circulerend bij 
mensen en bij Europese varkens, zijn afkomstig van het pandemisch A/Hong 
Kong/68 virus. Omwille van de tragere antigene drift bij varkens, zijn de antigene 
verschillen tussen de porciene en de humane virussen toegenomen. Tot op heden is 
het onbekend hoeverre dit leidt tot een vermindering van kruisbescherming tussen 
recente humane en porciene H3N2 influenzavirussen. Gebruikmakend van het 
varkensmodel voor influenza, hebben we het effect van eerdere infectie met een 
oude (1975) of recente (2005) humane H3N2 virus op een challenge met een 
hedendaags Europees H3N2 SIV bestudeerd. Voorafgaande infectie met het oude 
humane virus resulteerde in volledige virologische bescherming tegen challenge. 
Varkens die eerder geïnfecteerd werden met het recente humane virus vertoonden 
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dezelfde virustiters in de ademhalingswegen als de eerder niet-geïnfecteerde 
controle dieren, maar de gemiddelde duur van virusuitscheiding verkortte met 1.2 
dagen. Dit werd geassocieerd met een snellere ontwikkeling van VN antistoffen 
tegen het challengevirus dan in challenge controle dieren. Onze studie suggereert 
dat de Europese H3N2 SIV's een gevaar kunnen vormen voor jonge mensen die 
enkel zijn blootgesteld aan de recente humane seizoensgebonden H3N2 virussen. 
De oudere populatie daarentegen kan nog beschikken over een immuniteit uit 
eerdere blootstelling aan historische seizoengebonden H3N2 virussen die zijn 
gerelateerd aan de Europese H3N2 SIV’s. 
In hoofdstuk 5.2. wordt de prevalentie van antistoffen tegen H3N2 SIV in de 
humane populatie weergegeven. Deze studie bevestigde de leeftijd-afhankelijke 
immuniteit voor H3N2 SIV's bij de mens. Serumstalen, die werden verzameld bij 
mensen van 0 tot 100 jaar (n=843) in 2010 in Luxemburg, werden geanalyseerd met 
behulp van HI en VN testen tegen een Europees H3N2 SIV, een Noord-Amerikaans 
H3N2v-virus, en humaan seizoensgebonden H3N2 virus geïsoleerd in respectievelijk 
1975, 1995 en 2005. HI antistoffen (titer ≥10) tegenover Europese H3N2 SIV’s 
werden bijna uitsluitend gedetecteerd in degenen die vóór 1990 zijn geboren, 
waarvan 70% seropositief bevonden werd. HI antilichamen tegenover H3N2v werden 
voornamelijk gevonden in degenen die zijn geboren vóór 2000, waarbij 86% 
seropositief bleek. Hetzelfde patroon werd teruggevonden in de VN-test. Een sterke 
correlatie tussen HI titers van het Europees H3N2 SIV en H3N2v en hun humane 
voorouders, A/Victoria/3/75 en A/Nanchang/933/95 werd waargenomen. Deze 
bevinding en het minimaal contact tussen mens en varken in Luxemburg suggereert 
dat de anti-SIV antistoffen in de humane sera het gevolg zijn van serologische 
kruisreactiviteit met historische humane H3N2 virussen. De hogere prevalentie van 
antilichamen ten opzichte van H3N2v in vergelijking met de Europese H3N2 SIV 
bewijzen dat een groot deel van de humane populatie immunologisch gevoelig is 
voor de virussen die potentieel schadelijker dan H3N2v zijn als deze direct naar en 
tussen de mens kunnen spreiden.  
In hoofdstuk 6 worden alle experimentele studies besproken. In het algemeen tonen 
onze studies aan dat de kruisbescherming tussen influenzavirussen in varkens goed 
correleert met virale genetische en antigene verschillen. Hoewel mucosale immune 
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B-cel responsen werden geassocieerd met een brede bescherming, blijft het de 
vraag welke immuunsysteemcomponenten best correleren met bescherming. 
Voorafgaande infectie met pH1N1 kan kruisbeschermende immuniteit ten opzichte 
van Europese H1N1 en H1N2 SIV's teweegbrengen, wat maakt dat deze virussen 
heel onwaarschijnlijk een volgende pandemie zullen veroorzaken. Ter vergelijking, 
gevoeligheid voor Europese H3N2 SIV is aanwezig bij mensen geboren na 1990, die 
niet zijn blootgesteld aan H3N2 SIV of gerelateerde virussen. De recente uitbraken 
van H3N2v, van varkensoorsprong, bij jonge mensen in de VS, wijst ook op het 
zoönotische potentieel van de Europese H3N2 SIV's. Verdere studies zijn nodig om 
de bewaarde epitopen tussen humane en porciene H3N2 virussen te identificeren, 
alsook strategieën te bepalen om immuniteit tegen humaan H3N2 SIV verbeteren.  
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